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Abstract 
Poor health and injury represent major obstacles to the future economic security of 
Australia. The national economic cost of work-related injury is estimated at $57.5 billion 
p/a. Since exposure to high physical demands is a major risk factor for musculoskeletal 
injury, monitoring and managing such physical activity levels in workers is a potentially 
important injury prevention strategy. Current injury monitoring practices are 
inadequate for the provision of clinically valuable information about the tissue specific 
responses to physical exertion.  
 
Injury of various soft tissue structures can manifest over time through 
accumulation of micro-trauma. Such micro-trauma has a propensity to increase the 
risk of acute injuries to soft-tissue structures such as muscle or tendon. As such, the 
capacity to monitor biomarkers that result from the disruption of these tissues offers 
a means of assisting the pre-emptive management of subclinical injury prior to acute 
failure or for evaluation of recovery processes.  
 
Here we have adopted an in-vivo exercise induced muscle damage model 
allowing the application of laboratory controlled conditions to assist in uncovering 
biochemical indicators associated with soft-tissue trauma and recovery. Importantly, 
urine was utilised as the diagnostic medium since it is non-invasive to collect, more 
acceptable to workers and less costly to employers. Moreover, it is our hypothesis 
that exercise induced tissue degradation products enter the circulation and are 
subsequently filtered by the kidney and pass through to the urine.  
 
To test this hypothesis a range of metabolomic and proteomic discovery-phase 
techniques were used, along with targeted approaches. Several small molecules 
relating to tissue damage were identified along with a series of skeletal muscle-
specific protein fragments resulting from exercise induced soft-tissue damage. Each 
of the potential biomolecular markers appeared to be temporally present within urine. 
Moreover, the regulation of abundance seemed to be associated with functional 
recovery following the injury. This discovery may have important clinical 
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applications for monitoring of a variety of inflammatory myopathies as well as novel 
applications in monitoring of the musculoskeletal health status of workers, 
professional athletes and/or military personnel to reduce the onset of potentially 
debilitating musculoskeletal injuries within these professions. 
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Chapter 1: Literature Review 
1.1 INTRODUCTION 
Musculoskeletal disorders (MSD) present a significant problem to many 
industrialised nations, having an effect at an individual level that is subsequently 
experienced at an economic level. Conservative estimates of the cost of workers‘ 
compensation in the USA alone are between 15 and 20 billion dollars according to 
the Occupational Safety and Health Administration (USA) (OSHA 2000). Other 
reports have placed the indirect cost of work related musculoskeletal disorders (WR-
MSD) in the vicinity of 55 billion dollars annually (NRC 2001). This aligns with the 
estimated indirect costs within Australia of 57.5 billion dollars for expenses relating 
to medical, legal and retraining, along with losses of productivity and morale within 
the workforce (ABS 2011). Such expenses are expected to increase due to an aging 
work-force and the pressures placed on individual workers due to the current 
economic climate. As well as placing a heavy economic burden on the workplace 
compensation system, work-related injuries also impact the employees at both a 
mental and physical level, often involving substantial pain, reduced mobility and 
increased psychological morbidity (Mason et al. 2002). In light of this it is clear that 
a novel and non-invasive means of monitoring musculoskeletal health in the 
workplace is required. 
 
Work-related MSD (WR-MSD) represent a specific subgroup of MSD which 
occur through occupational exposure to key risk factors associated with the 
epidemiology of these disorders. The impact of MSD in the workforce is highlighted 
by the fact that the accumulation of lost workdays and physical disabilities is far 
greater for sufferers of musculoskeletal disorders than any other disease group 
(Punnett and Wegman 2004). Through numerous occupational epidemiological and 
scientific investigations, various research groups have shown strong links between 
MSDs and exposure to particular job features (risk factors). These include forceful 
over exertions, rapid work pace, repetitive motions, sustained static muscle loading, 
awkward body postures, localised mechanical stress, exposure to vibration or 
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extremes in temperature and lack of recovery (Forde et al. 2002); all of which 
contribute to the development of WR-MSDs. 
 
Current opinion is that musculoskeletal tissue injuries can manifest over time 
through induction of micro-trauma or can occur as a result of acute tissue trauma 
(NRC 2001). The former archetype (i.e. accumulation of soft tissue micro-trauma) 
has been around for some time (Radin 1976; Armstrong et al. 1993; Forde et al. 
2002) and is perhaps a more suitable explanation within a workplace context as 
workers tend to be exposed and re-exposed to subtle levels of physical exertion that 
would bring about repeated micro-trauma to specific tissue structures. The major 
implication with this type of cumulative exposure model is that each additional 
exposure to a particular stressor (i.e. a high risk task) will result in further micro-
trauma. This micro-trauma will continue to manifest over time, possibly without the 
worker experiencing any noticeable physical pain, until functional failure occurs at 
the site of injury. Unfortunately, workers may not always be cognisant of the 
underlying sequence of events leading to failure; this results in the perception that an 
acute injury has occurred when in actual fact if the chronic condition was realised 
earlier the injury may have been avoided. To date it would seem there is no truly 
objective method of diagnosing the onset of these kinds of injury. 
 
Although there have been some discoveries made regarding indicators of soft 
tissue damage, this area of research is still relatively young. Current markers within 
this field provide poor diagnostic capacity and as a consequence, exhibit lower 
classification power. This is likely due to the recent attempts at biomarker 
identification having been largely univariate in nature where only single markers of 
interest have been targeted (Kuiper et al. 2005; Amat et al. 2007). The drawback 
with this approach is that the majority of disease states, including MSD, are 
multivariate by nature, both in the context of input stressors (i.e. a physical stressor 
known to induce tissue damage) and the physiological response to such stressors (i.e. 
the tissue adaptation following injury). As such, it is unlikely that a particular single 
protein, peptide or metabolite will always be a characteristic indicator of a biological 
state. 
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1.2 ETIOLOGY OF SOFT TISSUE DAMAGE: 
Soft tissue injuries occur when external loads are converted to internal loads 
which consequently jeopardize the structural integrity of the tissue. This type of 
damage can be caused by over stressing the tissue, resulting in a strain or shearing 
injury (Ettema et al. 2006). Shearing injuries occur in a range of soft tissues, for 
example, tendons acting as pulleys can sustain shearing injuries as they endure load 
while moving over bone or through adjacent tissue. This is a typical mode of injury 
sustained by the supraspinatus tendon in the shoulder joint as it glides through the 
sub-acromion space during shoulder-joint abduction. Skeletal muscle tissue is also 
prone to shearing damage created through friction between individual muscle fibres 
resulting in Z-disc streaming (Friden et al. 1988). In extreme cases this kind of 
loading results in high tensile forces, often followed by tendon ruptures (Kongsgaard 
et al. 2005) or subsequent necrosis of the myofibres (Schiaffino and Partridge 2008). 
Nonetheless, compared to other soft tissues such as ligaments and tendons, muscle 
tissue has an exceptional ability to repair if an appropriate recovery time is provided. 
However, when the recovery time is too short, a cumulative load injury may arise 
through the mechanisms described above. This is a consequence of exposure to 
physical stressors followed by re-exposure without allowing enough time to repair 
the injured tissue (Kumar 1990; Kumar 2001).  
 
Several other factors are apparent in determining a tissue‘s predisposition to 
injury or its capacity to recover (Peake et al. 2005). The nature of injury and 
likelihood of occurrence can be exacerbated by other factors known to promote the 
development of soft tissue injuries. 
 Age has been associated with poor repair and increased injury 
prevalence and is partially explained by the well characterised 
degenerative loss of muscle mass, i.e. sarcopenia. Data to support high 
susceptibility and poorer prognosis in the elderly has revealed a greater 
severity in ultrastructural damage following exercise with an additional 
negative outcome of slower recovery in patients following soft tissue 
damage (Dedrick and Clarkson 1990; Roth et al. 2000; Ploutz-Snyder 
et al. 2001). Using an eccentric loading model, Hamada et al. (2005) 
demonstrated the attenuation of CD18 and transforming growth factor-
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β1 (TGF-β1), which are known to trigger neutrophil transmigration in 
elderly patients, indicating that senescence of human muscle reduces its 
capacity to initiate repair (Hamada et al. 2005).  
 Severe exercise-induced muscle damage tends to occur through 
excessive eccentric movements, which can immediately lead to 
ultrastructural changes in the skeletal muscle or tendon tissues after 
exposure (Friden et al. 1991; Lieber et al. 1991; Hesselink et al. 1996; 
Merrick 2002; Tagliafico et al. 2011). It is clear from the literature that 
eccentric contractions produce the most damage to soft tissue, not just 
to the muscle tissue but also to the myotendinal junction (Tidball et al. 
1993).  
 Gender differences have been shown to play a role in the ability to 
recover from injuries (Clarkson and Hubal 2001) and propensity to 
accrue an injury (Treaster and Burr 2004), although the mechanisms for 
this aren‘t entirely understood. 
 Pre-exposure to physical stressors with optimal recovery time allotted 
has been shown to decrease the risk of injury, a biological adaptation 
referred to as the repeated bout effect (Nosaka et al. 2001). 
 
It is clear that the potential to sustain an injury can be increased by one or 
several of the factors discussed above. Regardless, the final result is soft tissue 
adaptation which begins with an initial inflammatory response. 
 
1.3 SOFT TISSUE INFLAMMATION: 
Soft tissue damage brings about the influx of leukocytes which drive the innate 
inflammatory process following an injury and can last for well over a week in acute 
injury cases (Paulsen et al. 2009). As a result, continued physical activity using the 
injured tissue will exacerbate inflammation through additional exposure to both high 
and low force loading which culminates in a chronic inflammatory response 
previously described by Barr and Barbe (2004) in a workplace context. These authors 
and others have directly implicated the inflammatory response following soft tissue 
damage in the progression of cumulative-load injuries. This is due to the 
6 
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inflammatory response itself contributing to the reduction in the tissue tolerance 
threshold which subsequently reduces the maximal load point of the tissue during 
work (Barr and Barbe 2004; Cutlip et al. 2009).  
 
1.3.1 Acute inflammation 
Following overload injuries, an influx of leukocytes migrating from the blood 
to the injured tissue is often observed (Malm et al. 2000). This is characterised by an 
early invasion of Ly6C
+
/F4/80 - neutrophils which have been observed within 
damaged muscle as soon as 1 to 2 h after injury and can persist for up to 24 h 
(Tidball 1995; Belcastro et al. 1996). Shortly following neutrophil invasion there is 
an increase in the presence of macrophages which can persist for up to 10 days 
following injury (MacIntyre et al. 1995; Paulsen et al. 2009). The influx of 
leukocytes contributes to localised edema at the site of injury, along with capillary 
venous thrombosis, cellular swelling or venous compression (Napier et al. 2006). 
The swelling is further exacerbated by the production of various inflammatory 
stimulation factors excreted by these cells which drive the repair process. Although 
the particular inflammatory response depends a lot on the type of injury sustained, it 
would seem that initially a Th1 response to damage activates the M1 macrophage 
pathway in unison with mast-cell infiltration occurring within 24 h, resulting in a 
pro-inflammatory response (Stauber et al. 1990; Clarkson and Hubal 2002). 
 
1.3.2 Pro-inflammatory response to injury 
Historically macrophages have been seen as necrotic tissue scavengers, which 
populate the area in order to remove cellular debris so that tissue regeneration can 
commence at the site of injury. However, more recently the appearance of 
phenotypically distinct macrophage populations across a temporal time scale has 
been observed in recovering soft tissue (Tidball and Villalta 2010). This involves two 
distinct subpopulations of macrophages orchestrating the M1 and M2 responses. 
Initially CD68
+
/CD163
-
 macrophages inundate the wound area early, peaking at 24 h 
before rapidly decreasing in concentration (Ciciliot and Schiaffino 2010), their 
primary role is to remove debris. The CD68
+
 expressing macrophages seem to be 
highly specific of a pro-inflammatory M1 phenotype (Clarkson and Hubal 2002; 
 6 Chapter 1: Literature Review 
Paulsen et al. 2012). The increase in M1 macrophages is characterised by the 
augmented expression of pro-inflammatory cytokines, interleukin-6 (IL-6), 
interleukin-1 β (IL-1β), interferon-γ (IFNγ) and tumor necrosis factor-α (TNF-α) 
which appear early in order to initiate muscle cell lysis (Nguyen and Tidball 2003; 
Villalta et al. 2011). Interestingly, this early and consistent appearance of particular 
cytokines led to the discovery that both IL-6 and TNF-α are actively expressed by 
skeletal muscle tissue following damage (Steensberg et al. 2002), predominantly by 
myoblasts and myofibres (De Rossi et al. 2000; Collins and Grounds 2001). It is 
however, unclear whether the observed levels of these so-called ‗myokines‘ induce a 
macrophage response, or if such a response is actually due to the cytokines produced 
during the influx of neutrophils earlier on. Additionally, leukemia inhibitory factor 
(LIF) and hypoxia inducible factor (HIF-1β) have both been shown to increase 
following strenuous activity (Barnard et al. 1994; Malm et al. 2004; Dehne et al. 
2011). 
 
1.3.3 Anti-inflammatory response to injury 
The M1 response is attenuated by anti-inflammatory M2 macrophages, which 
typically exhibit the phenotypic presence of CD68
-
/CD163
+
. These macrophages are 
activated by IL-4, IL-10 and IL-13 to prevent inflammation and subsequent chronic 
damage to the tissue so that the repair processes can commence. M2 macrophages 
are present from around 2 to 8 days post acute injury (Tidball and Villalta 2010). 
Additional pro-fibrotic signalling appears to occur within the first week of acute 
strain injuries with TGF-β1 being detected 48 h following soft tissue strain injuries in 
rat gastrocnemius (Smith et al. 2007). Each of these pro/anti-inflammatory cytokines 
and myokines could be potential targets for early detection of potential soft tissue 
injuries in the workforce, except they can be endogenously produced by the body 
under different circumstances, thereby confounding their accurate interpretation.  
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1.4 INFLAMMATION PROMOTES TISSUE DEGRADATION WHICH 
COULD HAVE APPLICATIONS IN DIAGNOSING TISSUE DAMAGE 
The metalloproteinase family of zinc dependent endopeptidases have been 
shown to play a role in extracellular matrix homeostasis, along with injury repair and 
remodelling (Carmeli et al. 2004). Recently the temporal expression of matrix 
metalloproteinases (MMPs) has been illustrated in and around muscle cells. For 
instance MMP-9 has been shown to be up-regulated following a single bout of 
exercise (non-damaging), while MMP-2 and MMP-14 were elevated after 10 days 
following repeated bouts of exercise (Rullman et al. 2009). Along with MMP-2, -9 
and -14, skeletal muscle tissue also contains MMP-3 and -7 (Carmeli et al. 2004; 
Yamada et al. 2008). Typically MMPs are related to ECM remodelling during 
normal tissue turnover, however, it has been demonstrated in humans that collagen 
metabolism is significantly influenced directly following eccentric exercise (Moore 
et al. 2005) indicating that MMPs play a role post injury during the remodelling 
phase. 
 
Aside from MMP activity, other proteases may also be active following 
damage. The intracellular release of Ca
2+
 into skeletal muscle tissue has been well 
characterised following muscle damage in mice (Brotto and Nosek 1996; Lynch et 
al. 1997), and it is thought that this early release of Ca
2+
 into skeletal muscle tissue is 
a result of sarcolemmal ruptures. This has subsequently been shown to up-regulate 
calcium dependent proteases, notably calpain activity in human quadriceps following 
eccentric muscle damage (Raastad et al. 2010). An increase in Ca
2+
 mediated protein 
degradation via calpain correlates with the invasion of neutrophils following exercise 
induced damage (Raj et al. 1998). This suggests that protein degradation products act 
as damage associated molecular patterns (DAMPS) which attract these neutrophils to 
the site of injury. 
 
1.5 UBIQUITIN PATHWAY 
Several studies have demonstrated an increase in various heatshock proteins 
(HSP) following soft tissue stress and damage which are detectable 1 - 14 days 
following exercise, particularly in skeletal muscle (Khassaf et al. 2001; Thompson et 
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al. 2001; Feasson et al. 2002; Thompson et al. 2002; Thompson et al. 2003; Morton 
et al. 2006; Paulsen et al. 2009). It is hypothesised that this response serves to 
stabilise damaged cells against further assaults, and that they may assist with protein 
refolding after the cell has stabilised. However, it is also known that particular HSPs 
act as DAMPS which consequently initiates the innate inflammatory machinery 
discussed earlier (Battista 2011). Under normal conditions HSPs play an important 
housekeeping role as chaperones in undamaged cells (Fehrenbach and Niess 1999; 
Fehrenbach and Northoff 2001; Morton et al. 2009). Ubiquitin is the smallest of the 
family of HSPs and is of particular interest as it is part of the ubiquitin proteasomal 
pathway which requires the covalent attachment of multiple ubiquitin moieties to 
proteins marking them for proteasomal degradation (Glickman and Ciechanover 
2002).  
 
A range of HSP were shown to increase in response to muscle damage. 
Thompson et al. (2001) has shown HSP27 increases 2 fold following damage to 
biceps (Thompson et al. 2001; Thompson et al. 2002; Thompson et al. 2003). Others 
have measured mRNA expression in muscle tissue following eccentric exercise and 
found a number of genes involved in the ubiquitin-proteasomal degradation system 
expressed in higher amounts, in particular ubiquitin splice form variant 1 was up 
regulated in the first 24 h after eccentric muscle actions (Nedergaard et al. 2007). 
Additionally, increased ubiquitin mRNA and protein levels have been reported 
following eccentric muscle damage protocols (Thompson and Scordilis 1994; 
Willoughby et al. 2002; Willoughby et al. 2003). Research at a protein level found 
that proteasome peptidase activity also increased substantially in muscle tissue as a 
result of mechanically injured human skeletal muscle (Seiffert et al. 2007) and 
repeated swimming bouts in rats (Radak et al. 1999).  
 
From these data, one can confidently deduce that soft tissue injury initiates 
complex tissue degradation pathways involving enzyme mediated protein cleavage 
events, which in-turn signal an innate inflammatory response resulting in further 
degradation. Prognostic and diagnostic targeting of such degradation products may 
provide greater sensitivity in work-related soft tissue injuries. 
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1.6 POTENTIAL POST-TRANSLATIONAL MODIFICATION TARGETS 
DUE TO OXIDATIVE STRESS COULD BE USED TO ASSESS 
PHYSICAL ACTIVITY 
Skeletal muscle is a metabolically active tissue. As such its protein constituents 
are prone to damage through oxidative stress and oxidative damage (Gomez-Cabrera 
et al. 2010). Oxidatively modified proteins have a propensity to lose their 
physiological activity and may as a consequence be sensitive to digestion by 
endogenous proteases (Tetik et al.; Stadtman and Oliver 1991). Such modifications 
consist of carbonylation which occurs through the oxidation of proline, arginine, 
lysine and threonine residues, or reaction of cysteine, lysine and histidine residues 
with aldehydes or other reactive carbonyl species (Dalle-Donne et al. 2003; 
Stadtman and Levine 2006). Others have demonstrated an augmented superoxide 
release response from within the muscle into the extracellular space which is 
accompanied by a reversible oxidation of muscle protein thiols (Freeman et al. 1995; 
McDuffee et al. 1997). Such adaptations in carbonyl derivatives have been reported 
previously using western blot analysis of rat gastrocnemius muscle tissue following a 
series of 60+ min daily bouts of swimming over a period of 9 weeks (Radak et al. 
1999). Endurance studies have also illustrated an increase in protein carbonyls 
measured by ELISA within the blood of resistance trained men (Bloomer et al. 
2007). Factors influencing the rate of protein modification due to oxidative stress 
depend on the rate of protein degradation and the degree of oxidative stress (Radak et 
al. 1999). Such modifications might be present in the muscle of workers from the 
heavy labour industries where prolonged and repeated physical activity is involved.  
 
These oxidative modifications to proteins may come about due to the 
increased presence of metabolic by-products produced during physical exertion, or 
they may come from an oxidative burst which contributes to secondary injury 
following initial invasion by neutrophils and macrophages (Toumi et al. 2006; 
Vasilaki et al. 2006). Neutrophils lyse muscle cell membranes, presumably to begin 
the repair process by removing unusable cellular debris. This occurs via a superoxide 
dependent mechanism (Tidball 2005), hence with the invasion of neutrophils there is 
an assorted increase in superoxides which have been shown to increase muscle cell 
lysis in rodents (Nguyen and Tidball 2003). Superoxides can be converted readily 
into a stronger oxidizing agent, hydrogen peroxide, which has the ability to induce 
 10 Chapter 1: Literature Review 
lipid peroxidation, causing degradation to polyunsaturated lipids which can cause the 
subsequent rupture to cell membranes (Hampton et al. 1998). The oxidation of 
polyunsaturated lipids results in the reactive electrophile bi-product, 
malondialdehyde (MDA), which is commonly used as an indicator of oxidative stress 
(Pryor and Stanley 1975; Moore and Roberts 1998). Hydrogen peroxide can 
naturally be converted in vivo into hydroxyl radicals or under enzymatic conditions 
to hypochlorous acid by myeloperoxidase, a hemeoxido-reductase which is increased 
within one hour of eccentric exercise (Hirose et al. 2004). Clearly muscle tissue is 
under oxidative assault due to normal homeostasis during high energy tasks and as a 
result of muscle damage. Such an environment may lend itself to an increased 
incidence of oxidatively modified proteins and subsequently, an increase in protein 
digestion due to an oxidation event. As is the case with protein degradation products, 
these post-translational modification events may provide additional routes for 
diagnostic targets of muscle damage within the workforce. 
 
1.7 JUSTIFICATION FOR A BIOMARKER APPROACH 
The importance of objectively diagnosing MSD through tissue pathology has 
been discussed previously as a complementary means of corroborating a patient‘s 
injury status in conjunction with self reported symptoms (Forde et al. 2002). This 
presents a welcome change to the conventional clinical diagnosis which relies on 
subjective interpretation by a medical practitioner (Punnett and Wegman 2004). 
However, this approach only addresses pathological state and not progression, or 
recovery, of injured tissues and can become cumbersome if an appointment with a 
physician is required for each potentially injured worker. That is, diagnostic efficacy 
may be increased while neglecting potential prognostic outcomes, all at considerable 
time and monetary cost to the patient. While this may be a shift in the right direction, 
what might be more beneficial is an approach that acknowledges the requirement for 
more longitudinal data relating to the progression/onset and subsequent repair of 
MSDs. With this in mind, analyses that provide both qualitative and quantitative data 
on the pathological mechanisms involved with the onset and recovery of these 
conditions have been investigated (see Table 1.1). As such there is mounting 
evidence for proteins and small molecules involved with various exercise-related soft 
tissue pathologies, injuries and repair pathways (Table 1.1). Nevertheless, several 
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problems still need to be overcome if they are to be used in a workplace context; 
these relate to sample collection and biomarker specificity for regular monitoring.  
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Table 1.1 
Human soft tissue damage phenotypes and common biomarkers due to various physical stressors 
Exercise Intensity Muscle group Altering cellular components Tissue sample Timeframe investigated and 
general notes 
Reference 
Concentric and 
Eccentric actions 
Mild-intense Biceps brachii ↑ α1-antichymotrypsin 
↑ C-1 protease inhibitor 
↑ CK 
↑ Mb 
↑ LDH 
↑ AST 
Blood Temporal changes up to 72 h post damage (Sietsema et al. 2010) 
45 min up hill and 
downhill running  
Mild-intense Legs ↑ CK in downhill runners 
↑ Cortisol 
↑ Testosterone 
Between-group differences in CD11b, 
LIF, HIF -1β, CD3 
↑ blood Leukocytes (all) 
↑ Granulocytes (all) 
MESF CD45: ↑ CD62L on CD3+, CD4+ 
and CD8+ cells 
Lymphocytes: ↑ CD3+, ↑ CD3+/CD4+,  
↑ CD3+/CD8+ cells 
Muscle, epimysium 
biopsies and serum samples 
Temporal changes up to 7 days post 
exercise were investigated 
(Malm et al. 2004) 
  Legs ↑ CD11b (neutrophils) 
↑ CD163 (macrophages) 
↑ CD56 antigens in muscle 
↑ IL-1β 
↑ IL-1α 
 Markers might be due to previous muscle 
biopsies (refer to discussion in (Malm et 
al. 2004)) 
(Malm et al. 2000) 
Eccentric forearm 
actions 
Intense Biceps Brachii ↑ Mb 
↑ CK 
↑ G-CSF 
↓ TNF-α 
↓ IL-8 
↑ IL-10 after second bout of exercise 
Blood 4 day test period (Hirose et al. 2004) 
Eccentric knee 
extension 
Intense Quadriceps ↑ Tenascin-C 
↑ PIIINP 
↑ Calpain activity 
Muscle biopsies 7 day study. (Raastad et al. 2010) 
Eccentric 
contractions 
Intense Biceps Brachii ↑ LDH 
↑ CK 
↑ Leukocytes, Eosinophils, Neutrophils, 
Lymphocytes and Monocytes. 
Blood 4 day study (Milias et al. 2005) 
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↑ C3 
↑ PAF 
Eccentric 
contractions 
Intense Quadriceps ↑ GH 
↓ C3bc 
↓ TCC 
↑ CRP 
↑ CK 
↑ MCP-1 
↑ followed by significant ↓ from baseline 
levels of M-CSF 
↑ G-CSF 
↑ IL-6 
Blood 7 day study. (Paulsen et al. 2005) 
Treadmill exercise Moderate Legs ↑ Endostatin 
↓ VEGF 
Blood 6 hours (Gu et al. 2004) 
Eccentric/concentric 
Knee flexion 
Intense Hamstrings ↓ sIL-6R 
↑ CK 
Blood 4 day study (Robson-Ansley et al. 
2010) 
5 km run Moderate but 
prolonged 
exercise 
Legs ↑ IL-6 
↑ Hepcidin 
Blood 24 h study (Robson-Ansley et al. 
2011) 
Range of concentric 
and eccentric 
muscle contractions 
Moderate Musculi lateralis and 
trapezius 
↑ HSP27 
↑ HSP70 
↑ αB-crystallin 
Skeletal muscle biopsy 11 week period. Sampling did not occur at 
regular intervals 
(Paulsen et al. 2011) 
Downhill running Moderate to 
intense 
Legs ↑ MCH 
↑ sTnI 
↑ Mb 
↑ CK  
Blood 24 h study (Sorichter et al. 2001) 
Aerobic sprints Moderate Whole body ↑ 2-Hydroxyisovalerate 
↑ 2-Hydroxybutyrate 
↑ 2-Oxoisocaproate 
↑ 3-Hydroxyisobutyrate 
↑ 3-Methyl-2-oxovalerate 
↑ 2-Oxoisovalerate 
↑ Lactate 
↑ Alanine 
↓ Pyruvate 
↑ Citrate 
↑ 2-Oxoglutarate 
↓ Trimethylamine N-oxide 
↑ Glycine 
↑ Fumarate 
↑ Tryptophan 
↓ Hypoxanthine 
↑ Formate 
Urine Fluctuations in metabolites was made 
between two different exercise groups and 
not an exercise and control group or 
exercise and baseline groups.  
(Pechlivanis et al. 2010) 
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↓ Histidine 
Interval training Intense Whole body  ↑ 6-phosphofructokinase  
↓ Aconitase hydratase 
↑ Actin, aortic smooth 
↑ Muscle 
ATP synthase 
subunit a 
↑ ATP synthase 
subunit b 
↑ Desmin 
↑ Elongation factor 1-a 
↑ Heat shock 70 kDa 
protein 1 
↑ Heat shock cognate 
71 kDa protein 
↑ Myotilin 
↑ NADH dehydrogenase 
[ubiquinone] 
flavoprotein 1 
↑ Phosphoglucomutase 1 
Protein-arginine 
↑ deiminase type 2 
↓ Pyruvate kinase 
isozymes M1/M2 
↑ Serum albumin 
↑ Succinate dehydrogenase 
[ubiquinone] 
flavoprotein 
subunit 
↑ Trifunctional enzyme 
subunit a 
↓ Tubulin a-4A chain 
↑ Very long-chain 
specific acyl-CoA 
dehydrogenase 
Muscle biopsies Duration was over 6 weeks with 3 
sessions per week comprised of 1 min 
intensive bouts at 90-100% V O2max 
separated by 4 min at 50% V O2max. 
Expression levels are relative to baseline 
levels in a 2D gel / iTRAQ labelled MS
2
 
experiment. The changes in muscle 
proteins reflect muscular adaptation and 
not injury or recovery in this case. 
(Holloway et al. 2009) 
LIF = Leukemia inhibitory factor, HIF = hypoxia inducible factor 1 beta, Mb = Myoglobin, G-CFS = Granulocyte colony stimulating factor, CD = Cluster of Differentiation, 
NK = Natural Killer, PIIINP = N-terminal propeptide of procollagen type III, C3 = complement 3 PAF = Platlet activating factory MCP-1 = Monocyte chemoattractant 
protein-1 M-CSF = macrophage colony-stimulating factor MIP1-beta = macrophage inflammatory protein-1 beta, C3bc = complement activation products, TCC = Terminal 
complement complex, sIL-6R = Soluble interleukin-6 receptor, MHC = Myosin heavy chain fragments, sTnI = Skeletal troponin I
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1.8 DIRECT AND INDIRECT MARKERS 
Direct markers originate from the damaged tissue itself and provide 
information on irregular anabolic or catabolic activities within the tissue under 
investigation. Indirect markers on the other hand may be components that are not 
necessarily derived from the tissue itself, but are involved with its metabolism or 
homeostasis. These are generally systemic, and as such, can be found within multiple 
systems in the body. 
 
1.8.1 Indirect biomolecules of physical exertion or tissue damage 
Indirect indicators such as C-reactive protein (CRP), IL-1β, tumour necrosis 
TNF-α and IL-6 have been described as potential markers of MSD. This was due to a 
strong correlation found between upper extremity overuse disorders and serum levels 
of CRP, while IL-1β, TNF-α, and IL-6 displayed moderate correlations (Carp et al. 
2007). IL-6 was also found to be elevated following a series of muscle contraction-
based studies, while α-actin significantly increases within the plasma of individuals 
who had sustained musculoskeletal damage (Febbraio and Pedersen 2005; Amat et 
al. 2007). Furthermore, serum levels of lactate dehydrogenase (LDH), an enzyme 
that converts lactate to pyruvate under anaerobic conditions, has been used as an 
indirect indicator of MSD (Paschalis et al. 2007). Ubiquitinylation and sumoylation 
have also been discussed as potential indirect biomarkers, particularly in 
musculoskeletal injury based studies (Lammi et al. 2006). Ubiquitin plays a key role 
in targeted protein degradation as discussed above (Dahlmann 2005) and may 
provide insight into the onset of musculoskeletal tissue degradation (Ordway et al. 
2000; Lammi et al. 2006). Various oxidative stress biomarkers have also been 
discussed in the literature in studies looking at athletes (Yan et al. 2009), and have 
been suggested for applications to workers, which due to their lack of tissue 
specificity can be considered indirect indicators of physical exertion (Lu et al. 2006; 
Mignini et al. 2008; Pan et al. 2008). 
 
A more current marker present at elevated levels in a cohort of active mining 
workers compared to sedentary workers was the C-terminal bioactive proteolytic 
fragment of endorepellin, called Laminin G-like Domain 3 or ‗LG3‘ (Parker et al. 
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2012). Interestingly, endorepellin is the C-terminal active peptide of a larger protein 
called perlecan which is a high abundant ECM constituent of basement membranes, 
with particular prevalence in articular cartilage and neuromuscular junctions and all 
basement membranes (Hassell et al. 1980; Bayne et al. 1984; SundarRaj et al. 1995). 
Although research is still being conducted to identify the source of this protein, what 
is promising about this discovery is its appearance in urine, making it applicable to a 
range of exercise related biological problems. 
 
1.8.2 Direct biomolecules of physical exertion or tissue damage 
The biomarkers discussed above can be considered as indirect biomarkers of 
musculoskeletal injury as they are utilised by many different systems within the 
body, not just within musculoskeletal tissues. However, there have been attempts to 
investigate direct markers. In serum, type-1 collagen markers carboxyterminal 
propeptide (PICP) and carboxyterminal telopeptide (CTx) have been used to monitor 
the influence of load bearing exercise on the body (Langberg et al. 2000). In 
addition, these two markers have been used to compare the physical exertion of 
construction workers to that of sedentary workers. It was found that alterations in 
serum concentrations of PICP and CTx appeared to be related to heavy physical 
work. However, the authors comment that further validation was still required 
(Kuiper et al. 2005). Elevated blood levels of myoglobin (Mb), the oxygen 
transporting protein found specifically in muscle cells, has also been discussed as a 
possible indicator of MSD (Santos et al. 2006). Another common marker used to 
indicate muscle damage is creatine kinase (CK) which is involved with the regulation 
of intracellular ATP levels, particularly in tissues with high energy demands 
(Lazarim et al. 2009). When muscle tissue is compromised the CK can ‗leak‘ from 
muscle cells into the circulation. CK is also tissue specific, resulting in isoforms from 
cardiac muscle, brain tissue and skeletal specific CK (CK-MM). This direct marker 
has been used extensively to indicate the presence or absence of muscle damage. The 
only caveat over the use of this marker is the requirement for an invasive blood 
sample which is not appropriate for a work-related situation.  
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1.9 URINE AS A MEDIUM FOR BIOMARKER ANALYSIS: 
Others have used serum and synovial fluid to assess soft tissue damage 
(Lohmander 1991; Zivanovic et al. 2009), however, the key disadvantage with such 
samples is the invasive nature in which they need to be collected. In addition, serum 
analyte concentrations (protein/metabolite) have a large dynamic range (protein = 
approx. 14 orders of magnitude) which can hamper the discovery of useful 
biomolecular markers (Schiess et al. 2009). Furthermore, justifying the use of serum 
markers for application in a workplace scenario is less than ideal as it would mean 
that invasive blood samples would be required for monitoring of musculoskeletal 
health. This is sure to cause concern amongst workers, as well as slowing down 
productivity. As such, other biological fluids need to be investigated. 
 
Based on the evidence reviewed thus far, it is becoming clear that small 
proteins, along with potential degraded, cleaved or modified protein products, are 
capable of entering the blood-stream from the interstitial environment following soft 
tissue damage (Liotta et al. 2003). They are then circulated to the kidney and have 
the ability to pass through the glomerular filtration process into the urine (Camici 
2005). The reported incidence of muscle damage mediating the onset of 
rhabdomyolosis also supports the hypothesis that proteins originating from muscle 
tissue make it to the kidney (Clarkson et al. 2005); albeit this is an extreme case and 
is not typical of a physical activity model, but rather a traumatic crush injury. This 
excreted low molecular weight (LMW) fraction of urinary protein is thought to 
contain substantial amounts of valuable diagnostic and potential prognostic 
information (Liotta et al. 2003). 
 
Although serum-derived biomarker candidates have been examined in relation 
to tissue damage and fatigue in athletes, few validated biomarkers currently exist to 
monitor the effects of physical load and soft tissue damage in workers (Petibois et al. 
2002). Urine samples are routinely used for drug and alcohol examination in the 
workplace and because they are not invasive to collect like blood samples, workers 
are more willing to provide them for routine testing. Furthermore, due to several key 
urinary proteomic studies, the diverse range of proteins and polypeptides which are 
filtered into the urine by the kidneys is now becoming clear. These include 
extracellular, plasma membrane and lysosomal proteins, along with an abundance of 
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soft tissue-specific polypeptides (Adachi et al. 2006; Li et al. 2010; Marimuthu et al. 
2011; Nagaraj and Mann 2011). 
 
The potential use of urine for biomarker discovery has proven promising in 
the past (Kemna et al. 2005; Wittke et al. 2005). Briefly, within each kidney there 
are around one million nephrons which carry out the blood processing requirements 
of the organism. Each nephron consists of a structure called the glomerular apparatus 
which selectively filters proteins and peptides into the urine from the adjacent blood 
source (Boeniger et al. 1993) in a manner that favours the filtering of low to medium 
molecular weight (MW) constituents (D'Amico and Bazzi 2003). Once past the 
glomerular barrier the protein components travel through a series of tubules 
(proximal convoluted tubule, loop of Henle and distal convoluted tubule) where 
some are resorbed back into the body, while those that are not are excreted into a 
collecting duct. Thus the cumulative microtrauma of musculoskeletal structures due 
to over-exertion leads to protein degradation and metabolite accumulation which 
may be excreted via the kidney, into the urine. As such, these proteins and peptides 
should be detectable using modern analytical profiling strategies. Moreover, this 
illustrates the potential for the use of urine as a source of proteins and peptides, as 
healthy individuals excrete up to 150 mg of protein into urine over a 24 h period 
(Kost 2002). It is therefore possible that the biomolecular components of urine will 
reflect the natural homeostatic balance of soft tissue turnover during a tissue loading 
scenario such as those seen in heavy labour industries. 
 
1.10 WHAT MAKES A GOOD DIAGNOSTIC BIOMARKER 
It is important to remember there are many modes of assessing disease 
pathology using biochemical or biomolecular markers; and there are pros and cons 
associated with each. However, the overarching rationale relates to the ability to 
correctly identify those who have the disease (sensitivity). The following is an 
interpretation of potentially important factors in the development of a biochemical 
marker for detection of degradative soft tissue pathologies. 
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1.10.1 Characteristics of a good diagnostic 
Based on the previous literature regarding biomarkers and their applications 
(BDWG 2001; Frank and Hargreaves 2003; Kimball et al. 2004; Baker 2005; 
Salanova et al. 2008) the following criteria were determined to be important. 
1) A marker should reflect the physiology of the tissue and thus be sensitive to 
changes in the underlaying biology. 
 
2) The early detection of a biomarker is always preferential than later 
detection in order to stem the pathology of the disease/disorder under 
investigation. In this case early detection of soft tissue damage, i.e. the 
cumulative microtrauma, may bypass tissue failure completely. 
 
3) The presence or absence of a molecule to diagnose a disease will always 
provide greater disease sensitivity than assessing temporally changing 
levels of a marker that is present both before and after injury. 
 
4) High priority biochemical markers are those in which their metabolism is 
directly and impartially involved within the physiological process or 
disease state under investigation. This includes both tissue-specific markers 
and endogenous proteins that contain disease pathology-specific post 
translational modifications. Theoretically these markers should provide 
similar disease sensitivity to those in observation 3 above. 
 
5) Low priority biochemical markers are those that are involved in multiple 
pathways within multiple tissue types. Diagnostic markers of this type 
require panels of markers to be assayed to gain the same disease sensitivity 
as a single marker from observation 3 or 4. However, using this type of 
marker in conjunction with one of the specific markers (observations 3 and 
4) above might prove beneficial in the determination of a particular disease 
pathology and may provide additional prognostic information. This kind of 
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marker includes factors like inflammatory cytokines which can come about 
due to any number of environmental or endogenous causes. 
 
1.10.2 Additional considerations in biomarker development 
Disease sensitivity and specificity are important considerations regarding 
biochemical markers. However, it is also important to bear in mind practical aspects 
relating to biomarker measurement as follows. 
1) An ideal urinary biochemical marker should not have a fast clearance rate. 
If clearance of the biomolecule is too fast, the window in which a diagnosis 
needs to be made becomes small, hence making an accurate diagnosis 
difficult. 
 
2) Ideally inter-laboratory detection coefficients of variation should be as low 
as possible to ensure accurate measurement of the marker. 
 
3) Biochemical markers that come under observation 3 and 4 (in section 
1.10.1) should always be prioritised as they are likely to be commercially 
cheaper to produce due to a smaller number of (possibly one) disease-
specific biochemical targets which will result in similar specificity to a 
panel of low priority markers. 
 
4) Ideally a biochemical marker should involve relatively little sample 
preparation, and the platform used to assay it, should be one of a high 
throughput nature. 
 
5) Assay platform dependency: A biomarker means very little if it cannot be 
reliably measured. As such, the final mode of analysis (i.e. type of assay) 
should be carefully considered. 
 
6) The costs of final assay should be minimal. 
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7) Orthongonal information: Ideally the selection of biomarkers carried 
through to clinical application should carry independent information, i.e. 
not be highly correlated with other variables. 
 
1.11 BIOMOLECULAR PROFILING 
The ‗omics‘ paradigm came about due to the need for technologies that were 
capable of addressing the inherent complexity of biology. The term ‗omics‘, 
incorporates genomics which relates to the study of genes within particular 
organisms and pathologies. Transcriptomics, investigates the expression levels of 
mRNAs derived from specific genes, proteomics focuses on the comprehensive study 
of gene products and their structure and function. Metabolomics on the other hand 
investigates small molecules produced by a system, the premise being that these 
metabolite signals will be an amplification of the activity which occurs at the 
proteome level, and thus changes should be more distinct than that seen at the protein 
level. Glycomics involves the sudy of free or complex sugars within a system. 
Finally, a relatively new field is ‗fluxomics‘, which looks at the dynamic nature of 
multiple molecules through a metabolic pathway per unit cell mass per unit time 
(Wiechert et al. 2007). Each of these fields contributes to the understanding of 
biology, and the integration of information from each one or several of these sources 
is commonly referred to as systems biology and provides a comprehensive insight 
into a biological system. 
 
1.11.1 Proteomics 
Proteomics has corresponded with a technologically advancing period in 
biology, incorporating the genomic era and coinciding with an increase in the 
computer processing power required for these complex analyses. The human genome 
provides a blueprint for protein products that can be estimated and eventually 
predicted from the genome databases. However, it is clear that the number of genes 
does not coincide with the number of gene products observed. The combined 
evolution of gene and protein sequence databases and increased computing power 
has brought about the introduction of peptide sequence database searching. Such 
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advances meant that predicted protein sequence data could be proteolytically 
digested in-silico using the same enzymes and experimental conditions as those 
observed in the laboratory. From this, a theoretical spectrum can be computed and 
compared to the mass spectra produced experimentally. This is a common procedure 
in proteomics and is known as peptide mass fingerprinting (PMF), the outcome of 
which is identification of multiple proteins within a biological system. 
 
1.11.2 Bottom-up proteomics 
So called ‗bottom-up‘ proteomics involves the analysis of peptide fragments 
from larger protein structures followed by in-silico protein reconstruction of the 
peptide mass sprectra to determine the original protein identity. Bottom-up 
proteomics is an efficient gel free method for protein identification and quantification 
in complex biological samples. These approaches require that the proteins in a 
sample be proteolytically digested, as described above, in order to make sequencing 
of the protein in the sample easier to analyse on a mass spectrometer and therefore 
easier to interpret. Typically sequencing grade trypsin is used due to its specificity to 
cleave amino acid sequences (i.e. proteins) after lysine and arginine residues, thereby 
resulting in a pool of small peptides, also called tryptic peptides, that originated from 
a particular protein. The complex tryptic peptides are then separated through liquid 
chromatrography (LC); usually a one dimensional approach is taken in which a 
separation occurs across a single reverse phase (RP) column. However, 
multidimensional applications are common whereby the mixture is initially separated 
using a particular stationary phase chemistry, for example strong cation exchange 
(SCX), followed by a complementary separation technique such as RP to further 
reduce the complexity, thus increasing the range of ions the mass spectrometer (MS) 
can detect. Both arginine and lysine share a common characteristic in that their side 
chains retain a positive charge at neutral pH. This characteristic can be exploited by 
mass spectrometers because these particular residues will remain positively charged 
in buffers at neutral through to acidic pH ranges. Due to this positive peptide charge, 
their gas phase characteristics can be manipulated and measured through a mass 
spectrometer under a vacuous atmophere. 
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1.11.3 Top-down proteomics 
It is evident from the ‗bottom-up‘ proteomic approach that the complex protein 
mixture is first degraded enzymatically, thus removing information pertaining to its 
original structure, for example its original size. A key disadvantage with such an 
approach is the discontinuous nature of the identification. As such, these protein 
identities can only be inferred by applying protein identification algorithms to solve 
the peptide to protein identification problem. An additional problem with this 
approach is that subsets of proteins may carry a modification on a particular moiety 
within a sample, and such information can not be easily deduced using a bottom-up 
proteomic approach (Chait 2006). An alternate methodological workflow within 
proteomics that negates some of these problems is termed ‗top-down‘ analysis. Top-
down proteomics investigates the native protein/polypeptide and lets the mass 
spectrometer fragment the molecule. While this removes the disconnection between 
peptide identifications and their parent protein, the molecule does not respond 
particularly well to traditional fragmentation methods such as collision induced 
dissociation (CID) which is common in bottom-up proteomics studies. Typically 
identification-based mass spectrometry in top-down proteomics requires less 
common fragmentation cells be incorporated into the MS. Common fragmentation 
methods in top-down proteomics are electron-capture-dissociation (ECD) and 
variations on the theme, such as activated-ion ECD (AI-ECD). Another common 
fragmentation method for proteins is electron transfer dissociation (ETD) which 
produces fragment ions that have a lower propensity to lose labile post translational 
modifications (PTM), e.g. phosophorylations and glycosylations. Cui et al. (2011) 
provide a current review of top-down methodologies and their applications within 
proteomics (Cui et al. 2011). 
 
One of the cruicial caveats of the previous top-down workflows is the 
requirement for specific and advanced mass spectrometry platforms. Another 
approach commonly adopted in top-down studies involves fingerprinting or profiling 
the biomolecular components and deducing their identity later. Profiling strategies 
for discovery phase biochemical analysis are popular methods for initial examination 
of a biological system (Svensson et al. 2006). Such profiling strategies also extend to 
the analysis of other biomolecules and not just proteins (Thysell et al. 2007). A 
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typical experiment requires the use of an instrument working under a single 
dimension of analysis to acquire a fingerprint which represents the underlying 
biology. For example, mass spectrometric analysis using only the survey scan data 
(MS
1
), such as that seen with the surface enhanced laser desorption ionisation mass 
spectrometers (SELDI-TOF/MS), will produce a glimpse of the underlaying biology 
at that point in time. Another example of a profiling method common to 
metabolomic analysis is Nuclear Magnetic Resonance spectroscopy (NMR) analyses 
which will also provide a fingerprint of the sample which can later be explored using 
statistical methods that assess each of the molecular components contributing to the 
profile together; these are termed multivariate analysis methods. 
 
1.12 SUMMARY AND RATIONALE: 
WR-MSDs pose considerable health and economic problems to individual 
workers, employers, the workplace compensation scheme, government and the 
economy. WR-MSDs can affect multiple soft-tissue structures, however, it is known 
that certain manual tasks can bring about the onset of soft tissue damage resulting in 
acute and chronic symptoms. Severe types of tissue damage results in ultrastructural 
events that lead to the incidence of injury, which is observed as an acute failure or at 
minimum, a disturbance in mobility at or around the particular injury site. Clearly 
various protein structures are affected during the soft tissue damage process and 
throughout the regeneration process. Perhaps it is therefore possible to detect 
fluctuations in these proteins, degradation products or metabolites prior to the acute 
perception of injury. If so, how are these metabolic by-products phenotypically 
present during injury and following repair of soft tissue itself? This information in 
regards to work-related injuries appears to be limited, despite what is already known 
about the cellular mechanisms of injury and repair. To accommodate these 
knowledge gaps, comprehensive studies designed to monitor the potential 
biomarkers prior to injury and following recovery are required to provide more 
clinically relevant outcomes. Only through development of our understanding of 
these stages can the introduction of a prognostic approach towards management of 
work-related MSDs take place. As such, biomarker analysis across multiple time-
points will improve our understanding of the presence of molecular degradation 
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products due to soft tissue injury and would appear to hold particular promise for 
discovery of a diagnostic.  
 
Current research indicates that some of the intricate protein structures found 
in a variety of soft tissues are degraded as a result of strenuous exercise or as a result 
of overuse. Such soft tissue constituents leak into the pericellular space were they 
eventually dissipate into circulation. While there have been many studies which have 
attempted to identify the protein components in urine, to date, we are yet to find 
evidence of investigations interested in isolating biochemicals that are present as a 
result of overexertion factors. 
 
Previous research on the topic indicates that the manifestation of WR-MSDs 
involve many factors (Punnett and Wegman 2004). With this in mind, the 
momentum gained through the identification of single markers is now being re-
directed to techniques that enable investigation of multiple markers. The combination 
of multiple markers to assess a given trait affords a far more powerful approach with 
an increased ability to discriminate between experimental subgroups (e.g. diseased 
from control). Thus urine combined with biochemical profiling strategies might have 
potential to identify biochemical markers that are present due to soft-tissue damage, 
which will aid in a greater understanding of the pathomechanisms of muscle injury, 
along with repair, and their relationship to the onset and incidence of WR-MSDs. 
Such markers may also have applications for athletes to assist in the determination of 
overuse/over training injuries.  
 
1.13 HYPOTHESIS AND AIMS 
The specific aims of this project were tailored to answer the hypothesis that 
during the onset of injury or an innate-inflammatory response due to injury, 
degradation products including endogenous protein fragments or metabolites, will be 
present within urine at levels that can be measured with current analytical 
instruments. In light of this hypothesis the broader aim of this PhD project was to 
establish if proteins and metabolites from soft tissue damage appear within urine, and 
if so, what they are. To this end several aims were persued. These included:  
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1. Implementing a strategy to bring the body into a soft tissue repair state. This 
was accomplished by: 
a. Producing soft tissue damage in an in-vivo model. 
b. Validating that soft tissue damage had occurred. 
c. Measuring and recording the functional effects of soft tissue damage. 
d. Addressing the benefits and limitations of this model. 
e. Collecting urine and blood samples for biochemical profiling. 
 
2. Investigating one dimensional biomolecular profiling strategies in order to 
obtain a fingerprint of the underlying biology. This was accomplished by: 
a. Optimising a protein and metabolite fractionation protocol. 
b. Investigating the use of one dimensional Nuclear Magnetic Resonance 
Spectroscopy (
1
H-NMR) for analysis of the urinary metabolome. 
c. SELDI-TOF/MS was also used to profile the ~2-20 kDa proteome 
region. 
 
3. Applying multivariate analysis techniques to investigate potential patterns of 
markers by: 
a. Using classical statistical approaches. 
b. Using current classification methodologies. 
c. Applying dimension reduction and exploratory analysis 
methodologies. 
 
4.  Characterising protein samples using current tandem mass spectrometry (LC-
MS/MS) technologies and relevant label-free quantification technologies. 
This was accomplished by: 
a. Fragmentation and analysis of urinary proteins using an ABSciex 
Hybrid Quadrupole tripleTOF™ 5600. 
b. Incorperating an open-source tandem mass spectrometry analysis 
pipeline to assign high quality protein identifications. 
c. Using Gene Ontology (GO) analyses to assess molecular functions 
and cellular component characteristics of proteins. 
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d. Applying label-free analysis strategies to discern relative protein 
abundance across the damage and healing stages. 
 
5. Applying mass spectrometry validation strategies to a potential candidate 
biomarker by: 
a. Developing a novel Selected Reaction Monitoring (SRM) assay. 
b. Assessing the presence of a previously identified marker of interest, 
LG3, in the eccentric damage/recovery model. 
 
Chapter 2: Characterisation of an In vivo Soft Tissue Damage Model 29 
Chapter 2: Characterisation of an In vivo 
Soft Tissue Damage Model 
2.1 INTRODUCTION 
To assess the presence of soft tissue constituents in human urine it was first 
necessary to induce soft tissue damage and to verify injury post induction. The soft 
tissue damage induction model is a crucial component of this research program, 
given the overall goal was to investigate the proof of concept that biomolecules from 
moderate soft tissue injury can be detected within urine. Due to difficulties with 
monitoring muscle, ligament and tendon loads in a work environment an alternate 
strategy was required. As such, a controlled method of tissue damage was adopted; 
the key advantage with this approach was that: 
 
1) Functional data could be obtained during the damaging actions, to 
provide additional evidence that damage had occured. 
2) Specific damage protocols known to cause optimal amounts of tissue 
damage could be employed. 
3) The primary muscle group involved with the damaging procedure could 
be specifically isolated, a task which is otherwise difficult in untrained 
workers. 
4) As specific muscle groups could be damaged in isolation, the detection 
of potential soft tissue damage biomolecules from other muscle groups 
within the body could be controlled.  
 
Based on these criteria, damage was induced using eccentric muscle actions as 
these have a tendancy to produce a greater severity of soft tissue damage compared 
to other contraction types (Newham et al. 1983). Furthermore eccentric loading is 
typically experienced in workplace environments that require heavy lifting (Hsiang 
et al. 1997). Such tissue damage will cause immediate inflammation and reduction in 
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controlled limb locomotion. Additionally this injury model will promote a post injury 
recovery phase consistent with over-exertion injuries in heavy labour industries. 
 
Typically in soft tissue damage models, panels of blood markers are also 
considered to determine the severity of damage. To reiterate from Chapter 1, serum 
levels of LDH, an enzyme that converts lactate to pyruvate under anaerobic 
conditions within cells, has been used as an indirect indicator of MSD (Paschalis et 
al. 2007). In addition, elevated blood levels of Mb, the oxygen transporting protein 
found specifically in muscle cells, has also been discussed as a possible indicator of 
MSD (Santos et al. 2006). Another common marker used to indicate muscle damage 
is CK which is involved with the regulation of intracellular ATP levels, particularly 
in tissues with high energy demands such as skeletal muscle (Lazarim et al. 2009). 
Each of these markers can ‗leak‘ from the damaged tissue where they are circulated 
systemically. Due to their previous applications for the monitoring of soft tissue 
injury, in particular skeletal muscle injury, serum levels were measured in this study. 
 
Based on the above logic, an approach tailored to guarantee soft tissue damage, 
which can be verified through functional torque generating capacity and 
measurement of the aforemention markers of injury was optimal for this proof of 
concept study. Such a methodological design will ensure the detection of 
biomolecules of soft tissue damage within urine if there are indeed any present. The 
aim of this study was to implement a strategy to bring the body into a soft tissue 
repair state. By taking this approach temporal changes in biomolecular profiles will 
become apparent throughout the recovery and repair periods. 
 
2.2 ETHICS 
Ethics approval to conduct these studies and use the protocols was granted by 
the Queensland University of Technology (QUT) Human Research Ethics 
Committee (HREC). Ethical clearance for the use of two human participant cohorts 
was granted, details as follows: 
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Project Title:              Applied biomarker research into soft tissue injury 
Ethics Number:         0900000846 
Clearance Until:        26/10/2012 
Ethics Category:        Human 
 
2.3 METHODS 
2.3.1 Subjects 
In total, 21 subjects were recruited to participate in the 60 day damage and 
recovery study. Each subject was asked to participate under their own free will, with 
no incentives or monetary reimbursements offered. Subjects were recruited only if 
they were of sound health with no serious chronic or acute soft tissue injuries that 
hindered their day to day living. Additionally, subjects suffering from muscle 
degenerative weakness, motor neuron diseases, mitochondrial disorders, liver 
diseases, glycogen storage diseases, sickle cell, LDHA deficiencies, endocrine 
disorders, cushings syndrome and central serous retinopathy were also excluded from 
the study. Subjects who reported having sustained soft tissue injuries (excluding 
biceps brachii) in the past year were retained in the study and the nature of their 
injury was noted unless their attending physician had directed them to light duties.  
 
2.3.2 Study design 
Participants were recruited via advertisements throughout the QUT community 
to participate in this program of research. This was a quasi-experimental study design 
(Campbell and Stanley 2005) where each participant was tracked across a set of 
preselected time-points, with their pre-intervention time-points serving as the within 
subject controls. The intervention in this case was a bout of eccentric actions through 
the biceps brachii to induce tissue-damage. It is also evident as part of this process 
that other adjacent tissues, such as the sub-lamina regions, would also be damaged 
(Lauritzen et al. 2009). Participants were asked to refrain from any vigorous 
unaccustomed exercise during the course of the study. After receiving a concise oral 
and written brief on the study, subjects signed an informed consent agreement before 
undergoing the baseline sampling measurements. 
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2.4 IN VIVO ECCENTRIC SOFT TISSUE DAMAGE INDUCTION 
MODEL: 
2.4.1 Pre-exercise familiarisation and warm-up 
Prior to the first exercise session participants were familiarised with the Biodex 
System 3 Pro isokintetic dynamometer (Biodex Medical Systems, Shirley, NY, 
USA), and their personalised setup. Before each session on the dynamometer, the 
elbow joint and surrounding tissues were warmed up by arm cranking on a bicycle (3 
min, 30-50 W) followed by two submaximal concentric or eccentric contractions for 
the respective functional recovery and muscle damage protocols. 
 
2.4.2 Eccentric muscle damage protocol 
Briefly, participants were seated with their torso restrained at the waist and 
shoulders (Figure 2.1a) and the elbow stabilised on a support in such a way that the 
input axis of the dynamometer (Figure 2.1a, b and e) bisects the longitudinal axis at 
the distal end of the humerus. Importantly, the participants‘ forearm was fully 
supinated using the forearm and wrist adapter (Figure 2.1c) to assist isolation of the 
biceps and avoid uncontrolled damage to the brachioradialis, brachialis and adjacent 
connective tissue. The elbow support was setup such that the shoulder joint was only 
slightly flexed (30 - 35° from the vertical axis), see Figure 2.1a, d and f. The 
eccentric muscle damage protocol consisted of 14 sets of 5 repetitions with 30 s rest 
in between each set. Each repetition was performed over a 135° range of motion 
from 40 - 175° flexion to extension where 180° equates to full extension of the elbow 
joint. Participants were verbally encouraged to resist the dynamometer throughout 
the entire soft tissue damage protocol. Following each eccentric muscle action, the 
arm was returned passively to the starting position. The entire exercise lasted 
approximately 15 min as described previously (Lauritzen et al. 2009). 
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Figure 2.1. Biodex assembly and anatomical position: a) Complete assembly and anatomical position, b)  
Biodex System 3 Dynamometer, c) Forearm and wrist adapter, d) Elbow support pad to system 3 seat assembly, 
e) Dynamometer to forearm/wrist assembly and f) Elbow support pad. 
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2.4.3 Muscle function 
Functional recovery of the biceps brachii was assessed by measuring the force - 
generating capacity of the damaged muscle. Two functional recovery protocols were 
used, these included a maximal voluntary isometric torque test at 90° flexion (5 s 
actions; 2 attempts; 30 s rest in between) and a peak torque measure over three 
consecutive maximal voluntary isokinetic, concentric elbow contractions at 60°.s
-1
 
(175°-40°). This protocol was adapted to our dynamometer according to previous 
studies that have used the same procedure to damage soft tissue in and around the 
biceps brachii (Lauritzen et al. 2009; Paulsen et al. 2009). 
 
2.4.4 Sample collection 
Before the exercise session (Post) and before the exercise session on day 3 
(D3) and 30 (D30), 8 mL of blood was collected from a subset of subjects (refer to 
Table 2.1 below) while three urines were collected between day -30 and the exercise 
protocol and within 2 h after the exercise protocol (Post). Samples were then 
collected each day until day 7 (D7), and then on days 14 (D14), 30 (D30) and 60 
(D60) (Table 2.1) from every participant. The urine samples collected during the 
baseline period prior to performing the exercise (Table 2.1) were used to establish 
normal within subject variation in urinary profiles prior to muscle damage (i.e 
variability due to the absence of muscle damage). Blood sample collection was 
purely voluntary, however, urine sample collection was a requirement of the study. 
 
Table 2.1 
Biodex experimental design 
  
Baseline measures 
 
Recovery period 
    
 
-30  Pre Post D1 D2 D3 D4 D5 D6 D7 D14 D30 D60 
 
                      
 B B B A B B B B B B B B B B 
S •  • • • •  • • • • •  • 
U               
Outline of the experimental design. -30 to +60 indicate the day of trial. ----- indicates the intervention 
(eccentric protocol), B = Before exercise session (1 h), A = After exercise session (within ~2 h); = Yes 
to either the collection of serum (S) or urine (U). • = No sample collected. 
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2.4.5 Blood and urine sample collection 
Each blood sample was collected in serum separator tubes (orange) (Becton 
Dickinson Pty Ltd, NSW, Australia, cat # 367958) and allowed to clot at room 
temperature for 1 h, before centrifugation at 2500  g. Aliquots of the serum 
(supernatant) were snap frozen under liquid nitrogen then stored at -80°C, until 
analysis. For the collection of urines, each participant was asked to provide a clean 
catch mid-stream urine sample which was immediately frozen at -20°C at the time-
points discussed above (Table 2.1). 
 
Serum samples were analysed in a pathology laboratory (Sullivan and 
Nicholaides Pathology, Brisbane, Australia) using standard operating procedures to 
determine the levels of current benchmark biomarkers of muscle tissue damage; 
these included CK, LDH and Mb. 
 
2.4.6 Statistical analysis 
All values are presented as mean ± the standard error of the mean (SE) unless 
otherwise indicated. The raw data were introduced into statistical tests while the 
graphical representations were normalised relative to the baseline measure for easier 
interpretation. Torque outputs at each time-point were normally distributed and as 
such, formal comparisons across each of the time-points were assessed using a linear 
mixed model (LMM) with an auto-correlation covariance matrix on the raw data. For 
dependent pairwise comparisons a one-way ANOVA was performed and a 
significant difference was accepted at p ≤ 0.05. All calculations were performed in 
SPSS (version 19, IBM®) and the open source „R‟ statistical computing and graphics 
program, version 2.14.0 (www.r-project.org). 
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2.5 RESULTS 
2.5.1 Participant demographics and questionnaire data 
Twenty-one male subjects (age = 31.06 ± 8.52 years, weight = 76.3 ± 10.29 kg, 
height = 156.0 ± 10.97 cm; Mean ± SD) were successfully inducted into the study. A 
health screen questionnaire was used to assess cardiac risk factors, current exercise 
habits and injury status. The health screen questionnaire showed three participants 
who reported having not engaged in exercise outside of normal day to day activity 
for the past 12 months. The physical activity status across the cohort varied from 
relatively sedentary to physically active, i.e. ≤ 3 exercise session a week (Table 2.2). 
There were six participants who did three exercise sessions per week at a moderate 
intensity, and one participant at a vigorous intensity. Four participants completed 
four sessions per week, three of which described their workout as vigorous and one 
as moderate. The remaining participants performed two or less exercise sessions per 
week, all at a moderate level of intensity except for V24 who performed two exercise 
sessions per week at a vigorous level. The most popular modes of exercise were 
those that required aerobic pathways such as running, jogging and swimming, second 
to that was resistance training.  
 
The cohort included participants taking various types of medications or dietary 
supplements. Within this cohort three asthmatics were recruited. Three participants 
reported taking dietary supplements including multivitamins, garlic and horseradish 
capsules, whey protein or creatine. Another two participants reported taking FDA 
approved drugs including Proscar
®
, Panadol
®
, codeine and loratadine. V22 was 
taking anti-inflammatory drugs (ibuprofen) at the time of this study. Others have 
shown that ibuprofen has no effect on the extent of injury or the time course of 
recovery following eccentric loading of the biceps brachii (Howell et al. 1998). Of 
all the subjects, there were two who had sustained noteworthy injuries (Table 2.2), 
V8 had an eight year old herniated disk in the lumbar spine and V4 had damaged his 
left hand 10 months prior to commencing this study. It is important to note that these 
injuries were not serious enough to hamper their day to day living and their physician 
had not put them on light duties at the time of their participation in this study. It is 
also notable that both of these participants were amongst the most active involved in 
this study, both participating in four exercise sessions a week at a vigorous level; as 
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such, the decision was made to include them in the study under the assumption that 
their injuries would not influence the results of subsequent analyses. A summary of 
each participant‘s physical activity status is summarised in Table 2.2. 
 
Table 2.2 
Participant exercise history, injury status and medication details 
# Participant 
code 
General activity status Activity details Intensity Exercise in 
the last 48 h 
Injury 
status in 
the last 
18 
months 
Notes 
1 V1 3 exercise sessions per week Jogging and 
cycling 
Moderate Yes None  
2 V2 3-4 exercise sessions per 
week 
Weights and 
Cardio 
Moderate Yes None  
3 V3 Sedentary N/A Sedentary No None  
4 V4 4 exercise sessions per week Running, cycling 
and weight 
training 
Vigorous Yes Yes, see 
notes 
section 
Participant 
damaged a muscle 
in left hand 10 
months ago during 
a workout session. 
5 V5 3 exercise sessions per week Soccer, touch 
football, 
occasional weights 
and running 
Moderate Yes None  
6 V6 3 exercise sessions per week cycling Moderate Yes None Garlic and 
horseradish 
supplementation 
7 V7 3 exercise sessions per week Combat sport 
(Brazilian Jiu Jitsu) 
Vigorous Yes None  
8 V8 4 exercise sessions per week Squash, 
swimming, weight 
training 
Vigorous N/A None, 
see 
Notes 
section 
L4/5 disc 
herneation ~ 8 
years ago. Subject 
has been managing 
injury fine for this 
period 
9 V9 Sedentary N/A Sedentary No None Participant takes 
Proscar® and is 
asthmatic. 
10 V10 N/A N/A N/A N/A N/A  
11 V11 2 exercise sessions per week Cardio Moderate No None Panadol and 
Codeine 
12 V12 Sedentary N/A Sedentary No None  
13 V15 3 exercise sessions per week Cycling Moderate Yes Yes Subject is 
asthmatic and 
sprained an ankle 5 
months prior to the 
study 
14 V16 3 exercise sessions per week Ice hockey and 
resistance training 
Moderate Yes No Subject 
supplements diet 
with 3 x 35 g 
protein per week 
15 V17 1 exercise session per week Light Cardio Moderate No None  
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16 V18 3 exercise sessions per week Resistance training 
and running 
Moderate No None Athmatic: takes 
symbicort inhaler 
17 V19 4 exercise sessions per week Resistance training Moderate Yes None Subject currently 
takes Whey protein 
and Creatine 
18 V24 2 exercise sessions per week Touch  football Vigorous Yes None  
19 V21 4 exercise sessions per week Running, 
resistance and 
weight trainings 
Vigorous Yes None  
20 V22 2 exercise sessions per week Walking with light 
jogging 
Moderate No None Takes Men’s 
multivitamin, 
loratadine (anti-
histamine) and 
ibuprofen 
21 V20 1 exercise session per week Jogging Moderate Yes None  
 
2.5.2 Eccentric actions using the biceps brachii induces torque loss 
Combined Eccentric Results 
Although statistical tests were performed on the raw data, each participant‘s 
time-point data were normalised to the first-set maximal contraction to account for 
differences in strength and make visualisation of the data more intuitive. Maximal 
voluntary eccentric torque was significantly reduced after participants underwent the 
muscle damage protocol. Eccentric torque loss across the entire cohort was 46.39 ± 
2.62% in the exercise arm. The progressively reducing trend in eccentric torque 
generating capacity was clear, indicating that soft tissue damage had taken place. 
Using a LMM, each of the eccentric sets (5  eccentric actions = one set) were 
compared to the final set (14
th
) to determine if eccentric torque generating capacity 
was depleted prior to the end of the exercise session. Using the 14
th
 set as the 
comparator, we found sets 1 through 8 were significantly different (DF = 19, p ≤ 
0.05) which suggests that tissue damage had occurred before the final set. As such, 
the final six sets can be viewed as cautionary to ensure each participant had accrued 
tissue damage. These repetitions (nine through to thirteen) were not significantly 
different from 14 (Figure 2.2a). The progressive decline was also observed with the 
eccentric work output (Figure 2.2b), 1 to 10 were significantly different from set 14 
(DF = 19, p ≤ 0.05).  
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Set 
 
Figure 2.2. Maximal eccentric actions using the biceps brachii results in decreased eccentric 
strength and work capacity. Percent loss in eccentric torque from baseline (a) and absolute work (b) 
losses across the cohort during the muscle damage induction session (n = 21). A LMM was used to 
determine significance between individual sets and set 14 ( = p ≤ 0.05). Significance was 
calculated from the absolute data in both cases, however, figure a) represents a percent loss 
from baseline for ease of interpretation. 
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Individual eccentric results reveal differential eccentric torque losses 
The individual eccentric torque losses during the session varied from 68.07% 
to 24.43%. The participants‘ tended to respond similarly to the eccentric loading 
protocol with a decreasing trend in torque observed across the 14 sets. Some 
participants exhibited a linear decrease in torque (V1, V5, V6, V12 and V15), while 
others exhibited dynamic fluctuations in percent torque loss (V3, V7, V9, V10, 
V11,V19 and V20, see Figure 2.3). Based on the eccentric torque production, there 
were three notable high responders (large loss of eccentric torque production) in V5, 
V22 and V15, each of whom experienced greater than 60% losses of eccentric 
strength by the end of the exercise session (Figure 2.3). As expected, the work 
output by the end of the session tended to plateau in most subjects with the exception 
of V7, V9, V21 and V19 whose work output fluctuated toward the end of the session. 
Note that the eccentric results were recorded for V17, however, the results file was 
corrupted and thus is not included in Figure 2.3 and Figure 2.4. The concentric and 
isometric results were able to be collected. Taken together, it is clear that the 
participants appear to respond differently to the eccentric tissue loading protocol, 
suggesting that some participants may be more or less accustomed to muscle actions 
through the biceps brachii and thus are less susceptible to sustain muscle damage. 
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Figure 2.3. Eccentric actions cause eccentric torque declines during a series of contractions of 
the biceps brachii. Individual eccentric torque loss across 14 sets of 5 repetitions. V1 through V24 
represent participant codes. Dashed lines highlight eccentric torque losses of 60% (---), 50% (---) and 
40% (---). 
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Figure 2.4. Eccentric actions cause eccentric work declines during a series of contractions of the 
biceps brachii. Individual eccentric work losses across 14 sets of 5 repetitions. V1 through V24 
represent participant codes.  
 Chapter 2: Characterisation of an In vivo Soft Tissue Damage Model 43 
2.5.3 Concentric and Isometric Recovery 
Combined pre and post torque output (concentric and isometric) indicate soft 
tissue damage has occurred 
Concentric and isometric contractions were used to assess the damage 
produced by the eccentric actions. Concentric and isometric actions were used for 
this purpose in low repetitions so as not to induce further muscle damage. The Pre 
and Post concentric and isometric torque responses corroborate the eccentric damage 
results with a mean torque loss, across the entire cohort, of 43.58% ± 2.32% 
(concentric) and 49.39% ± 2.57% (isometric) was measured in the exercise arm 
immediately after the exercise session (Figure 2.5a and b). The individual torque 
losses sustained as a result of the eccentric exercise session ranged from 60.34% to 
20.63% (concentric) and 69.09% to 18.25% (isometric). Analysis of variance 
revealed significant losses of absolute torque between Pre and Post muscle damage 
in both the concentric (DF = 1, F-value= 6.55, p ≤ 0.05) and isometric (DF=1, F-
value = 11.38, p ≤ 0.01) functional tests, see Figure 2.5c and d.  
 
Combined concentric and isometric strength requires over 7 days to return to 
basal levels 
The largest increase in strength was observed in the first 24 h following muscle 
damage; both the concentric and isometric results reflect this finding with 
improvements in torque generating capacities of 17.35% (± 3.28%) and 14.95% (± 
3.36%), respectively (DF = 20, p ≤ 0.001, Figure 2.5a and b). The concentric 
functional results demonstrate a linear increase in strength from D1 to D4 post 
exercise at a steady rate. However, the torque result at each of these time-points 
remained significantly lower than the baseline (Pre) (DF = 20, p ≤ 0.001). Both the 
isometric and concentric results indicated a slightly different trend with the D4 time-
point exhibiting a secondary loss of torque generating capacity, which was 
significantly different from D5 (DF = 20, p ≤ 0.001 and DF = 20, p ≤ 0.05, 
respectively). Importantly, the torque generated at each of the time-points up to D4 
remained significantly lower than baseline (DF = 20, p ≤ 0.001). The next greatest 
gains in functional recovery was observed at D5 in both the concentric (DF = 20, p ≤ 
0.05) and the isometric contractions (DF = 20, p ≤ 0.01) before a third decrease of 
0.17% (concentric, DF = 20, p ≤ 0.01) and 0.96% (isometric, DF=20, p ≤ 0.01), 
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respectively, at D6. The D7 time-point marked the final significantly different 
recovery data, indicating that on average the participants‘ concentric muscle function 
had recovered somewhere between 7 and 14 days post injury. Conversely, the 
isometric torque output was not consistent with that of the concentric results since on 
average, full recovery was not achieved until sometime between D30 and D60. The 
isometric torque data for D14 and D30 remained significantly lower than that of the 
Pre time-point (DF = 20, p ≤ 0.05, Figure 2.5a and b).  
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Figure 2.5. The muscle damage induced during the eccentric damaging protocol requires over 7 
days for subjects to functionally recover. Relative concentric (a) and isometric (b) torque 
production across the recovery period. Significance was determined using a LMM ( = p ≤ 0.05) and 
⊗ indicates secondary loss of strength (p ≤ 0.05). Concentric (c) and isometric (d) Pre and Post 
muscle damage highlight the immediate loss of strength. Significance was determine via ANOVA ( 
= p ≤ 0.05 and  = p ≤ 0.001 respectively). Results are from n= 21 participants.  
 46 Chapter 2: Characterisation of an In vivo Soft Tissue Damage Model 
Individual Concentric and Isometric recovery reveals different recovery 
profiles from the eccentric muscle damage protocol 
Individual functional recovery profiles reveal that participants did not all 
follow the same average recovery trend observed in Figure 2.5a and b. The two 
subjects that indicated they ingested supplements (whey protein and creatine) did not 
appear to have distinctly different recovery profiles to others who had not taken 
supplements. There appeared to be two primary types of response to the eccentric 
muscle damage protocol. Some began the recovery process immediately, which was 
reflected in an initial and substantial increase in torque generating ability. For 
example, V1, V9, V19 and V20 were largely recovered by 4 - 5 days following 
injury, while others exhibited a consistent lag in functional recovery over a 
prolonged period of time which was characterised by a ―U‖ shaped recovery profile 
(Figure 2.6 V5, V3, V12 and V22). Interestingly, individual inspection revealed that 
almost every participant exhibited a secondary loss of torque generating capacity 
between 2 and 5 days post muscle damage. In addition, these data characteristics are 
not as clearly observed in the concentric pooled data due to the effect of averaging 
the data (Figure 2.5). However, it is reflected more clearly as the observed decrease 
in recovery at D4 and D6 in the isometric pooled data. 
 
Based on these individual results participant V5, V12, V15, V20 and V22 were 
the highest responders to the muscle damage protocol, suffering concentric and 
isometric losses close to 60% (red dashed line Figure 2.6). Interestingly, of these 
five participants, three (V5, V12, V22) had lagging recovery profiles (―U‖ shaped 
recovery trajectory). Not surprisingly, the three highest responders based on 
eccentric torque losses are also the high responders based on concentric and 
isometric torque (V5, V15, V22). 
 
Taken together, the combined isometric/concentric and individual 
isometric/concentric data indicated a significant functional impairment in the biceps 
brachii of all subjects for at least 7 days after damage. This was further supported 
biochemically in the next section. 
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Figure 2.6. individual concentric and isometric functional results across the recovery period 
reveals different recovery profiles due to eccentric tissue damage. Individual muscle recovery for 
each of the participants, V1-V24, based on concentric and isometric torque generating capacity. 
Dashed lines represent a torque loss of 60% (---), 50% (---) and 40% (---).  
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Blood samples indicate clinically significant levels of CK, LDH and 
Myoglobin 3 days after eccentric muscle damage 
While the previous results demonstrate functional impairment and had been 
validated by others previously (Paulsen et al. 2009; Paulsen et al. 2009), it was 
important to ensure tissue injury had occured using known biochemical markers of 
soft tissue damage in serum samples. For this purpose, blood samples were collected 
from a subset (n = 3) of participants for additional analysis of serum LDH, CK and 
Mb levels. Blood sampling was not an essential study inclusion criteria and as such 
only 3 subjects agreed to provide blood samples. These included participants V2, V3 
and V15. Blood collection time-points were chosen based on the literature (Jones et 
al. 1986; Hirose et al. 2004) and collections were at pre-damage, D3 and D30 (refer 
to Table 2.3). 
 
Formal statistical analyses were not performed as Sullivan and Nicolaides 
Pathology indicate clinically significant levels for each of the three participants‘ 
results. However, as expected, changes in the levels of CK, LDH and Mb in these 
participants were observed, although not all of them were clinically significant. V3 
and V15 had clinically significant elevations of all markers tested (LDH, CK and 
Mb) by D3, while V2 exhibited clinically significant increases in CK and an increase 
in Mb that was not significant (Figure 2.7). Interestingly V2‘s LDH levels did not 
alter outside of the normal range (Table 2.3). Relative changes in these biomarkers 
are presented in Figure 2.7 and absolute measures are presented in Table 2.3. 
 
Table 2.3 
Clinical blood assay results 
LDH: normal range = 120 - 
250 U / L 
Participant Pre D3 D30 
V2 100 149 155 
V3 147 710 # 129 
V15 165 259 # 124 
CK: normal range = 45 - 
250 U / L 
V2 103 767 # 122 
V3 135 19436 # 102 
V15 83 3413 # 91 
Mb: normal range < 70 ng / 
mL 
V2 25 41 29 
V3 36 2030 # 30 
V15 27 1410 # 34 
The # indicates a clinically significant increase in levels of Lactate Dehydrogenase (LDH), 
Creatine Kinase, (CK) or Myoglobin (Mb). Clinical significance was reported in the Sullivan 
and Nicolaides Pathology results. 
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Figure 2.7. Clinical blood assays of common soft tissue damage markers indicate the incidence 
of muscle damage. Clinical blood results from three participants (V2, V3 and V15) across three 
timepoints, Pre, 3 days post eccentric loading (D3) and 30 days post eccentric loading (D30). The 
clinical markers of soft tissue damage were Lactate Dehydrogenase (LDH), Creatine Kinase (CK) and 
Myoglobin (Mb). The red # indicates a clinically significant augmentation in marker levels. 
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2.6 DISCUSSION 
The aim of this study was to induce and verify soft tissue damage in a group of 
participants. This study formed the foundation on which urinary biomolecular 
profiles that arise from the damage and recovery process could be investigated in 
later chapters. Using a Biodex System 3 isokinetic dynamometer eccentric loading 
actions on the biceps brachii were performed to induce damage. A total of 21 
participants were successfully inducted into the study and underwent the eccentric 
muscle damage protocol. The response to damage was assessed both functionally, 
through the capacity to produce torque, and by using currently known and widely 
accepted biomarkers of muscle tissue damage. 
 
A challenge with this study was the recruitment of participants without offering 
an incentive. As such it is a noteworthy observation that the majority of the 
participants who signed up were physically active in their day-to-day lives and as a 
result were reasonably fit. This presents a probable bias in this cohort which may be 
reflected in some of the functional data results where particular participants have 
recovered rapidly in comparison to others, e.g. V21 recovered in three days. 
 
A rapid recovery directly following injury was observed in all participants 
(Figure 2.6). This observation reflects previous observations in other eccentric 
damage induction studies. For example, Raastard et al. (2010) found that a majority 
of the functional strength was restored within the first 6 h after eccentric loading of 
the musculus quadriceps (Raastad et al. 2010). In addition, Lavender and Nosaka 
(2008) found the largest increase in muscle function occurred within the first 24 
hours after eccentric muscle damage to the biceps brachii (Lavender and Nosaka 
2008; Newton et al. 2008). In addition, the recovery data presented in this chapter 
was consistent with the original work by Paulsen et al. (2009) on which the protocol 
in this study is based. 
 
The original work by Paulson and Lauritzen et al. (2009) investigated the 
muscle response to repeated bouts of eccentric loading. The concentric and isometric 
functional recovery results presented in this study successfully emulated those 
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reported by Paulsen and Lauritsen et al. (2009). The evaluation and comparison of 
functional recovery served as an important quality check for the protocol used in this 
study, particularly given that this study utilised a different dynomometer to Paulsen 
et al. (2009) (Lauritzen et al. 2009; Paulsen et al. 2009). Importantly, based on 
Paulsen and colleagues bout one results the concentric reduction in torque (60°.s
-1
) 
was 45% ± 2% compared to 43.58% ± 2.31% observed in this study. Furthermore, 
their isometric torque (at 90°) was 51% ± 2%, which also corresponded well with the 
49.39% ± 2.57% reported herein (Paulsen et al. 2009). Importantly, however, the 
authors‘ study only assessed concentric and isometric characteristics up to 9 days 
post damage. These results showed that at 9 days post damage their participants‘ 
concentric and isometric torque levels remained approximately 13% and 19% below 
baseline respectively (Paulsen et al. 2009). An additional study performed by this 
research group in the same year using the same damage induction procedure showed 
similar isometric and concentric functional results (n = 5 participants) up to 20 days 
post injury and these participants had still not completely recovered to basal levels by 
the end of the monitoring period (Lauritzen et al. 2009). Importantly, the data 
presented in this thesis chapter extends the functional testing period of the Paulsen 
protocol out to 60 days post damage. Based on the concentric data obtained, 
functional recovery occurred between 7 and 14 days post damage (Figure 2.5a), 
whereas the isometric functional data indicate that recovery occurs somewhere 
between 30 and 60 days post damage (Figure 2.5b). Given the recovery data 
presented herein matches that of Paulsen et al. (2009), some of the disparity in 
functional recovery found in this study compared to that of Lauritzen et al. (2009) 
may be due to the inclusion of 5 participants in their study which were a highly 
homogenous cohort of high responders, and would therefore have delayed recovery. 
Moreover, the statistical approaches used in our analysis of the functional recovery 
data were different to that used by Paulsen and Lauritzen et al. (2009). A LMM 
approach was deemed more appropriate than a one-way ANOVA for our study 
because it is designed to take into account the multicollinearity within the data. 
 
Upon closer inspection of individual recovery results a biphasic trend in the 
recovery results was evident in almost all participants between days two and five 
after damage (Figure 2.6). Interestingly, the day where the second loss of torque 
occurred was not consistent between participants, so when the data were averaged 
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the intensity of the second decline was no longer apparent (Figure 2.5a). It is well 
understood that aberrations in muscle tissue function occur as a result of eccentric 
loading which culminates in an initial loss (within minutes, and most likely due to 
fatigue) of functional strength (Smith and Newham 2007). From a structural 
perspective the secondary loss of strength appears to be due to partial or full length 
myofibre necrosis at the site of injury (Armstrong 1990), as was described by the 
original authors (Lauritzen et al. 2009; Paulsen et al. 2009). Mishra et al. (1995) 
studied the effects of administering a non-steroidal anti-inflammatory drug 
(flurbiprofen) after eccentric loading of the anterior compartment of rabbit hind 
limbs. They found that the treated group had an increased ability to produce torque 
over the untreated group within the first 7 days (Mishra et al. 1995). These data 
indicate that the inflammatory process itself causes additional damage to the tissue 
which is secondary to that caused by the eccentric contractions and might explain the 
observed biphasic recovery trajectories in the data presented in our study. 
Furthermore, others have also hypothesised that the secondary decrease in torque 
generating ability comes from the additional inflammatory assault that follows 
eccentric tissue loading (Friden and Lieber 2001). In addition, serum levels of 
muscle specific CK is highest in concentration 3 - 4 days following damage, which 
also supports the secondary strength loss theory by providing evidence of muscle cell 
rupture and subsequent CK leakage, which correlates with reduction of torque 
generation through the damaged muscle tissue. 
 
In addition to assessing tissue integrity through functional tests, the levels of 
three commonly used biochemical markers of muscle tissue damage, CK, Mb and 
LDH, were evaluated in a subset of particpants. CK and Mb are considered specific 
to muscle tissue and are typically used to gauge the extent of skeletal muscle tissue 
damage or cellular necrosis after acute or chronic wounding (Mokuno et al. 1987; 
Brancaccio et al. 2010). LDH on the other hand is indicative of general tissue 
turnover and as such, in the absence of any other inflammatory condition, an 
increased response in LDH activity is often observed following eccentric loading 
exercises (Brown et al. 1997). Each of the day 3 post exercise blood samples were 
elevated above that of the pre and day 30 samples except for V2‘s LDH results 
(Figure 2.7a). In addition, V2‘s Mb levels, while elevated at day 3 were not elevated 
to a clinically significant level. V2‘s LDH and Mb levels might have indicated that 
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relatively little muscle damage had occurred were it not for this participant‘s CK 
levels which were 7.5 times greater than baseline and clinically significant (Figure 
2.7b). These data indicated that myofibres had been ruptured and as such muscle 
tissue damage had occurred.  
 
Based on the blood panel results and the functional recovery data, in 
conjunction with the histology results reported by Paulsen and Lauritzen et al. 
(2009), it appears muscle tissue damage was successfully induced within this cohort. 
Such damage is characterised by: 1) initial tissue swelling due to an influx of fluid 
and inflammatory cells (Friden et al. 1988; Tidball 1995); 2) extensive myofibrillar 
disruptions originating from the Z-disk space of the tissue (Gibala et al. 1995); and, 
3) myotendinal damage, a characteristic of eccentric exercise, particularly with 
reference to the biceps brachii, and where soreness tends to be localised to the distal 
myotendinal junction (Howell et al. 1985). In summary, the damage associated with 
this protocol will not only produce aberrations in skeletal muscle tissue but also 
adjacent connective tissue structures. This includes the perimysium structures which 
package multiple muscle fibres, the endomysium which surrounds individual muscle 
fibres, and the outermost layer of epimysium tissue and the biceps tendon. 
 
2.7 CONCLUDING REMARKS 
Based on the functional data, the clinical blood assays and data from previous 
peer reviewed studies, it was clear that a substantial amount of soft tissue damage has 
been accumulated using the protocol described. More specifically, this damage is 
localised to the skeletal muscles (biceps brachii) and the myotendonal junction which 
sustain most of the load during the exercise protocol. As such, the participants were 
successfully placed in a state of tissue recovery, characterised by reduced strength 
and increased inflammation. Urine samples collected from this study will be 
subsequently used for biomolecular profiling. 
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Chapter 3: Urinary Proteome Analysis 
using SELDI-TOF/MS 
3.1 INTRODUCTION 
Urine samples contain a broad array of proteins and protein fragments that 
accumulate in the bladder after filtration through the kidneys. These include proteins 
from the lower urinary tract and kidneys, but more importantly to this PhD program, 
proteins that derive from the various soft tissues via the blood circulation. Although 
the dynamic range of proteins in urine is smaller than that of serum, this sample type 
still suffers from difficulties relating to high abundance proteins and their 
interference during measurement. The top six most highly abundant protein species 
in urine are serum albumin, kininogen-1, prosaposin, zinc-α-2-glycoprotein, 
apoliproprotien D and IC κ chain C region (Nagaraj and Mann 2011). The detection 
of low abundant proteins is often a requirement in proteomics, and as such these high 
abundant proteins are often removed from urine samples to avoid interfering with the 
measurement of lower abundant species. Based on the overarching thesis hypothesis, 
it was proposed that the low molecular weight region of the urinary proteome will 
contain soft tissue proteins and protein fragments that will be indicative of either 
damage or repair in humans.  
 
With this goal in mind, a method that is often used to reduce sample 
complexity while minimising sample handling is the SELDI-TOF/MS. There is 
currently no single mass spectrometer which serves all the requirements and needs of 
the fundamental ‗omics‘ research areas. There are many different types of ionisation 
methods and mass analysers, each offering a trade-off in mass accuracy, resolution, 
analyte sensitivity and dynamic range characteristics (McLafferty 2011; Yates 2011). 
For the study described herein the SELDI-TOF/MS approach was applied. This 
technology was chosen for its unique protein profiling capacity of LMW proteins and 
polypeptides in their native state, high throughput capability, its compact size, 
sensitivity, minimal sample requirements and its capacity to reduce sample 
complexity with minimal sample handling. The SELDI-TOF/MS can be considered a 
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low resolution MALDI system which lends itself for use on a range of biological 
research questions, largely due to its high-throughput capability. It has been 
successfully used in cancer research (Jr et al. 1999; Tolson et al. 2004), neurology 
(Huang et al. 2008), hypertension (Abdul-Salam et al. 2006) and renal transplant 
research (Wittke et al. 2005). Moreover, its application has been applied to a range of 
biological fluids including tears (Grus et al. 2005; Hida et al. 2005), plasma 
(Svensson et al. 2006; Wu et al. 2006), sweat (Baechle et al. 2006), human nipple 
aspirate (He et al. 2007), cerebrospinal fluid (CSF) (Suzuyama et al. 2004) and 
cervical and amniotic fluids (Gravett et al. 2004; Ruetschi et al. 2005). 
 
To date, there have been several successful studies utilising SELDI-TOF/MS 
technology on urine samples for a range of biological problems (Schweigert et al. 
2004; Moore et al. 2005; Wu et al. 2006; Huang et al. 2009). This and the capacity to 
provide valuable information on the LMW region of urine make it a logical choice 
for application in this research project. The typical SELDI-TOF/MS experiment 
begins by applying the biological sample to one of several proprietary surface 
chemistries in order to bind the protein and polypeptides onto the surface of the chip. 
Following application of the sample, several wash steps are typically used to 
selectively remove those protein species that do not interact or weakly interact with 
the surface chemistry under the specific buffer conditions. This results in the 
enrichment of the desired subset of proteins onto the surface of the protein chip 
array. A matrix, also called an energy absorbing molecule (EAM), is then applied to 
the sample before allowing it to co-crystallize with the analyte. α-Cyano-4-
hydroxycinnamic acid (CHCA) and sinapinic acid (SPA) are popular EAMs in 
SELDI analysis. 
 
After successfully spotting the complex sample onto the chip, the analyte is 
introduced into the mass spectrometer by applying a focused beam of energy to the 
chip surface whereby the matrix absorbs the majority of the energy while the protein 
and polypeptides are simultaneously ionised via proton donation and desorbed from 
the chip surface into the gas phase (Aebersold and Mann 2003). Theoretically, once 
the ions have been sublimed they are sent to the drift region of the mass spectrometer 
via a pulsed accelerating potential of the same polarity as their charge state to 
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remove them from the source. Upon reaching the electric field-free (and magnetic 
field free) drift region the kinetic energy of each molecule should be equal based on 
the formula ½mv
2
 (where m = mass and v = velocity). As a result, each of the ions 
should have the same kinetic energy, thus the smaller ions will reach the detector in a 
shorter period of time than larger ions. Each of these ions is detected and the mass 
calculated based on the time taken to reach the detector. A display of the masses is 
produced which is commonly referred to as a mass spectrum. An important note with 
the SELDI-TOF/MS technology is that it is not capable of providing protein 
identities through peptide or protein fragmentation; as such, masses of interest need 
to be identified using other complementary methods. 
 
It is hypothesised that the low molecular weight region of the urinary proteome 
is likely to contain degradation products that come about due to muscle tissue 
damage. Therefore, the aim of this study was to apply a proteomic profiling strategy 
to assess fluctuations in the low molecular weight region of urine due to the soft 
tissue damage and recovery described in Chapter 2. In addition, the profiling 
capacity of SELDI-TOF/MS for this biological problem is also assessed in this study. 
 
3.2 METHODS 
3.2.1 Materials and reagents 
CM10 ProteinChip
®
 arrays were purchased from Bio-Rad (Bio-Rad, Hercules, 
CA, USA), as were bioprocessors, protein standards, SPA. Sodium acetate (NaAc), 
Trifluoroacetic acid (TFA), ammonium citrate (C6H14N2O7), ammonium phosphate 
((NH4)3PO4) and pure water (ddH20) were all purchased from Sigma (SIGMA
®
 Life 
Sciences, Castle Hill, NSW, Australia). Ethanol (EtOH), hydrochloric acid (HCl), 
and Acetone were purchased from Merck (Kilsyth, VIC, Australia). All reagents and 
chemicals were of HPLC-grade quality. 
 
3.2.2 Urine concentration protocol for SELDI-TOF/MS 
Samples were thawed in a 25
o
C waterbath followed by clarification at 1500--
g for 10 minutes (min). The supernatant was then passed through a 0.2-µm syringe 
filter to remove any remaining bacterial contamination and high molecular weight 
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protein aggregates. The filtrate was then concentrated in a pre-rinsed (with ddH2O as 
per manufacturers instruction) 3K-NMWL Amicon
®
 Ultra-4 centrifugal filter device 
(Millipore™, Billerica, MA, USA), run at 4000--g for 30 min in a swing bucket 
centrifuge. The retentate was washed (twice) with 20 mM NaAc (pH 4.5) at 4000  
g for 30 min. Concentrated protein derived from each sample was then aliquoted into 
low bind eppendorf tubes, labelled and stored at -80
o
C. Protein concentrations were 
established for each test sample by the Bradford assay according to the 
manufacturer‘s instructions (Sigma Aldrich Pty Ltd, Castle Hill, NSW, Australia). 
 
3.2.3 Quality control 
Samples were collected according to the urinary protein concentration protocol 
outlined in section 3.2.2. A pooled quality control (QC) sample comprised of all 
participant concentrated protein samples was aliquoted into low bind eppendorf 
tubes, labelled and stored at -80
o
C. Protein concentrations were established for each 
sample by the Bradford assay (Sigma Aldrich Pty Ltd, Castle Hill, NSW, Australia). 
Prior to application onto ProteinChip
®
 arrays, each sample was diluted to 0.5-
mg.mL
-1
 with ddH2O. 
 
3.2.4 Optimisation-phase strong cationic exchange (CM10) spotting protocol 
SELDI-TOF/MS ProteinChip® array spots were equilibrated with 50-µL of 
equilibration buffer (10 mM HCl) and placed on a plate shaker for 5 min. This was 
repeated with fresh buffer. The protein concentration of each sample was adjusted 
(see relevant optimisation section) with binding buffer (20 mM NaAc, pH 4.5) before 
transferring 50-µL into the SELDI-TOF/MS bioprocessor. Each sample was allowed 
to bind for 1 h on a plate shaker (Perkin Elmer
®
, Waltham, MA, USA). Following 
sample binding, each spot was washed 3 times for 5-min in binding buffer, followed 
by 2  1 min washes with ddH2O. After each wash the bioprocessor was inverted 
and gently tapped onto a paper towel to discard any excess solution. The chips were 
left to dry at RT (24
o
C) prior to 2  1 µL application of 50% SPA. Each chip, buffer 
and matrix combination was then analysed on a PCS 4000 personal edition SELDI-
TOF/MS (Bio-Rad, Hercules, CA, USA). 
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3.2.5 Scanning electron microscopy (SEM) 
ProteinChip arrays were gold coated using a Leica EM SCD005 sputter coater 
(~10 nm; WD = 5 cm, 75 s, 30 mA) (North, Ryde, NSW, Australia) and were 
subsequently analysed on an FEI Quanta 200 Environmental scanning electron 
microscope at the Analytical Electron Microscopy Facility (AEMF), Queensland 
University of Technology, Brisbane, Australia. 
 
3.2.6 Modified SPA protocol 
To test the effects of ‗cluster busters‘, which reduce matrix clusters upon 
ionisation, three matrix solvents were made up as follows: 1) To an eppendorf tube 
300 L EtOH was added along with 150 L of Acetone, 2.5 L of TFA and 5 L of 
1M (NH4)2PO4, making a final solution of 60% EtOH, 30% Acetone, 0.5% TFA and 
10 mM (NH4)2PO4. 2) The second solvent was made as described in 1) but with the 
addition of 10 mM ammonium citrate (C6H14N2O7) instead of (NH4)2PO4. The third 
solvent was made as described in 1) but without the addition of ‗cluster busters‘ (i.e. 
10 mM (NH4)2PO4). Each solvent (210 L) was used to dissolved 5 mg of SPA. The 
tube was initially vortexed to dissolve the SPA and to remove SPA residue from the 
side of the tube before centrifugation for 10 min at 2000 rpm to remove excess SPA 
that could not dissolve. From this, 200 L of saturated SPA solution was added to 
200 L of the original solvent to make 400 L of: 
I. 50% SPA in 60% EtOH, 30% Acetone, 0.5% TFA and 10 mM (NH4)2PO4,  
II. 50% SPA in 60% EtOH, 30% Acetone, 0.5% TFA and 10 mM C6H14N2O7, 
and; 
III. 50% SPA in 60% EtOH, 30% Acetone, 0.5% TFA. 
 
3.2.7 Shots collected and rolling average optimisation results 
A considerable amount of interference found in spectral signals acquired from 
laser-desorption/ionisation mass spectrometer modalities (MALDI, SELDI etc.) has 
been reportedly due to fluctuations in the matrix applied to the sample. As such the 
effects of desorption and subsequent ionisation on non-critical (NC) samples were 
assessed. Fifty L of 0.84 mg.mL
-1
 of clarified, concentrated and buffer exchanged 
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(20 mM NaAc, pH 4.5) NC urinary protein sample was spotted onto a strong cation 
exchange (CM10) array as outlined above (section 3.2.4). High organic SPA solution 
containing 10 mM (NH4)3PO4was applied (section 3.2.6). 
 
Using a laser intensity of 5000 nJ, spectra from a single pixel on one spot was 
repeatedly acquired 40 times. The spectra were averaged across each of the 40 
acquisitions (rolling average) and visualised individually to determine what effect, if 
any, the matrix has on the signal produced by the instrument. 
 
3.2.8 Buffer optimisation 
A QC sample which had previously undergone clarification, protein 
concentration and desalting with ddH20 was adjusted to 0.84 mg.mL
-1
 and applied to 
a CM10 protein array as previously described. The analyte binding properties were  
tested using 5 mM NaAc from pH 4.0 to pH 5.5. Each of these samples was then 
subjected to increasing laser intensities from 5500 to 7000 nJ in increments of 500 nJ 
to consider the risk of in-source fragmentation using so called ‗cluster busters‘ for 
each of the different buffer conditions. Additionally, in a separate experiment the 
NaAc concentrations were adjusted from 5 mM to 100 mM, all at pH 4.5 (see Table 
3.1). Peak counts were collected using a valley depth of 3.0 times the noise with a 
peak height of 5.0 times the noise from 3000 Da to 30,000 Da. A centroid fraction of 
10% of the proportion of the entire peak was used to estimate mass. 
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Table 3.1. 
CM10 buffer Stringencies 
Buffer name NaAc Concentration (mM) pH 
Buffer 1 5 4.5 
Buffer 2 10 4.5 
Buffer 3 20 4.5 
Buffer 4 30 4.5 
Buffer 5 40 4.5 
Buffer 6 50 4.5 
Buffer 7 60 4.5 
Buffer 8 70 4.5 
Buffer 9 80 4.5 
Buffer 10 100 4.5 
  
3.2.9 Protein serial dilution  
Given that some urinary samples can contain generous amounts of protein 
while others scarcely contain any, it was important to perform a serial protein 
dilution experiment to examine the effects that differing total protein concentrations 
have on the resulting spectra and peak count characteristics. A QC sample which had 
previously undergone clarification, protein concentration and buffer exchange into 
20 mM NaAc, pH 4.5, was adjusted to 0.5 mg.mL
-1
 and serially diluted down to 
0.0153 mg.mL
-1
 and adsorbed onto a CM10 protein array as previously described. 
 
3.2.10 Surace enhanced laser desorption/ionisation spectra processing 
Calibration ProteinChip
®
 spot: 
A peptide calibration chip containing Porcine Dynorphin A[209:225] (Mr = 2147.5 Da, 
[M+H]
+
 = 2148.5), Human Beta-endorphin[61:91] (Mr = 3465.0 Da, [M+H]
+
 = 
3466.0), Arg-insulin (Mr = 5963.8 Da, [M+H]
+
 = 5964.8) and Bovine Cytochrome C 
(Mr = 12230.92 Da, [M+H]
+
 = 12231.92) (Bio-Rad, Hercules, CA, USA) was used to 
calibrate the masses within each spectrum. Briefly, a calibration chip was run prior to 
every SELDI cassette, each of which contained 12 SELDI chips. The calibration 
parameters were determined from the vendor supplied calibration equation: 
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, 
Equation 1 
 
where U (25000.00 V) is a known voltage and a, b and t0 are fitted using a three 
parameter equation and a least squares result. The resulting calibration parameters 
were then applied to each spectrum that was run within the same batch.  
 
3.2.11 Injury/recovery data acquisition and peak detection 
Prior to acquiring the data a blank spot was used to warm the laser. Spectra 
were generated within the range of 1000 to 30000 Da, while matrix attenuation was 
set to 1000 Da, focus mass was set to 3000 Da and a sampling rate of 800 MHz using 
a high (5000 nJ) and a low (2500 nJ) laser intensity with a spot partition of 1 of 4 and 
2 of 4, respectively. A total of 1166 shots were fired per spot with the first 6 shots of 
each pixel serving as warming shots. A total of 848 shots per spot were kept and the 
consensus spectra for that sample was the result of averaging these accumulated 
spectra together. Data generated from the warming shots were excluded from the 
averaged spectra. A source voltage of 25 kV was used to transfer ions from the 
source into the drift region of the instrument. 
 
All samples were normalised to total ion current between 1000 Da and 30000 
Da for both the high energy (5000 nJ) and low energy acquisition settings (2500 nJ) 
using the ProteinChip software. These spectra were then imported into ‗R‘ (version 
2.15.0, www.r-project.org) for analysis. Spectra with a normalisation factor (Nf) 
outside of 2  the SD (2500 nJ = 2.766, 5000 nJ = 5.532) were excluded from 
further analysis (Appendix A1, Figure 2). The second level of quality control 
involved further scrutinizing the data using robust PCA analysis to identify outlaying 
spectra. This involves calculating the score distance (ScD) and the orthogonal 
distance (OD) and removing points that have a large influence on the data (leverage 
points). This is an exploratory method; see Daszykowski et al. (2007) for details on 
such methods for outlier detection (Daszykowski et al. 2007). These analyses were 
performed on individual technical replicates. Based on the above approaches 118 and 
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51 outlaying spectra were removed from the original 753 spectra acquired under low 
and high laser energies, respectively. 
 
An external calibration equation was then applied to each spectrum. A 
smoothing window of 25 points was used before fitting the baseline and filtering 
parameters were set to ‗on‘ with an average width of 0.2 times expected peak width. 
The spectra were collected and the peaks were clustered using Cluster wizard™ 
(Bio-Rad, Hercules, CA, USA) with the following parameters unless otherwise 
stated; peak height = 5.0, valley depth = 3.0, minimum peak threshold = 8.33%, 
cluster mass window = 1  the peak width, and second pass option was switched 
off. This minimum peak threshold was chosen because there are 12 timepoints in the 
experimental protocol all together (section 2.3.2) and there is a chance that a peak 
will be present in one of these time-points but not the others as such 100% ÷ 12 = 
8.33% of spectra with the possibility of having peaks present that are not apparent in 
the other time-points. Peak detection parameters for each of the QC datasets were the 
same as above except the minimum peak thrshold set at 20%, a default setting. 
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3.3 RESULTS 
3.3.1 There are no microscopic differences in the crystal structure of SPA after 
application of matrix ‘cluster busters’ 
Our research group has previously observed that a strong cationic exchange 
chemical interaction (CM10 arrays) tends to result in more protein binding from 
urinary protein samples. Bio-Rad also note the propensity for high noise in the lower 
region of SELDI-TOF/MS spectra. Previous work in the MALDI mass spectrometry 
field has attempted to use so-called ‗cluster busters‘ to reduce the effects of matrix 
noise during ionization and subsequent detection (Zhu and Papayannopoulos 2003; 
Nabetani et al. 2006). ‗Cluster busters‘ are molecules, usually salts, that are spiked 
into the crystal matrix that are thought to improve signal characteristics (e.g. 
increased S/N ratios). To the best of my knowledge, the application of cluster busters 
had never been tested for use on the SELDI-TOF/MS platform at the time of writing 
this thesis. As such, the SELDI-TOF/MS signal was compared between SPA spiked 
with C6H14N2O7 or (NH4)3PO4 as these have been regularly used for peptide/protein 
analysis within the literature. See section 3.2.4, 3.2.5 and 3.2.6 for details. 
 
Other groups have used microscopy to visualise the christal structure (Bailes et 
al. 2009). As such, SEM was used to investigate the differences in crystal structures 
of SPA, SPA10 mM ammonium phosphate and SPA10 mM ammonium citrate. The most striking 
feature of the SPA crystals was their large size and the relatively sparse distribution 
with which they form over the spot surface (see Figure 3.1a, Figure 3.1c, and matrix 
control Figure 3.1f) compared to the blank spot (Figure 3.1e). In each of these spots 
the surface of the ProteinChip array can still be clearly seen. There did not appear to 
be substantial differences in crystal size between the SPA-only spot (Figure 3.1f) 
and the two spots containing ammonium salt (Figure 3.1a and c). The only 
noticeable difference at the microscopic level was that the crystal structures formed 
with SPA10 mM ammonium phosphate appeared to be more uniform (Figure 3.1a) and had a 
smoother surface (Figure 3.1b) when compared with SPA10 mM ammonium citrate (Figure 
3.1c and d). The appearance of crystal structures did not seem to be the determining 
factor regarding the reported superioriority of desorption and ionization of protein, 
which means the improved signal when using ammonium phosphate must be due to 
molecular events during ionisation.   
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Figure 3.1. The crystal structures of SPA when spiked with ‘cluster buster’. SEM images of 
showing the topographical characteristics of SPA matrix with 10 mM ammonium citrate (a and b), 10 
mM ammonium phosphate (c and d), blank spot with no matrix (e) and straight SPA only (f). The 
scales on a), c), e) and f) are 400 m while b) and d) are 100 m. 
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3.3.2 ‘Cluster busters’ in a high organic matrix solution improves ionisation 
The next step was to investigate a method for reducing the amount of time 
required for the matrix crystals to dry. Extensive drying times can result in poor 
matrix dispersion and thus poor ionisation of the sample into the instrument. The 
merit in adding ‗cluster busters‘ to the matrix of SELDI-TOF/MS protein chip arrays 
showed promise in a preliminary study (Appendix A1, Figure 1) and in the 
microscopy work (Figure 3.1). From these experiments there did not appear to be 
major differences in the microscopic characteristics of the matrix. To further assess 
the analyte delivery efficiency of these matrices a direct comparison between Bio-
Rad‘s recommended matrix and a modified high organic matrix solution containing 
10 mM (NH4)3PO4 was made. The hypothesis underlying this experiment was that 
the matrix-solvent vapourisation would be improved under high organic conditions 
and this would be reflected in the quality of the spectra obtained. The original (Bio-
Rad method) SPA recipe contained 50% SPA in 50% ACN, 0.5% TFA and was 
compared with a modified SPA recipe consisting of 50% SPA in 60% EtOH, 30% 
Acetone, 0.5% TFA and 10 mM (NH4)3PO4 to investigate if differences in spectral 
quality characteristics could be improved by drying the solvent off faster.These two 
matrix solutions were tested on a NC sample that was applied to a CM10 array 
surface. The data demonstrate that the number of peaks detected using matrix 2 (60% 
EtOH, 30% Acetone, 0.5% TFA and 10 mM (NH4)3PO4 was significantly larger than 
with matrix 1 (Bio-Rads recipe) (DF = 1, n = 6 technical replicates, p-value ≤ 
0.001)(Figure 3.2a). Although there was an increase in the number of peaks able to 
be detected between the two matrix types, the S/N across each spectra were, on 
average, the same and thus no statistical differences were observed. However, there 
was a noticeable reduction in the variability of the S/N across the entire spectra with 
the use of matrix 2 (Figure 3.2b). 
 
The other noticeable difference between the two matrices was the reduction in 
matrix interference on the detector in the low 1000 to 3000 m/z range (Figure 3.2c 
and d), a range typically excluded from analysis due to matrix interference. The 
increased S/N was also obvious with the use of matrix 2 (Figure 3.2d) when 
compared to the matrix 1 sample (Figure 3.2c). As such, the peak selection 
algorithm is far more likely to select peaks that represent polypeptides/proteins and 
not peaks produced by matrix interference.  
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Figure 3.2. SPA in a high organic solvent spiked with 10 mM ammonium bicarbonate produces 
better SELDI-TOF/MS signal characteristics. The custom SPA solution (matrix 2) allows the detection 
of more peaks (a) with closer S/N within replicates (b). In additon, the S/N and matrix derived noise in 
the low (m/z = 1000 – 3000) range is comparitively low using the d) high organic matrix composition 
containing the 10 mM NH4PO4, compared to the c) recommended (Bio-Rad) matrix composition. 
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3.3.3 The first six laser shots contain signal noise 
The SELDI-TOF/MS works by accumulating multiple spectra and averaging 
them to return a single representative spectrum for each of the samples. Ionisation 
matrix-effects are more prominent in the earlier spectra than the later spectra. This 
was clearly illustrated using a PCA plot which indicated the trajectory of each 
spectra collected from the same pixel on a spot, beginning with low quality (noisy) 
spectra on the top left of the two-dimensional PC space (Figure 3.3a). The higher 
quality spectra tend to end up on the top right as can be seen in the individual 
replicates (Figure 3.3a, red). These data suggest that good quality spectra can still be 
acquired from the same pixel of the same spot (under these loading conditions) for 
up to 40 acquisitions. The first six individual spectra (Figure 3.3a, red) exhibit 
different spectral characteristics which was apparent in their distance from the last 20 
spectra acquired in the PCA space. Addtionally, as the spectra are progressively 
averaged, the affects due to the matrix had less and less influence on the final spectra 
(Figure 3.3a, green).  
 
It is likely that this disparity between good and poor quality spectra is largely 
influenced by the random effects that SPA has during ionisation from the earlier laser 
shots. This became clearer from the loadings plot (Figure 3.3b) of the first two 
components which illustrates the influence of these variables is due to the low 
molecular weight region of the spectra (small black to dark red pixels). It was also 
noticeable that the high quality spectra, that is, the spectra that are less influenced by 
the low m/z noise caused by matrix interference, were found in the top right corner of 
the plot, which is also where the final averaged spectra was located. 
 
Based on these data the first six spectra, which contain mostly interference due 
to the matrix, can be removed before beginning the rolling average in order to 
improve the resulting spectra. 
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Figure 3.3. The first 6 laser shots acquire spectra which are primarily comprised of matrix signal. a) A 
prinicipal components analysis highlighting the disparity between spectra acquired at the begining of acquisition 
which contain matrix-signal interference (‗Individual spectra‘, •, 01 to 12) compared to spectra aqcuired and 
averaged as data from the same spot is collected (‗rolling average‘, •). b) The majority of the signal in the top left 
quadrant, where the lowest quality spectra tend to be, is primarily due to low m/z values (black, small pixels), 
while the beter quality spectra tend to consist of high m/z values (red to yellow, large pixels), and are located 
primarily in the right-hand quadrants of PC 1. 
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3.3.4 Increasing laser energies do not increase the number of observed peaks 
when using ‘cluster buster’ indicating a reduction of in-source decay 
In SELDI-TOF/MS experiment, it is vital to provide optimal buffer conditions 
to complement both the surface array chemistry and sample binding characteristics. 
Small adjustments in buffer stringency could have profound effects on the final 
experimental spectra by altering the physico-chemical interactions between the 
analyte and stationary phase. Previously our group has used 10mM NaAc at pH 4.5 
with urinary protein (Parker et al. 2012). At such a low salt concentration it is likely 
that this will attempt to bind everything; because of this, it may increase potential 
measurement variation across each replicate due to competitive binding. In order to 
have greater confidence in this buffering system further investigation was required. 
In particular, the effects of buffer pH and salt content on sample binding were tested. 
A pH range of 4.0 to 5.5 (5 mM NaAc) was used, as well as different NaAc 
concentrations ranging from 5 - 100 mM at a stable pH of 4.5. Moreover, the nature 
of in-source fragmentation using a range of laser intensities from 5500 to 7500 nJ 
was investigated on a NC sample to assess if the ‗cluster buster‘ reduces in-source 
ionisation. 
 
 The largest number of peaks were detected using 5 mM NaAc loading buffer 
with a 5500 nJ laser (Figure 3.4a ). However, the NaAc concentration did not appear 
to have any real influence on the number of peaks detected until the maximal 
concentration of 100 mM was reached. Under this buffer condition there was a 
reduction of the total number of peaks under all laser intensities, except for 7000 nJ 
which increased the number of peaks detected from 26 to 30. However, this trend 
was not observed at a laser intensity of 7500 nJ. It was hypothesised, based on 
previous results in our group that with an increase in laser energy comes an increase 
in peak number due to in-source peptide fragmentation events. The results reported 
here do not show this trend, as such increasing peak number was not correlated with 
increasing laser intensity using the matrix solution containing 10 mM (NH4)3PO4.  
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Figure 3.4. Laser energy optimisation. A QC urinary protein sample was assessed at a stable pH of 4.5 with 
increasing NaAc buffer content. Each salt concentration was tested under different laser intensities. There was little 
evidence of in-source decay due to increasing laser energies. 
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3.3.5 The optimal urinary protein concentration for SELDI-TOF/MS analysis is 
0.0313 mg.mL
-1
 
To limit sample wastage, it was important to assess a range of urinary protein 
concentrations for SELDI-TOF/MS analysis. Based on triplicate SELDI profiles 
from the same NC sample, a concentration of 0.5 mg.mL
-1 
produced the most peaks. 
This was closely followed by 0.0313 mg.mL
-1
 and 0.0156 mg.mL
-1
. However, the 
S/N ratio and overall variation in measurement was superior in the 0.0313 mg.mL
-1
 
sample with a mean peak count of 49 ± 3 and a mean S/N ratio of 35 ± 4 across the 
entire spectra, as compared to the 0.5 mg.mL
-1
 sample with a peak count of 55 ± 7 
and a S/N of 29 ± 2 (Figure 3.5). Therefore the optimal concentration was based on 
signal to noise and reproducibility where sample conservation was prioritised. As 
such, an optimal sample protein concentration of 0.0313 mg.mL
-1
 was chosen 
(Figure 3.5). 
  
Figure 3.5. Protein concentration optimisation. A non-critical urinary protein sample was serially 
diluted and applied to a CM10 array in order to determine the optimal concentration based on peak 
count, signal to noise ratio (S/N) and reproducibility. The • indicates the optimal concentration for the 
remaining experimental analyses. 
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3.3.6 Assessment of the soft tissue damage/recovery urinary proteome using 
SELDI-TOF/MS 
After optimisation, each of the urinary protein samples collected from the 
eccentric muscle damage study (section 2.4.2) were analysed using the optimal 
SELDI-TOF/MS setting discussed previously. The QC samples (section 3.2.3) were 
inspected for batch variability via a heatmap of m/z intensities chosen by the 
ProteinChip wizard. There did not appear to be any major batch discrepancies in the 
QC data, with the exception of the ―Sunday June 05th‖ samples which appeared to 
have some small batch anomalies (Appendix A1, Figure 3a and b). As such, the 
replicates that were analysed in this batch were removed from analysis.  
 
The extreme leverage points (red and orange) in both the high and low energy 
datasets, respectively, are shown in Figure 3.6a and b. Removal of outliers has 
inherent risk, on the one hand these extreme observations may be due to systematic 
variation, while on the other hand such extreme observations may be due to 
biological effects. With this in mind, those data-points that were not observed with 
their corresponding technical replicates were removed (orange points in Figure 3.6a 
and b). Potential outliers which were present along with each of the technical 
replicates were retained (red points Figure 3.6a and b) as these may have contained 
information relating to soft tissue damage and/or recovery. The explained variance 
for each of the models using 25 components is provided in Figure 3.6c and d. 
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Figure 3.6. Outlier detection and removal from SELDI-TOF/MS spectra. Outliers detected using Robust 
PCA analysis. The data are from the a) high energy and b) low energy datasets. The red • and orange • 
indicates those spectra exerting a large leverage on the data. Orange were removed completely, however, red 
illustrates those that were found to be outliers with each of the three technical replicates, thereby indicating they 
might contain important biological information. The red hashed (----) line indicates the ScD and OD critical 
values. Each of the Robust PCA models was built using 25 components, the distribution of variance for each 
component can be visualised for the c) high and d) low datasets. 
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Using CM10 arrays a total of 164 peaks were detected with a 2500 nJ laser 
intensity and 194 peaks with a 5000 nJ laser intensity. In this work, understanding 
the protein profiles that alter due to the soft tissue recovery process was of interest. 
Initially the maSigPro algorithm was used to analyse the data. This two stage 
algorithm attempts to first produce a regression model taking into account all of the 
proteins in the dataset before using a variable selection strategy in an attempt to find 
statistically significant protein profiles (Conesa et al. 2006). The algorithm was 
unable to demonstrate significant peak profiles in either dataset (data not shown). As 
such, data exploration using a traditional linear method (i.e. PCA) was used to see if 
any structure could be observed in the data. A useful method for visualising 
prominent trends in highly correlated data such as protein profiles is principal 
components analysis (PCA). PCA is able to reduce the dimensionality of the dataset 
in such a way that most of the variation in the dataset can be explained in fewer new, 
uncorrelated variables (typically 1 to 10 depending on how complex the data are). 
This less complex dataset was then analysed by searching for obvious clusters within 
the reduced dimensional space. In this case, clusters that corresponded to the 
particular time-point the sample belonged to, would be ideal for revealing time-based 
fluctuations in the dataset. While there appeared to be some trends, these data 
demonstrated that the change in protein abundance with time following soft tissue 
damage was not the dominant effect in the SELDI-captured data (Figure 3.7). 
Furthermore, there did not appear to be any clustering based on participant (data not 
shown). 
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Figure 3.7. PCA analysis of SELDI-TOF/MS data. The change in protein levels with time following 
soft tissue damage was not the dominant effect based on PCA. a) low (2500 nJ) and b) high (5000 nJ) 
SELDI–TOF/MS datasets showing no obvious clustering in the first 2 components. 
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Attempts to identify time-dependent associations/relationships in the datasets 
using a step-wise regression approach (maSigPro) and traditional dimension 
reduction techniques (PCA) did not show any protein patterns of interest. The next 
stage involved treating each mass as a univariate unit and inspecting significant 
changes in peak intensities. This approach does not treat the data as a multivariate 
dataset, thus correlations between masses are ignored, however, there is merit in this 
strategy as it is commonly used within the literature as a way of decreasing the 
complex nature of multivariate data (Hida et al. 2005; Bellei et al. 2010; Lu et al. 
2010; Takano et al. 2010).  
 
Non-parametric methods were used to test for changes in protein intensity 
using Bio-Rad‘s proprietary software, ProteinChip® Data Manager (3.0.7). The 
ProteinChip® Data Manager software uses the Kruskal - Wallis (KW) statistical test 
for greater than two groups, where the H0 is that the samples come from the same 
population. Non-parametric tests are commonly used with SELDI datasets because 
assumptions about normality are not always met. An example of histograms of the 
masses in Table 3.3 can be found in Appendix A1, Figure 4a through e.  
 
Only a small number of peaks were found to be significant in the low and the 
high laser energy data. As might be intuitively expected, the high laser energy dataset 
(5000 nJ) had more peaks, with six calculated to be significant peaks of interest (p-
value ≤ 0.05) (Table 3.2), while the low laser energy (2500 nJ) dataset had five 
significant peaks (Table 3.3). The peaks clusters between 15 and 16 kDa were 
present in both datasets, as were the low m/z peaks around 3110.1 and 3033.1. By 
increasing the laser energy to 5000 nJ an additional peak at 1967.4 was found to have 
a significantly different population distribution (p ≤ 0.05). Box and whisker plots of 
the significant peaks in Table 3.2 and Table 3.3 across the study time frame are 
presented in Figure 3.8 and Figure 3.9. 
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Table 3.2 
Kruskal - Wallis test results for high laser energy (5000 nJ) dataset 
Mass index Mass (m/z) KW p-value 
67   3110.1 0.0007 
181 15898.0 0.0025 
180 15813.0 0.0054 
179 15520.0 0.0057 
65    3033.1 0.0120 
20    1967.4 0.0266 
Only significant masses are shown, all p - values were considered significant at a cut-off of < 0.05. 
 
Table 3.3 
Kruskal - Wallis test results for low laser energy (2500 nJ ) dataset 
Mass index Mass (m/z) KW p-value 
144 15833.0 0.0014 
53 3109.2 0.0027 
143 15582.0 0.0070 
52 3032.8 0.0091 
145 16253.0 0.0115 
Only significant masses are shown, all p - values were considered significant at a cut-off of < 0.05 
 
  
 Chapter 3: Urinary Proteome Analysis using SELDI-TOF/MS 79 
  
Figure 3.8. Temporal changes in protein abundances measured by SELDI-TOF/MS using a low laser 
energy (2500 nJ). Significant peaks found in low energy (2500 nJ) using Kruskal–Wallis test. X-axis represents 
the timepoint and y-axis represents normalised intensity. 
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Figure 3.9. Temporal changes in protein abundances measured by SELDI-TOF/MS using a high laser 
energy (5000 nJ). Significant peaks found in high energy (5000 nJ) acquired SELDI–TOF/MS data using 
Kruskal–Wallis test. X-axis represents timepoint and y-axis represents normalised intensity. 
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3.4 DISCUSSION 
The SELDI-TOF/MS technology has been used successfully in applications 
searching for biomarkers, or panels of markers, indicative of a disease state in 
previous research areas. It is ideal for applications which need to prioritise for the 
low molecular weight region of the proteome i.e. < 20 kDa in complex samples. The 
major advantages of this instrument are in the high-throughput nature of analysis, the 
straightforward mode of sample preparation and the on-chip depletion of other 
proteins based on affinity for a surface chemistry. It was favoured for application in 
the present study as at the time of performing these experiments, there had yet to be 
any analyses performed on the soft tissue damage induction urinary proteome. In this 
study, SELDI-TOF/MS sample binding conditions and system parameters were 
assessed and optimised for application to urinary protein measurments. In addition, 
the low molecular weight fraction of the urinary proteome in 21 participants who had 
undergone maximal eccentric muscle loading exercises were surveyed to determine 
peptide and protein patterns under 20 kDa that had changed as a consequence of 
tissue damage/recovery. 
 
The binding of samples to ion-exchange arrays can be hampered by small 
differences in pH, salt concentration and protein amount across samples. Previously 
we have had success using cation exchange (CM10) affinity with urinary protein 
(Parker et al. 2012), as such this same chip surface was used here with some 
additional optimisations. A critical element to the quality control of this study was 
that each of the real samples underwent protein dialysis using ultra-centrifugal 
devices to ensure they were all in the same binding buffer with the same amount of 
salt at the same pH. In addition, the total concentration of protein was normalised to 
0.0313 mg.mL
-1
 in equal volume to ensure equal loading onto the ProteinChip arrays, 
and the selection criterion used to choose the appropriate SELDI chip binding and 
ionisation properties were objectively based on the S/N ratio, peak counts and 
reproducibility.  
 
A novel method within this study was the use of a high organic solvent in the 
SPA matrix which is a deviation from most protocols reported in the MALDI 
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literature which often used a 50% acetonitrile solvent based on Bio-Rad‘s original 
recipe. Furthermore, the addition of salt (10mM (NH4)3PO4) into the solvent used to 
dissolve the matrix provided a substantial increase in analyte S/N ratio in a purified 
peptide (Figure 1) which resulted in a greater number of peaks detected by the peak 
detection algorithms (Figure 3.2d). Of these peaks there was clear evidence of an 
increase in high quality peaks in the lower molecular weight region (Figure 3.2d). 
Typically the LMW region between m/z 0-3000 is ignored in SELDI profiles where 
due to interference by SPA ions. To my knowledge, the use of so-called ‗cluster 
busters‘ has not been previously reported within the SELDI-TOF/MS literature 
despite success using these in MALDI-TOF/MS research areas (Zhu and 
Papayannopoulos 2003). 
 
Typically cluster busters have been used to decrease the signal coming from 
low molecular weight CHCA adducts, thus increasing the peptide signal, particularly 
when peptide is present at very low amounts (Zhu and Papayannopoulos 2003). 
Others have also shown that the addition of ammonium phosphate, as used here, can 
drastically increase the signal of molecules above the typical α-CHCA adduct region 
of m/z 800-1100 with a particular emphasis on acidic peptides (Nabetani et al. 2006). 
Certainly, a remarkable improvement in the number of low molecular weight peaks 
that could be detected was noticed (Figure 3.2d). Additionally, the cyclic signal 
attenuation noticed in the LMW region of the data presented here (m/z 1000-2160) 
was all but removed in the high organic SPA matrix in the presence of ammonium 
phosphate (Figure 3.2d) compared to the original Bio-Rad protocol (Figure 3.2c). 
These data suggest that the addition of ammonium phosphate suppresses ionisation 
of ions originating from the SPA matrix; this in turn appears to increase the signal of 
ions originating from the LMW region of the urinary proteome that are otherwise 
unseen by the detector. It is very likely these suppression effects are not just limited 
to the matrix but also apply to the proteins and peptides in the sample. While 
MALDI/SELDI applications are more robust to salts, they still suffer from ion 
suppression events (Annesley 2003). It is noteworthy that no detector saturation was 
observed using the ProteinChip® software in this experiment (even in the 5000 nJ 
dataset) as has been noticed in previous studies where detector saturation has 
hindered the signal coming from other proteins (Fernandez 2010). Taken together, 
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these data indicate that salt has an overall suppression effect on the entire spectrum. 
This effect appears to be more dominant for SPA ions and results in an increased 
analyte signal. 
 
In addition to increasing the analyte signal through suppression of matrix 
additives, the way in which the spectra are acquired and averaged can greatly affect 
the final spectrum. In this study it was found that the first six laser shots of each pixel 
should be discarded and that the spectra acquired thereafter could be used for the 
final interpretation. This will result in a higher quality final spectrum by further 
reducing spurious signal due to the matrix effects. To the best of this author‘s 
knowledge, this has not been formally investigated with SELDI-TOF/MS analysis. 
 
Further efforts to increase the quality of the data involved the collection of 
spectra under two different laser energies, 5000 nJ and 2500 nJ. The premise with 
this strategy was that the data collected under the low laser intensity would be less 
susceptible to detector saturation events. Furthermore, it could be used to validate 
those masses found in the high laser energy data while allowing the determination of 
potential in-source decay ions which is known to occur in MALDI/SELDI 
experiments (Pfeifer et al. 1999; Ekblad et al. 2007). Additionally, the data collected 
under high energy conditions would have greater success at ionizing larger molecular 
weight proteins within the 0- 20 kDa molecular weight range.  
 
In this study, an initial multivariate statistical investigation using maSigPro 
(see, Conesa et al. (2006)) did not demonstrate significantly different profiles based 
on damage or recovery of participants. This observation was further substantiated 
using an exploratory analysis with PCA where no obvious structure relating to time-
point or participant was observed. Based on this initial investigation it was clear that 
the cohort investigated was quite heterogenous in nature, and that variation in 
profiles may have come about due to any number of exogenous factors (for example 
exercise, age, diet, diurnal regulation, instrumental variation etc.), despite my best 
efforts in controlling for some of these (sections 2.3.1, 2.4.4, 2.5.1, 3.3.1, 3.3.2). As 
such, a univariate approach was adopted which revealed a total of 11 peak clusters 
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within the high and low laser energy datasets (Table 3.2 and Table 3.3) showing 
signs of change in protein abundance over time. Of the 11 peaks in both datasets, 
masses 16253, 15833, 15582, 3109.2, and 3032.8 in the 2500 nJ dataset were also 
found to be significant in the 5000 nJ dataset at 15898, 15813, 15520, 3110.1, and 
3033.1, respectively. The disparity in mass is due in part to the low mass accuracy of 
the instrument and in part to the manner in which ProteinChip® Data Manager labels 
the peak cluster. Peak masses are estimated for each spectra, followed by alignment 
of peaks using the software, and the final reported mass of a cluster (peaks that share 
the same m/z value from different spectra) is the result of taking the median m/z 
value for that cluster. An additional peak at m/z 1967.4 was found to exhibit 
significantly altered abundance levels in the high laser energy dataset. However, due 
to its low mass and absence in the low laser energy dataset it was disregarded, since 
it may be a possible in-source decay product. Upon closer inspection of the 
significant peaks found through Kruskal Wallis via box and whisker plots, there did 
not appear to be strong time-point specific biological variability, although some 
trends were apparent (Figure 3.8 and Figure 3.9). 
 
In the past SELDI-TOF/MS has been heavily criticised by the wider scientific 
community, particularly in the field of proteomics and cancer research. One of the 
first studies was performed by Petricoin et al. (2002), who applied the SELDI-
TOF/MS technology to detection of ovarian cancer resulting if very strong 
classification results. Others have mentioned that such staggering results should have 
prompted them to re-interpret the data (Pearl 2002). Later critique found errors 
primarily due to poor data pre-processing which resulted in non-biological bias in the 
data that happened to explain their strong predictive ability (Baggerly et al. 2004). 
Other studies that have also been criticised include a serum analysis study looking at 
prostate cancer biomarkers (Adam et al. 2002) and a study investigating nipple 
aspirate fluid (Coombes et al. 2003). However, other issues with the instrument have 
also been reported. Ekblad et al. (2006) semi-quantitatively described the propensity 
for the SELDI-TOF/MS platform to produce in-source decay products upon 
ionisation. Importantly, the majority of the criticisms raised by the scientific 
community can be addressed through sound study design, careful sample handling 
and preparation, proper utilisation of quality controls and rigorous post acquisition 
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data analysis. When such precautions are adhered to, the SELDI-TOF/MS platform 
has been very successful. Its most notable success has been the OVA-1 test for 
ovarian cancer screening which led to the first FDA-approved proteomics biomarker 
panel (Fung 2010). 
 
Based on the data presented in the present study, the SELDI-TOF/MS platform 
was not able to provide convincing evidence of biological time-related fluctuations in 
proteins or small polypeptides despite substantial effort to address the above 
concerns. Nevertheless, based on the data presented in this chapter the application of 
the modified matrix with spiked ‗cluster buster‘ is recommended when sinapinic acid 
is used on ProteinChip® arrays in future experiments.  
 
3.5 CONCLUDING REMARKS 
In summary, the analysis of the soft tissue damage urinary proteome using the 
SELDI-TOF/MS technology did not produce any peak profiles of striking interest. 
Possible reasons for this include inter- and intra-participant variability. However, the 
data presented in Chapter 2 strongly indicate that tissue function was compromised 
after exercise. Given the size of the tissue area that has sustained damage it seems 
unlikely that none of these degradation and inflammatory products reach the urine, 
certainly within the first week of recovery where inflammation is greatest. This 
indicates that while the SELDI-TOF/MS procedure was optimised, perhaps the 
addition of other surface chemistries and buffers would complement these results by 
detecting different polypeptides/proteins. In future studies it is recommended that a 
more stringent buffer should be used to further reduce the complexity of the sample 
or that an additional depletion method prior to sample application is implemented. 
The caveat with this approach, however, is that the SELDI-TOF/MS platform is 
promoted as a simple three-step process (sample application, wash, spectral 
acquisition). As such the inclusion of these additional steps defeats the purpose of 
using the system in the first place. However, by removing more of the proteins and 
peptides that bind to the surface, individual m/z values are likely to be more 
reproducible. While the SELDI-TOF/MS approach did not yield time point relavent 
abundance profiles, further analysis of the LMW region of urine for evidence of soft 
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tissue damage or recovery is still of great interest given the propensity for these 
molecules to pass through the kidneys and into the urine. 
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Chapter 4: Metabolomic Profiling of the 
Injury/Recovery Metabolome 
with 
1
H-NMR 
Concepts and methods from this chapter have been published. Refer to 
Sampson DL, Parker TJ, Upton Z, Hurst CP (2011) A Comparison of Methods for 
Classifying Clinical Samples Based on Proteomics Data: A Case Study for Statistical 
and Machine  Learning Approaches. PLoS ONE 6(9): e24973. doi:10.1371/-
journal.pone.0024973 
 
4.1 INTRODUCTION 
Applications of metabolomic analysis to a range of biological problems is fast 
becoming popular within the biological sciences. Unlike proteomics, metabolomics 
has the advantage of examining the products of proteins where the relative 
abundance of a particular metabolite heavily outweighs that of the enzyme that 
produced it. Thus changes in a biological system are likely to be amplified within the 
metabolome. The metabolome contains a large number of small molecules that can in 
themselves provide valuable information on a variety of diseases (Zhang et al. 2012), 
but are now often being combined with proteomic approaches to provide a 
complementary analysis of the underlying biological problem (Oberbach et al. 2011).  
 
Metabolomics is used in the analysis of a range of small biological molecules 
including lipids, free amino acids, nucleic acids, vitamins, carbohydrates and 
peptides (Pan and Raftery 2007; Arakaki et al. 2008; Zhang et al. 2012). As is the 
case with proteomic analysis, metabolomic analysis can involve non-targeted 
profiling approaches or targeted analysis with each strategy offering different pros 
and cons. Such differences include dissimilar quality of quantification, differences in 
the complexity of sample preparation and an additional consideration is that the 
former is hypothesis-generating, while targeted approaches are hypothesis-driven 
(Dunn et al. 2012). Accounting for each of these aspects of experimental design will 
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also influence the choice of analytical platform used during the analysis of which 
there are multiple possibilities. The primary instruments used for metabolomic 
analysis are Nuclear Magnetic Resonance Spectroscopy (NMR) (Li et al. 2010; Cho 
et al. 2012) and MS-based approaches (Dervilly-Pinel et al. 2011). Of course there 
are varieties of each, for example 
1
H-NMR or 2D-NMR (Goudar et al. 2010), and 
within MS analysis the primary differences are in sample introduction into the mass 
analyser, typically through gas-phase chromatography (GC) (Koek et al. 2011), 
HPLC (Yoshida et al. 2009) or MALDI (Wang et al. 2008). As well as mass analyser 
specifications itself (Dunn et al. 2012). 
 
Metabolomics has been applied to a range of biological problems. Wang et al. 
(2008) used MALDI ionisation coupled with a fourier transform MS to find seven 
metabolites that may be able to distinguish renal allograft rejection in the urine of 
transplant patients (Wang et al. 2008). In another urinary metabolite study, Li et al. 
(2010) employed GC-MS to detect differences between knee osteoarthritis patients 
and healthy controls; they discovered metabolites involved with the tricarboxylic 
acid cycle (citric cycle), along with inflammatory mediators like histamine (Li et al. 
2010). Other areas include microbial (Pope et al. 2007; Kahar et al. 2011), plant 
(Roessner et al. 2001; Lugan et al. 2010) and exercise physiology (Enea et al. 2010; 
Pechlivanis et al. 2010). Such a diverse range of scientific research areas highlights 
the versatility of a metabolite-based profiling approach. 
 
The aim of this study was to apply a 
1
H-NMR metabolomic profiling strategy 
to the fraction of urinary biochemicals under 3 kDa. The hypothesis was that 
metabolites will hold information reflective of the damage and recovery trajectory of 
participants who accrued soft tissue damage (as outlined in Chapter 2). These data 
will complement the analysis of the 2-20 kDa protein/polypeptide region investigated 
in Chapter 3. Additionally, current and in-depth multivariate analysis methods were 
applied to determine which metabolite peaks were important enough to follow up in 
validation studies involving additional participants and other methods of 
measurment. 
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4.2 ANALYTICAL METABOLOMIC METHODS 
4.2.1 Materials and reagents 
All solvents were HPLC grade. The 500 L 3 kDa molecular weight cut-off 
(MWCO) Amicon ultra centrifugal filter devices were purchased from Millipore 
(Millipore™, Billerica, MA, USA). 3-(trimethylsilyl) propionic acid (2,2,3,3-D4, 
carboxyl-D, 98%) (TSP), Deuterium Oxide (D, 99.9%) and 5 mm disposable NMR 
Tubes were all purchased from Novachem Pty Ltd (NovaChem, Collingwood, VIC, 
Australia). The Na2HPO4.2H2O and NaH2PO4.H2O were purchased from Sigma 
(SIGMA
®
 Life Sciences, Castle Hill, NSW, Australia). 
 
4.2.2 Tissue damage and urine collection 
Urine samples were collected from otherwise healthy participants who 
underwent the eccentric tissue loading protocol as detailed in section 2.4.2. The 
damage protocol took place at the Institute of Health and Biomedical Innovation 
(IHBI) under controlled conditions. Each participant collected urine samples across a 
60 day damage and recovery period (refer to section 2.3.2) by either coming into 
IHBI to supply the sample on the date of collection or by collecting samples at home 
into a provided container. In either case the samples were immediately stored after 
collection at - 20°C until analysis. 
 
4.2.3 NMR sample preparation 
Urine samples (n = 277) were thawed at room temperature then clarified by 
centrifugation for 30 s at 13,000 rpm. Each 3 kDa MWCO (Millipore) Amicon ultra 
centrifugal filter device was rinsed as per manufacturer‘s instructions, and 3  500 
L aliquots of clarified sample were filtered for 10 min at 13,000 rpm. Samples were 
stored at 4°C between centrifugation steps. The filtrate was collected and 350 L was 
resuspended 1:1 with NMR buffer (0.2 M Na2HPO4.2H2O, 0.2 M NaH2PO4.H2O in 
D2O with 0.02% 3(trimethylsilyl) propionic acid (2,2,3,3-D4, carboxyl-D) (TSP). 
The pH of the resulting 700 L aliquots were measured using an Orion 3 star bench-
top pH meter (Orion Pacific) and a 600 L aliquot of metabolite solutions was 
transferred into 5 mm NMR tubes (Novachem Pty Ltd, Victoria, Australia) and 
stored at -20°C until NMR analysis.  
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4.2.4 1H-NMR analysis 
1
H-NMR spectra were acquired on a Bruker Avance™ - 500 spectrometer 
(Bremen, Germany) operating at 500.13 MHz. The instrument was equipped with a 
Bruker SampleXpress™ auto-sampler, a standard geometry 5 mm diameter Broad 
Band Inverse (BBI) probe head, and was controlled with TopSpin 2.1 NMR software 
(Bruker, Bremen Germany). All 
1
H-NMR data were acquired using the F1 
presaturation solvent suppression pulse sequence over a  13 sweep width with 64 
scans and 64k data points. Total acquisition time was 5.03 s, the recycle delay time 
set to 1 s, and the pulse width (90°) estimated from several NC urine samples. The 
probe temperature was set to 298 K. Processing of the Free Induction Decay (FID) 
was performed with line broadening (LB) set to 1.0 Hz. 
 
4.2.5 1H-NMR Signal Pre-processing 
Each 
1
H-NMR spectrum was manually phased, and an initial manual baseline 
correction was applied using TopSpin 2.1. All spectra were referenced to TSP = 0.00 
ppm using TopSpin 2.1 NMR software before they were imported into MatLab 
(version 2011a) with Prometab (version 3.3) (Viant 2003). Each spectrum was 
restricted to the region covering the range  0.2 to 10 ppm and the complexity of 
each spectrum was then reduced using consecutive bin steps of 0.005 ppm. To 
account for imperfect water suppression and the dominant effects of urea and lactate 
on spectral normalization, the spectral regions between  4.5 to 5.98 ppm were 
removed. Automated baseline correction was performed on each spectrum using the 
method outlined by Eilers and Boelens (2005) with a  (i.e. smoothness parameter) 
of 10
6
 and a p-value threshold of 0.01 (Eilers and Boelens 2005). Each of these 
binned spectra were then normalised to total spectral area. 
 
4.3 STATISTICAL METHODS 
4.3.1 A typical metabolomics dataset 
A typical metabolomic data matrix Xij will consist of response variables in the 
form of protein or peptide intensities and is composed of i rows (observations, 
participants, subjects), and j columns (resonances, metabolites etc.). In the case of 
classification, a vector of dummy variables, yi is coded to identify group membership 
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of the observations. For multiclass cases, yi is extended to Y by constructing an 
indicator matrix. 
pn
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Equation 2 
4.3.2 Partial Least Squares 
Partial Least Squares (PLS) is a canonical projection method which offers 
supervised dimension reduction capacity; this technique is used on datasets 
containing class membership variable/s, y, and predictor variable X. Unlike other 
popular dimension reduction techniques, such as PCA, the PLS algorithm calculates 
each latent variable from X based on y. The objective is to maximize the covariance 
between y and X, unlike PCA which maximizes the variance of the variables, X, 
alone. Thus PLS, unlike PCA, explicitly accounts for the covariates (e.g. class 
membership) within the model. 
 
In PLS, the latent variables (kPLS = 1,…,p where kPLS ≤ k) are a product of the 
iterative decomposition of X and y such that the original variables, in this case NMR 
x-axis variables (  ppm, resonances), get projected to a lower dimensional space 
where a sequence of bilinear models are fitted by ordinary least squares (at least 
originally this was the case), hence the name partial least squares (Dai et al. 2006). 
This is especially true for the Non-Linear Iterative Partial Least Sqaures (NIPALS) 
method, however, later methods used an eigen-analysis approach which brings it into 
line with most other classical multivariate methods. The goal of PLS is to find the 
linear relationship between the response and explanatory variables y and X:  
 
X = TP
T
 + Ex  
y = TC
T
 + Ey  
Equation 3 
 
Where T represents the scores (latent variables) that the data have been 
projected down to, P and C are loadings and Ex and Ey are the residual matrices 
obtained from the original X and y variables. Determination of the lower dimensional 
components requires: 
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iw
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Equation 4 
 
Subject to wi
T
wi = 1 and ti
T
tj = wi
T
X
T
Xwj = 0, as described in Boulesteix et al. (2008). 
 
The general PLS algorithm works as follows:  
1) PLS components are calculated as the latent variable which maximizes the 
covariance between X and y;  
2) The variance (information) from this component is removed from the original X-
data, a process known as deflation. The remaining residual matrix has equal column 
and row lengths to the X-data, only the intrinsic dimensionality has been reduced by 
one; and 
3) The next PLS component is calculated from the current residual matrix, and as in 
step 1, results in maximum covariance between X(1,...,j) and y subject to the constraint 
that it is mutually orthogonal with the previous one. This is repeated iteratively until 
little more improvement to the modelling of y can be achieved or X becomes a null 
matrix.  
 
Note that deflation of the X matrix is carried out differently between the 
numerous PLS algorithms available i.e. NIPALS, SIMPLS and Kernal PLS 
algorithms (Geladi and Kowalski 1986; Lindgren and Rännar 1998). An overview 
and history of PLS may be found in Geladi and Kowalski (1986), Wegelin (2000), 
Martens (2001) and Wold (2001) (Geladi and Kowalski 1986; Wegelin 2000; 
Martens 2001; Wold 2001). 
 
4.3.3 Classification for the assessment of model strength 
While PCA and PLS can provide class separation on a qualitative level, they 
are not strictly classification methods themselves, but are dimension reduction 
techniques. Typically these methods are used in conjunction with existing 
classification methods. In this study Linear Discriminant Analysis (LDA) was used 
for classification (McLachlan 1992). 
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In the context of this study, LDA seeks to find a linear combination of the new 
components, T, obtained from the preceding PLS dimension reduction process. A 
key pitfall with the implementation of LDA is its inability to deal with an n<<p 
dataset. As such, incorporating PCA or PLS prior to classification will result in a 
reduced dimensionality of the original X data that is better handled by the formal 
model that LDA provides. This is done by projecting the observations onto this new 
co-ordinate system and passing them onto the classifier. A model is then developed 
to predict the class of an unknown observation based on prior probabilities calculated 
from a learning set, Li. Ideally these priors are maximized for group membership in 
order to get the best separability. The linear combination is calculated such that it 
maximizes the ratio of between-class variance relative to the within-class variance: 
Ndd
Bdd
T
T
Ratio  
Equation 5 
 
Where B is the between class sample covariance matrix such that: 
g
i 1
B L
i 
T
ii tttt , 
Equation 6 
 
 and N is the within class sample covariance matrix,  
g
ji
i
11
L
N  L
i 
T
ijij tttt
 
Equation 7 
 
d is the direction that best distinguishes the difference between each class in the 
reduced dimensional space determined through PLS or PCA. Note that L
i 
is the 
learning set observations. LDA assumes that the data are multivariate-normally 
distributed with equal variance/covariance matrices (McLachlan 1992). 
 
4.3.4 Standardisation of pre-processed 1H-NMR spectra 
Two alternate data pre-processing steps were evaluated within the 
classification models. The first method used here was unit variance (UV) scaling 
(Equation 8) which transforms each of the variables to have equal importance with 
the caveat that it will also inflate measurement error. The second method used in this 
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study was pareto scaling which can be viewed as an intermediate between no pre-
processing and UV-scaling. pareto scaling reduces the large influence of high 
abundant metabolites while preserving the importance of the lower abundant 
metabolites thus partially preserving the structure of the original data. See van den 
Berg et al. (2006) for a comprehensive analysis of various spectral pre-processing 
methodologies (van den Berg et al. 2006). These standardisations were performed in 
„R‟, version 2.15.0 (www.r-project.org). 
 
UV- Scaling:      
           Equation 8 
 
 
Pareto Scaling:      
           Equation 9 
 
4.4 STUDY DESIGN 
4.4.1 Data analysis 
All processed data was analysed in the „R‟ statistical computing and graphics 
program, version 2.15.0 (www.r-project.org), unless otherwise indicated. The CMA 
package was primarily used for most of the classifiers described above (Slawski et 
al. 2008); while, my own scripts were developed and implemented within the CMA 
frame work. Each dataset contains a binary dummy variable set to either 0 or 1 where 
0 indicates baseline and 1 indicates any other timepoint aside from baseline.  
 
4.4.2 Comparison of different classifiers 
Learning sets, L, and test sets, T, were created for each dataset via bootstrap 
sampling and were built using randomly selected observations consisting of a fixed 
ratio equal to two thirds (0.66) of the original dataset, S. For each classifier k 
bootstrap learning sets were created and aggregated, producing a learning matrix 
consisting of size L1,...,kL. For each analysis datasets kL was set to 200 bootstrap 
learning sets. 
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Each classification rule generated and tested was assessed based on a global 
misclassification criteria generated from each of the test sets. That is, the number of 
times a classification rule created from L1,...,kL misclassifies a sample from the test 
set, T. This provides a non-biased way of assessing each of the models. Importantly, 
the same learning set was used for comparisons between the same classifications 
rules, for examples between datasets with all variables and datasets containing only 
the important (trimmed) variables. 
 
4.4.3 Comparing classification based on all variables to that based on 
preselected variables 
From a biologist‘s perspective an important step, particularly within ‗omics‘ 
studies, is to later identify the panels of features which were used to create the final 
classifier. This is generally more important for techniques that do not acquire this 
additional data, such as profiling strategies like 
1
H-NMR and SELDI-TOF/MS 
methods. For example a biologist will often want to identify a particular features 
useful in prediction in order to reveal its biological relevance which could then be 
used to inform future research directions.  
 
Variable pre-selection was performed using the coefficients from each of the 
PLS models, based on a global scoring criteria calculated from L1,...,kL. From each 
dataset, a reduced dataset of the most important variables (i.e. largest coefficients 
across all learning sets) were selected. The effects of variable selection on 
classification error were then compared to models built without any variable 
selection criteria. 
 
4.4.4 Model tuning 
PLS contains one adjustable hyperparameter, kPLS, which is the number of 
components used to build the model. For this method, a misclassification rate (MCR) 
was calculated using a 2-17 component model for comparative purposes. MCRs of ≤ 
0.3 were considered reasonable error rates for an exploratory study such as this. Not 
all of the datasets responded favourably when PLS models required greater than 17 
components, so for reasons of comparison model dimensionality was limited to 17. 
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Caution is advised when deciding how many components to use; on the one hand too 
many components may increase classification accuracy, while at the same time over-
parameterising the model may result in over-fitting. Very little is gained by setting 
the number of components too high as the model becomes superfluous with the 
additional parameters. The optimal parameter was selected based on the lowest 
global MCR from bootstrap validation sets. All classifiers and subsequent analyses 
were performed on a SGI Altix XE cluster (1316  64 bit Intel Xeon cores, 9376 
Gigabytes shared memory and a SUSE Linux Operating System). 
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4.5 RESULTS 
4.5.1 Pre-processed 1H-NMR spectra do not appear to contain any major 
outliers 
Spectral pre-processing is an important step to remove as much variation from 
the signal that is otherwise unrelated to the biology (i.e. systematic variation). Such 
influences on the spectrum can be due to small differences in pH, inconsistent 
sample handling and instrument drift. Spectral normalisation is also important to 
attempt to account for sample to sample variability, e.g. small differences in sample 
concentration. In this study normalisation to total spectrum area was performed 
following removal of the dominant water peak (Figure 4.1). The raw spectra (Figure 
4.1a) were first baseline corrected in order to remove aberrant signal due to baseline 
fluctuations (Figure 4.1b). Following baseline correction the spectra were then 
normalised to the total spectrum area (integral normalisation, Figure 4.1c). After 
signal processing in this manner, no major outliers were found based on visualisation 
via a PCA plot Figure 4.2. The processed spectra were then transformed using UV-
scaling and pareto scaling as described in the methods (section 4.3.4). 
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Figure 4.1. A visual workflow of the pre-processing outcomes for 
1
H – NMR spectra. a) Raw data, b) the 
spectra following baseline correction. c) The baseline corrected spectra following normalisation. 
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Figure 4.2. Outlier analysis of pre-processed 1H-NMR spectra. PCA analysis of the NMR dataset following 
signal processing steps comprising of spectral phasing, removal of dominant water, lactate and urea signals, 
baseline correction and normalisation to total spectrum area. Based on visual interpretation of the PCA plot no 
major outliers were present in the data. 
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4.5.2 The baseline sampling period exhibits high levels of biological variability 
Initially each PLS-LDA model was built using all variables in the dataset (1624 
variables after binning), incorporating each of the baseline samples collected within 
one month prior to soft tissue damage as the comparator group. The most noticeable 
feature in the data at this stage was that the strongest classification results were 
obtained between Pre and D7. This was a striking feature within the data and 
somewhat counter intuitive to what was expected; that is, at the very least that the 
first or second time points after damage would show the greatest differences within 
the spectral profiles. Additionally, these results indicated little difference between 
each of the models at different time-points. These initial findings indicated a large 
amount of heterogeneity between the pooled baseline samples and each time-point. 
This resulted in smaller detectable differences in variability due to exercise (Figure 
4.3a). 
 
4.5.3 The Post damage sample produces the strongest MCR 
Because of the large degree of baseline variation within the cohort an alternate 
avenue of analysis was pursued. Instead of using all of the baseline samples, only 
those samples collected directly before the induction of soft tissue damage were used 
as the comparator sample in an effort to reduce the heterogeneity within the baseline 
sampling period. Using the UV-scaled data, lower MCRs were observed. In addition, 
the models for each time-point after the first week (D7) failed during the model 
building process (at the LDA stage) due to the high collinearity between these 
timepoints and the baseline samples. This observation provided additional 
confidence in the modified approach, indicating the use of the single Pre sample was 
justified. The other assurance with respect to these models was that the first post 
damage sample produced the best classification results with a MCR of 0.211. This is 
a reasonable expectation given that the damage protocol which is known to produce 
major disruptions should be apparent in the urine the day after damage, more so than 
for example, two weeks after damage (Figure 4.3b). For each of the models, the best 
MCR were found within the first 2 components with the exception of Pre vs D5 and 
Pre vs D7 which required a 5 and 3 component model, respectively (Figure 4.3b). 
None of the samples besides Pre vs Post provided adequate enough classification 
errors (MCR < 0.3 is a reasonable error rate for an exploratory study such as this) to 
follow up at this stage of the analysis.  
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Figure 4.3. PLS-LDA classification of 
1
H-NMR spectra. a) PLS-LDA classification encorporating all of the 
baseline samples into the model indicated a large amount of biological variability, and b) classification using 
only the Pre sample to each recovery day up to D7.  
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4.5.4 Variable selection via PLS coefficients increases classification accuracy 
Feature selection is generally recommended to remove the fraction of variables 
that are present in the data but do not fluctuate as a result of soft tissue damage. By 
trimming the dataset in this fashion, only those variables that actually influence the 
separation of each class will be incorporated into the model. This reduces the effects 
that less-influential variables have on the models and thus emphasizes the variables 
that are present because of the underlying biology. A key advantage with the PLS 
algorithm is in its capacity to iteratively interpret the ‗importance‘ of variables whilst 
also reducing the dimensionality of the data, these variables can then be extracted 
and reanalysed, such methods are commonly referred to as ‗wrappers‘. When the top 
50 variables are considered in the UV-scaled data, each of the samples are classified 
more accurately, Figure 4.4a Note the considerable improvement when compared to 
the same classification models which use every variable in the dataset (Figure 4.3b).  
 
The above steps were performed on the pareto-scaled data, as well as the UV-
scaled data, and additional classification models were built using the top 50, 100, 
150, 200 and 250 variables in the dataset in an effort to determine the optimal 
number of variables to incorporate into the models. Blocks of 50 were used because 
variables tended to cluster to the same set of peaks otherwise. The best performing 
models for each of the classification rules using both UV-scaled and pareto-scaled 
datasets were generated (Figure 4.4b). From these data the majority of the 
timepoints performed best using the top 50 variables with the exception of Pre vs D2, 
Pre vs D3 and Pre vs D4 which had better classification outcomes when more 
variables were used (top 100) in the UV-scaled data (Table 4.1). Likewise the pareto-
scaled data generally performed best with the top 50 variables, the only exception 
was the Pre vs D3 which required the top 150 variables and Pre vs D6 which used 
the top 100 variables (Table 4.2). Under both scaling methods (UV-scaled and 
pareto-scaled) the lowest MCRs were between the Pre and Post sample and the Pre 
and D2 sample (Table 4.2). Additionally for both of these two timepoints, pareto-
scaling required substantially fewer components to reach an optimal solution, with 
six components in UV-scaled compared to 2 components in pareto-scaled data (Table 
4.2). As might be expected, with the addition of increasing numbers of variables the 
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trend was an increase in MCR, which is likely due to the addition of false positives 
(Figure 4.4b). 
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Figure 4.4. Classification model selection. a) An example of PLS-LDA MCRs after variable selection using the 
top 50 variables (UV-scaling). b) Variable selection using a range of the most important variables (see key in fig 
b), the numbers in the bars indicate the number of components used in the model. The strongest PLS-LDA 
classification models are between Pre vs Post tissue damage. 
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Table 4.1 
MCR of optimised classifiers from UV-scaled data 
 Pre vs Post 
(8 comp) 
Pre vs D1 
(6 comp) 
Pre vs D2 
(6 comps) 
Pre vs D3 
(14 comps) 
Pre vs D4 
(10 comps) 
Pre vs D5 
(6 comps) 
Pre vs D6 
(6 comps) 
Pre vs D7 
(12 comps) 
Top 50 0.116 0.126    0.244 0.140 0.121 
Top 100   0.108 0.172 0.161    
 
 
Table 4.2 
MCR of optimised classifiers from pareto-scaled data 
 Pre vs Post 
(2 comp) 
Pre vs D1 
(2comp) 
Pre vs D2 
(2 comps) 
Pre vs D3 
(3 comps) 
Pre vs D4 
(17 comps) 
Pre vs D5 
(5 comps) 
Pre vs D6 
(15 comps) 
Pre vs D7 
(15 comps) 
Top 50 0.202 0.430 0.293  0.326 0.337  0.352 
Top 100       0.426  
Top 150    0.391     
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4.5.5 Pareto-scaling highlights biological effect while UV-scaling inflates 
baseline noise 
Following MCR interpretation, it was observed that the UV-scaled data 
produced the lowest MCR and therefore the best results. However, upon extracting 
the top variables outlined in Table 4.1 from each of the UV-scaled models it was 
clear that the majority of these models were built from spectral areas with little to no 
metabolite signal. The reason they produced these spurious results is because UV-
scaling influenced the regions of the baseline spectra which contain little metabolite 
information such that these regions will have equal variance to spectral regions that 
contain peaks (Figure 4.5c). For these reasons this method would be more 
appropriately used on datasets which have undergone a peak picking step after 
Figure 4.5. UV-Scaling negatively influences the 1H-NMR spectra by inflating the signal from the baseline 
regions. a) The normalised spectra after the removal of dominant resonances. b) The effects of pareto-scaling on 
the data, notice the reduction of dominant peaks without losing too much information on the less dominant 
peaks. c) The UV-scaled data which inflates the baseline-spectral regions. 
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spectral pre-processing. Under these circumstances the variables will have come 
from an actual analyte within the sample, unlike the integration method used here 
which incorporated spectral-baseline regions into each of the classification models. 
In summary, in order to focus on biomarkers of soft tissue damage or recovery, the 
pareto-scaled data was used as it remains truer to the original spectra without losing 
information on the lower abundance peaks. The difference between UV-scaling and 
pareto-scaling on a subset of the 
1
H-NMR spectra is highlighted in Figure 4.5. 
 
4.5.6 Preliminary identification of Pre vs Post metabolites reveals molecules 
involved in tissue damage, energy metabolism, oxidation and inflammation 
From the pareto-scaled data, there was only one model that appeared to have a 
sufficiently low MCR to enable confident biological interpretation; this was the Pre 
vs Post model with a MCR of 0.202 using the top 50 variables and two components 
(Figure 4.4b). The next best model was the Pre vs D2 with a MCR of 0.293 using 
the top 100 variables (Figure 4.4b). The remaining models demonstrated a limited 
capacity to accurately classify each of the samples using each of the additional post 
time-points when compared to that of the Pre sample (Figure 4.4b). As such, 
preliminary identifications were made using data from the Pre vs Post model spectra. 
 
Upon extraction of the key resonances that the Pre vs Post models indicates 
being differentially present in urine, our collaborators at the Defence Science and 
Technology Organisation (DSTO) made the preliminary identifications. A list of the 
resonances of interest are provided in Appendix B1, Table 1, and the baseline 
corrected/normalised spectra along with these spectral regions of interest can be 
visualised in Appendix B1, Figure 5, all of which showed an increase in abundance 
based on the resonances that follow; Citrate (↑  2.66,  2.67,  2.53 and  2.57), 
creatinine (↑  3.04), glycerol (↑  3.80), histamine (↑  3.31,  3.30, 3.04), taurine 
(↑  3.28 and  3.23), 5-hydroxylysine (↑  1.66,  3.12 and  3.11) and Myo-
inositol (↑  3.28) (Figure 4.6).  
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Figure 4.6. Theoretical 
1
H-NMR spectra of identified metabolites. Preliminary identifications based on 
results from the Pre vs Post models are: a) Histamine, b) Citrate, c) Creatinine, d) Taurine, e) 5-hydroxylysine, f) 
Myo-inositol and g) Glycerol. 
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4.6 DISCUSSION 
4.6.1 Analytical methodology 
1
H-NMR provides a complementary analysis to the single dimensional (MS
1
) 
profiling strategy implemented in Chapter 3. It offered this project the capacity to 
measure small molecules, other than proteins and polypeptides, that may be 
enhanced due to the amplification effect enzymes have on their target substrates. 
This presents a major advantage to using metabolites over proteins. To date there 
have been several studies investigating the effects of physical activity on the 
metabolome, however, results from these studies have primarily been reported based 
on serum or plasma samples (Pohjanen et al. 2007; Yan et al. 2009; Lewis et al. 
2010). Despite the long standing use of urine as a biological medium in other areas 
of sports science (Beckett et al. 1967), it has not been extensively utilised as a 
biological fluid for applications in the area of soft tissue damage and metabolomics 
analyses. Additionally, the studies that have been performed in this area primarily 
focus on anaerobic and aerobic exercise schedules (Enea et al. 2010; Pechlivanis et 
al. 2010) and not on a truly tissue damaging protocol like the one presented here. 
Therefore, it was important to begin with a discovery-phase method such as 
1
H-NMR 
to characterise the LMW region that the SELDI-TOF/MS could not detect. 
 
Based on previous modelling results on similar datasets using a variety of 
classifiers including PLS-LDA, PCA-LDA, PLS-Random Forests (PLS-RF) and 
Support Vector Machines (SVM), a PLS-LDA approach for the analysis of these data 
was chosen (Sampson et al. 2011). This decision was made based on its successful 
application within our own laboratory and within previous ‗omics‘ studies 
(Boulesteix 2004; Dai et al. 2006). An additional advantage of a PLS approach is its 
inherent capacity to objectively distinguish influential variables (peaks/resonances) 
from those that are less important. Based on the models that were obtained from this 
study, a noteworthy observation within this dataset was that the baseline sampling 
period was biologically very noisy. As a consequence, when the models built using 
each of the baseline samples collected across a full month (BL1, BL2 and Pre) were 
tested, the classification accuracy did not appear to make biological sense. For 
example, the lowest MCR was between baseline and D7 samples when it was 
expected the better performing models would involve the timepoints sooner after 
 110 Chapter 4: Metabolomic Profiling of the Injury/Recovery Metabolome with 1H-NMR 
tissue damage (Figure 4.3a). Based on these models the best performance (lowest 
MCR) was between the pooled baseline and the seven days post damage (D7) 
samples (Figure 4.3a). These results suggested that the baseline sampling period 
may not have been controlled stringently enough and that perhaps the participants‘ 
physical activity status throughout this period may need to be monitored more 
closely. It is worth noting that urinary metabolomics is notoriously variable, often 
being influenced by additional exogenous factors such as diet, age, genetic factors, as 
well as gender (Dugue et al. 1998; Winnike et al. 2009), some of which were not 
explicitly assessed for this study. Although careful consideration was made to 
standardize the test conditions and sampling times, it might be wise to monitor 
physical exertion and diet through the baseline sampling period in future studies. We 
also note a large water peak within the NMR spectra that was difficult to suppress 
and thus additional sensitivity could still be gained through refinements to the sample 
processing protocol. 
 
In the absence of such baseline-monitoring processes within this study, the Pre 
sample was used as the principal baseline comparator, i.e. the sample taken directly 
before the exercise protocol. Based on this new approach the Pre exercise sample 
was modelled against each of the additional time-points. These results demonstrated 
the strongest classification accuracy (using the full 1624 variables) between the Pre 
and Post samples and appeared to make more biological sense, as the Post sample 
was notably different (based on MCR) than when all the baseline samples were used, 
which in that case, revealed D7 to be the important timepoint. Further evidence in 
support of using the Pre sample as the principal baseline comparator was the 
observation that for time-points D14, D30 and D60, the models failed due to high-
collinearity with the Pre sample. This indicated that D14, D30 and D60 were no 
different from the Pre samples in this cohort, and that the majority of fluctuations in 
the urinary metabolome that were due to soft tissue damage would only be seen 
during the first week following injury. This provides compelling evidence that the 
soft tissue damage and recovery urinary metabolome might have returned to a 
physiologically ‗normal‘ range after the first week. However, future studies 
incorporating a non-exercise control group are required to give an indication as to the 
expected fluctuations in the urinary metabolome to fully substantiate this. 
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Importantly, the data also supported findings by the concentric recovery data in 
Chapter 2 which found that participants functionally recovered between D7 and D14 
(Figure 2.6a). 
 
Within this analysis schema we used two scaling methods, UV-scaling and 
pareto-scaling, to standardize the data prior to analysis. Previously others have 
provided strong evidence for the application of UV-scaling methods on 
metabolomics data (van den Berg et al. 2006). Indeed, the classification accuracy of 
the analysis presented in this chapter is far better under these scaling conditions. 
However, upon visualisation of the influential variables according to each of the 
models, it was clear that the models were selecting baseline variables containing little 
evidence of a true peak. Because of this, results from the UV-scaled data were 
excluded from further analysis and instead, results obtained using the pareto scaling 
method was interpreted for biological variation. Based on data reported here, it is 
recommended that the use of UV-scaling prior to multivariate modelling is a good 
idea, but only when an adequate peak picking (i.e. a pre-processing method that 
extracts true peaks from the spectra) measure has been performed to avoid over 
weighting of low intensity regions of the NMR spectra. This was particularly 
important when variable selection was employed. 
 
A key advantage with a PLS approach to data analysis is that variable selection 
can be incorporated into the modelling process as has been proposed by Le Cao et al. 
(2008) with their ‗sparse-PLS‘ approach (Le Cao et al. 2008; Le Cao et al. 2009). 
Alternatively, another common approach is to use PLS to screen out variables for 
application in the final optimised model; this was the method used here. There are 
several metrics that can be used to infer variable importance using PLS, these include 
lasso methods (Tibshirani 1997; Il-Gyo Chong and Jun 2005), a PLS-variable 
importance method (VIP) (S. Wold et al. 1993), as well as PLS coefficients or 
loadings (Il-Gyo Chong and Jun 2005). The coefficients method in conjunction with 
a voting schema using each of the L1,...,kL learning sets was used here due to its 
previous successful application (Il-Gyo Chong and Jun 2005; Slawski et al. 2008). 
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Using the most important variables for each of the pareto-scaled models the 
Post sample showed the greatest difference to the Pre sample (i.e. lowest MCR). 
These data imply that the 
1
H-NMR detected acute differences in the urinary 
metabolome which appear to be associated with induced soft tissue damage, but did 
not detect changes in the urinary metabolite profiles beyond the first day. Evidence 
for this claim includes the Pre vs Post models which gave the lowest MCR results 
(MCR = 0.202, see Figure 4.4b). The remaining models had MCRs over 0.3, with 
the exception of Pre vs D2, which produced a MCR of 0.293 (Table 4.2). Based on 
these results downstream analysis of the variables influencing the Pre vs Post model 
were investigated further. Importantly, the Pre vs D2 MCR may warrant further 
investigation (i.e. metabolite identifications) in the future given the rigorous 
multivariate analysis procedure used here i.e. 200 bootstrap learning sets on 2/3
rds
 of 
the data. As a comparison, it is not uncommon to perform training on 6/7
ths
 of the 
data and then cross validate using the 1/7
th
 held out data (Anastasiadi et al. 2009). 
Clearly the risk of over-fitting the models using these criteria is greater than when 
using the approach outlined in this study. 
 
Based on the 
1
H-NMR spectra, preliminary metabolite assignments from the 
resonances selected using the Pre vs Post PLS models were made by collaborators at 
the DSTO. Below are the preliminary identifications based on the resonances that 
were extracted from the models. Relative abundance was estimated from the 
resonances shown in the results (section 4.5.6). The preliminary identifications were 
Citrate (↑ Post sample), creatinine (↑ Post sample), glycerol (↑ Post sample), 
histamine (↑ Post sample), taurine (↑ Post sample), 5-hydroxylysine (↑ Post sample) 
and Myo-inositol (↑ Post sample). Importantly, these are considered preliminary 
identifications because they are based on 
1
H-NMR data of a complex mixture. As 
such, due to the additive, and thus quantitative nature of NMR analysis, peaks from 
multiple metabolites might overlap and contribute to the signal or saturate out a 
lower abundant signal. These identities therefore need to be validated to increase 
confidence in the putative assignments (e.g. 2D-NMR). Nevertheless, confidence in 
their assignment can be appreciated as they do appear to have biological roles 
relevant to this study, and may lend themselves for use as indicators of tissue 
damage. 
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4.6.2 Summary of preliminary identifications in the context of soft tissue 
damage/recovery 
Biochemical markers of energy metabolism 
An examination of the literature concerning the putative metabolite 
identifications found a plausible relationship between their increased levels and soft 
tissue damage. Citrate is a notably product of energy metabolism pathways within 
the body, in particular it is involved with energy conversion from carbohydrates, fats 
and protein through the Krebs cycle as part of the aerobic energy system. It is a 
commonly cited metabolite in studies investigating exercise and has been found to be 
significantly different from baseline under a range of exercise schedules including 
strength-endurance training (Yan et al. 2009) and structured sprint training regimes 
involving altered rest intervals (Pechlivanis et al. 2010). Given the strenuous nature 
of the exercise regime conducted in this study, it is possible that citrate levels would 
be increased within the Post sample as a result of the exercise routine utilised in this 
program of research. 
 
Another metabolite involved with energy metabolism identified here was 
creatinine. In this PhD program urinary analytes (protein and metabolites) were not 
normalised to creatinine levels for any of the analyses, under the premise that the 
creatine-phosphate pathway, which results in creatinine production, would be 
heavily utilised during the muscle damage protocol (Calles-Escandon et al. 1984). 
Interestingly, within the literature there appears to be inconsistency with respect to 
creatinine as a normalisation strategy in urinary ‗omics‘ study designs. Some groups 
have demonstrated no differences in creatinine levels related to exercise (Enea et al. 
2010), while others report large increases due to short term intensive exercise 
protocols (Calles-Escandon et al. 1984). Serum creatinine has also been shown to 
increase after strenuous aerobic exercise, which correlated with an increase in 
urinary creatinine levels (Decombaz et al. 1979). In any case it seems to be largely 
dependent on the particular physical exercise routine employed, diurnal variations, 
diet and muscular mass (Pasternack and Kuhlback 1971; Mayersohn et al. 1983; 
Baxmann et al. 2008). Taken together, the results reported in this chapter reflect the 
fact that the eccentric soft tissue damage protocol employed was energetically 
intensive enough to augment levels of creatinine within the urine of our participants 
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post exercise. The results presented in this study, and the contradictory evidence 
reported in the literature, indicate that further investigation of creatinine for 
normalisation in tissue damage models would be beneficial. Such investigations 
could have potential clinical consequences. In the absence of creatinine 
normalisation, it is recommended that spectral normalisation (post-hoc) techniques 
should be applied to account for differences in total amounts of metabolite analysed 
by the instrument, which was the approach adopted here. 
 
Yet another energy-pathway specific metabolite is glycerol. Glycerol is 
irreversibly liberated through the lipolysis pathways (Vaughan 1962) and was found 
to be increased in our cohort following the exercise protocol. It has previously been 
found to drop 60 min post exercise in plasma samples when compared to mid-
exercise samples (Lewis et al. 2010). The data presented here, demonstrating an 
increase in levels within 2 h following damage, support the finding of others (Lewis 
et al. 2010). Additionally, this observation has been corroborated by others who 
found increasing levels from baseline following resistance exercise (Goto et al. 2007; 
Ormsbee et al. 2007). Interestingly, Lewis et al. (2010) hypothesised that glycerol 
might be indicative of general ‗physical fitness‘ based on its lower levels within unfit 
participants resulting in impaired lipid utilization as a response to exercise (Lewis et 
al. 2010). Given its elevated levels here, this may suggest these participants were of a 
reasonable physical fitness, a hypothesis which is reflected in their exercise history  
with only two out of 21 participants indicating they did not exercise at all (Table 
2.2). 
 
Biochemical marker of inflammation 
Histamine has been studied extensively in the area of physical activity and 
asthma due to its role as a constrictor of bronchial smooth muscles (Hallstrand et al. 
2005; Lee et al. 2005). Importantly, histamine has also been implicated as a factor 
involved with vasodilation during ischemic exercise (Sparks 1980). Curiously, 
research involving bouts of aerobic exercise and the examination of the urinary 
metabolome do not mention the appearance of histamine (Enea et al. 2010; 
Pechlivanis et al. 2010). Although, it is known that serum levels of histamine are 
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increased during exhaustive cycling tests in both trained endurance atheletes and 
controls (Mucci et al. 2000). Histamine is thought to be released by mast cells within 
minutes of muscle tissue injury as part of the vasodilation process to allow an influx 
of additional phagocytic leukocytes into the site of the wound (MacIntyre et al. 
1995). While histamine has not been previously reported in urine based on the 
aforementioned metabolomic-based exercise studies, its role as a vasodilator during 
the early phase of inflammation and its known excretion into the urine make it a 
possible candidate to incorporate into a greater panel of markers. 
 
Potential biochemical markers of oxidative stress/transport 
Contraction of skeletal muscle results in oxidative stress as indicated by 
elevated levels of oxidized glutathione in blood and increased lipid oxidation (Sastre 
et al. 1992; Radak et al. 1999; Gomez-Cabrera et al. 2010). It is also clear that upon 
administration of antioxidants, such as thiol-containing compounds, the skeletal 
muscle fatigue observed during contraction is reduced (Shindoh et al. 1990). As such 
it comes of no surprise that several antioxidants were identified in the early stage of 
soft tissue damage. Myo-inositol is common to all living cells in the body with over 
half of it being lipid-bound (Clements and Reynertson 1977). Myo-inositol, in its 
trispyrophosphate form, has been previously shown to act as an allosteric effector of 
haemoglobin, which results in increases in cellular oxygen content (Fylaktakidou et 
al. 2005). The ability to counteract hypoxic conditions has also been studied in mice 
with severe heart failure (Biolo et al. 2009). In this study the authors were able to 
demonstrate an enhanced capacity to endure exercise compared to baseline levels 
(Biolo et al. 2009). Due to these findings, myo-inositol based molecules have been 
suggested to be performance enhancing drugs that may have applications in sports 
(Wong et al. 2011). Interestingly, the enzyme involved with the conversion of 
various myo-inositol-based isoforms (in particular 1D-myo-inositol 1,4,5-
trisphosphate to 1D-myo-inositol 1,3,4,5,6-pentakisphosphate) is called Inositol 
polyphosphate multikinase (IPMK) and is most abundantly expressed in skeletal 
muscle (Chang et al. 2002). 
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Another metabolite that has previously been shown to play an important role 
during hypoxic conditions is Taurine. Taurine is present in high concentrations in 
skeletal muscle (Huxtable 1992). To assess its purpose, taurine supplementation has 
been shown to increase the running time till exhastion in a rat model (Yatabe et al. 
2003). Supplementation has also been shown to reduce the effects of lipid 
peroxidation in an exercise-induced muscle damage study thus avoiding collateral 
damage of lipid structures, such as cell membranes, by free radicals (Dawson et al. 
2002). It has also been reported to be elevated in urine after three sets of sprints with 
1 min rest between replicates (25 min between sets) compared to 10 s rest between 
intervals, although this elevation was not determined to be significant for this 
particular protocol (Pechlivanis et al. 2010). The potential observation of increased 
taurine within urine samples in this study is consistent with its role in reducing 
oxidative stress. 
 
Biochemical marker of collagen degradation 
Of key interest to this study was the observation of 5-hydroxylysine. This 
molecule is a derivative of lysine that has undergone hydroxylation (addition of -OH 
functional group). Interestingly, it is a major component of collagen and has been 
utilised previously as an indicator of collagen break-down. For example, Brown et al. 
(1997) reported a significant increase in urinary 5-hydroxylysine following voluntary 
eccentric actions of the knee extensors. Additionally, Tofas et al. (2008) measured 
serum levels in a control and exercise group who underwent plyometric box jumps; 
they did not observe a significant pre/post result but these two examples demonstrate 
its potential use of 5-hydroxylysine in exercise-related areas and as such may be 
applied to an over-exertion model such that seen in the workforce (Tofas et al. 2008). 
 
4.7 CONCLUDING REMARKS 
In this study 
1
H-NMR was used to assess the < 3 kDa metabolite fraction of 
urine, in doing so, providing complimentary analysis to the SELDI-TOF/MS data. 
The data presented in this chapter demonstrates the utility of 
1
H-NMR for analysis of 
urine from a soft tissue damage model. Moreover, preliminary identifications of 
metabolites that are associated with energy metabolism and oxidative stress within 
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the body were made. The two most interesting markers were histamine, because it 
has not previously been reported in exercise-metabolomic studies, and 5-
hydroxylysine, because it is specific for collagen breakdown. Each of these 
metabolites may contribute to a larger urinary soft tissue damage ‗profile‘ or 
‗fingerprint‘ in the future to gain additional sensitivity (refer to section 1.10.1). 
Finally, NMR is not the most sensitive instrument for complex samples thus the 
application of more sensitive analytical methods such as GC-MS or LC-MS may 
resolve some of the analytical limitations encountered such as water saturation. 
Alternately depletion strategies may be implemented to reduce the metabolome 
complexity, although this approach is more common in proteomics studies. 
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Chapter 5: LC-ESI-MS/MS Proteomics 
analysis of the Injury/Recovery 
Urinary Proteome 
5.1 INTRODUCTION 
In the previous chapters, two single-dimension analytical approaches were 
applied (SELDI-TOF/MS and 
1
H-NMR) in an effort to find ‗profiles‘ or 
‗fingerprints‘ that are indicative of damage or recovery of soft tissue. Importantly, in 
Chapter 3 an MS
1
-level analysis on a subset of LMW proteins/polypeptides (only 
those with a net positive charge) showed some interesting temporal patterns but none 
that were significantly different from the baseline levels. Due to the glomerular 
apparatus within the kidneys having an approximate cut-off of 40-60 kDa and the 
optimal mass range of SELDI-TOF/MS being between ~2-20 kDa, it was important 
to assess the wider urinary proteome and incorporate the 20-60 kDa region. This 
would allow the measurement of proteins/polypeptides that did not bind to the 
surface chemistry in the original proteomic profiling strategy. It was expected that 
this approach would provide greater proteome coverage along with confident 
identifications of the proteins in the sample, a capability which the SELDI-TOF/MS 
platform does not have. 
 
Several studies have reported biomolecular variation in blood and urine 
samples due to physical activity and soft tissue damage. Enea et al. (2010) had 
participants perform exhaustive anaerobic exercise at 75% VO2 max until failure 
before assessing their urinary metabolome via 
1
H-NMR spectroscopy (Enea et al. 
2010). They found significantly elevated levels of lactate, alanine, acetate, pyruvate, 
succinate and hypoxanthine due to the exercise procedure. In the same year another 
group published a similar 
1
H-NMR profiling study looking at a less exhaustive 
exercise protocol (a range of sprint drills) and found that the levels of the metabolites 
listed above were significantly increased due to exercise, except for succinate and 
acetate (Pechlivanis et al. 2010).  
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Potential protein indicators of tissue damage and degradation have also been 
discussed previously. However, most of these studies have concentrated on analysis 
of biopsy or blood samples and have focussed on a variety of soft-tissue models such 
as muscle damage (Holloway et al. 2009) and tendon ruptures (Jialili et al. 2011; 
Nuerai et al. 2011). This author is unaware of any studies reporting novel 
protenatious degradation products which leak into the blood circulation and then pass 
into the urine due to soft tissue damage. 
 
There are several benchmark studies which have investigated the protein 
components present in human urine (Castagna et al. 2005; Adachi et al. 2006; Chen 
et al. 2007; Li et al. 2010; Marimuthu et al. 2011). These cornerstone papers used a 
variety of proteomic pre-fractionation methods and mass spectrometry platforms to 
report on the large number of constituent proteins within urine. The common feature 
within each of these reports is that many of identified proteins were derived from 
various tissues within the body and not just from the kidney or lower urinary tract 
and they encompass a range of biological functions. Interestingly, some of the more 
tissue specific peptides identified were from proteins of such a large molecular 
weight that they would be unable to pass the glomerular filtration machinery without 
prior endogenous degradation. This suggests that additional proteomic investigation 
into protein components that SELDI-TOF/MS did not detect (i.e. > 20 kDa, non-
cationic complement) will provide complementary data and an interesting glimpse 
into the soft tissue ―degradome‖ following eccentric tissue loading. 
 
In summary, following soft tissue damage an overall change in the protein 
constituents at the site of damage is observed; this includes post translational 
modifications (PTM), as well as enzymatic changes resulting in protein degradation 
(Kachaeva and Shenkman 2012). It is clear that these proteins or protein degradation 
products can transfer from the tissue into the circulation (Sorichter et al. 1999). Once 
in the circulation proteins less than ~60 kDa will have a propensity to pass into the 
urine as discussed previously (section 1.9). Importantly, there is currently very little 
information regarding the urinary ‗degradome‘ due to soft tissue damage processes. 
The hypothesis that proteins due to soft tissue damage are present within the urine 
was investigated. The aim of this study was to assess a bottom up LC-MS/MS (see 
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1.11.2) proteomic method to determine the soft tissue damage and recovery 
constituents of the urinary proteome. This involved initial C18 capillary fractionation 
of non-labelled peptides, followed by high resolution tandem mass spectrometry and 
a thorough qualitative and semi-quantitative analysis of peptide/protein products. 
Information obtained from this study complements the previous chapters by 
analysing a wider protein mass range and providing confident identifications of 
proteins that appear to be temporally expressed in urine at altered levels due to 
eccentric tissue damage. 
 
5.2 METHODS 
5.2.1 Materials and reagents 
Pure HPLC grade water and a Bradford kit were purchased from Sigma 
Aldrich Pty Ltd (Castle Hill, NSW, Australia). Acetonitrile (ACN) and acetone were 
purchased from Merck (Darmstadt, Germany). Dithiothreitol (DTT) was purchased 
from Roche (Mannhein, Germany). Formic acid (FA) and 2,2,2-trifluoroethanol 
(TFE) came from Fluka (Buchs, St Gallen, Switzerland). Iodoacetamide (IAA) was 
purchased from GE Life Sciences (Little Chalfont, Buckinghamshire, UK). Sequence 
grade Trypsin was purchased from Promega (Madison, WI, USA). All reagents and 
chemicals were of HPLC-grade quality. 
 
5.2.2 Tissue damage and urine collection 
Urine samples were collected from otherwise healthy participants who 
underwent the eccentric tissue loading protocol outlined in section 2.4. The damage 
protocol took place at the IHBI under controlled conditions. The participant samples 
utilised in this study were provided by 6 participants (V5, V12, V15, V19, V20 and 
V22) and consisted of baseline through to seven days post exercise samples. The 
decision to use these participants was based on their individual functional recovery 
results (Chapter 2) which demonstrated either a large initial drop in functional 
strength or a prolonged recovery profile. As such, each of these participants can be 
considered ‗high responders‘ to the exercise intervention. Each timepoint after the 
first week was removed from the analysis because neither the SELDI or NMR 
studies suggested there was valuable information within these timepoints (i.e. urinary 
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phenotype did not suggest anything outside of ‗normal‘). Each participant collected 
urine by either coming in to the IHBI to supply the sample on the date required or by 
collecting samples at home with a container supplied (refer to section 2.3.2). In either 
case the samples were immediately stored at -20°C until analysis. 
 
5.2.3 Urinary protein concentration 
Samples were thawed in a 25
 o
C water bath followed by clarification at 1500-
-g for 10 min. The supernatant was then passed through a 0.2-µm syringe filter to 
remove any remaining bacterial contamination and high molecular weight protein 
aggregates. The filtrate was then concentrated in a pre-rinsed (with ddH2O as per 
manufacturers instruction) 3K-NMWL Amicon® Ultra-4 centrifugal filter device 
(Millipore™, Billerica, MA, USA), centrifuged at 4000--g for 30 min in a swing 
bucket centrifuge. The retentate was washed (3) with 15 mL ddH2O at 4000  g 
for 30 min to desalt the sample. Concentrated protein derived from each sample was 
then aliquoted into low bind eppendorf tubes, labelled and stored at -80°C. Protein 
concentrations were established for each test sample using the Bradford assay (Sigma 
Aldrich Pty Ltd, Castle Hill, NSW, Australia), as described previously (section 
3.2.2). A total of 20 g of > 3 kDa complex urinary protein was extracted for 
digestion and subsequent LC-MS analysis. 
 
5.2.4 Trypsinisation preparation for top-down label-free proteomics 
Each 20 g aliquot containing the > 3 kDa urinary proteome fraction was 
lyophilised by vacuum centrifugation (Labconco, Kansas City, MO, USA) prior to 
resuspension of the resulting pellet in 50 L of denaturation buffer, which contained 
20% Triflueroethanol (TFE) v/v, 50 mM (NH4)HCO3 (pH 7.8) and 20 mM 
Dithreothietol (DTT). Each sample was sonicated for 5 min and briefly centrifuged 
before incubation at 55°C for 1 h in a heating block. Following incubation, 55 mM of 
iodoacetamide (IAA) was added before incubating for a further 1 h at RT, in the 
dark. The volume was reduced by ~75% before resuspending in 50 L of 50 mM 
(NH4)HCO3 (pH 7.8), 5% ACN. Trypsin (Promega, Alexandria, NSW, Australia) 
was resuspended in trypsin buffer (acetic acid) to a final concentration of 0.5 g. L-1 
and 5 L was added to each sample. Each sample was then incubated in an oven set 
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to 37°C for 17 h. The following day, the samples were lyophilised to dryness before 
resuspending in 100 L 2% ACN, 0.1% FA. Tryptic peptides were then cleaned 
through 10 kDa microspin filter device for 5 min at 10,000 rpm which had been 
prewashed in Buffer A (2% ACN, 0.1% FA). The membrane was then further 
washed with an additional 500 L of Buffer A for 5 min at 10,000 rpm to rinse 
through any remaining peptide. The sample was then lyophilised and resuspended in 
100 L of buffer A prior to LC-qTOF analysis. 
 
5.2.5 LC-MS/MS analysis on the ABSCIEX Hybrid Quadrupole TripleTOF™ 
5600 
Complex urinary protein digests were separated on a Shimadzu Nexera nano 
HPLC system equipped with a SIL20AC autosampler. Inline desalting and pre-
equilibration was achieved by injecting 2 L of complex peptide mixture (400 ng 
protein) onto a C18 trapping column (Agilent Zorbax 300SB C18 5 m 5  0.3 mm, 
part no. 5065-9913) (Agilent Technologies, Forest Hill, VIC, Australia). Trapping 
and desalting was achieved with 100% Buffer A (2% ACN, 0.1% FA) at 30 L.min-1 
for 4 min. Separation of complex urinary peptide mixtures was performed on a nano-
LC resolving column (Vydac Everest C18 300 Å, 5 m reverse phase, 150 mm x 75 
m, part no. 283EV5.07515) (Grace Davison Discovery Sciences, Rowville, VIC, 
Australia) across a 30 min linear gradient of 2% - 40% (v/v , Buffer B). The organic 
component of the buffer was increased to 80% B over the next 5 min before flushing 
with 80% B for an additional 5 min. The column was then re-equilibrated in 2% B 
for 10 min in preparation for the following injection. Both the trap and resolving 
columns were maintained at a constant temperature of 40°C. 
 
The analyte was eluted from the resolving column directly into the MS through 
a NanoSpray® III nano-source. Ions were mobilized with an ionspray voltage of 
2000 V, and the solvent was removed with an interface heater temperature of 150°C, 
and nebuliser gas was set to a value of 10. An Information Dependent Acquisition 
(IDA) criteria was applied using the top 20 most abundant precursor ions resulting in 
the acquisition of 20 product ion scans across a ~2.5515 s cycle time for a period of 
54 min (~1,270 cycles). These product ion scans were collected only if a 300 cps 
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threshold was exceeded and were acquired twice with a dynamic exclusion of 8 sec 
for former target ions. A declustering potential (DP) of 100 was set and Collision 
Induced Dissociation (CID) of precursor ions was achieved with a rolling collision 
energy. Q1 was set to low resolution with a high sensitivity and high resolution TOF 
scan, the TOF scan range was between m/z 300 and 1800. 
 
5.3 OBJECTIVE PROTEIN IDENTIFICATION SCHEMA VIA MS/MS 
DATABASE SEARCHING 
5.3.1 Construction of databases 
A custom database was created from the first quarter (2012) SwissProt 
database and used for all peptide spectrum matching (PSM) searches (OMSSA and 
X!Tandem). The database was customised by first extracting each of the human 
proteins, which resulted in 20,243 protein entries. A contaminants database was then 
appended to the human only SwissProt entries above. This database was provided by 
the Global Proteome Machine (GPM) (http://www.thegpm.org, last accessed January 
2012) and titled common Repository of Adventitious Proteins (cRAP). The cRAP 
database consisted of 115 common contaminant proteins which are either: a) 
common in laboratories; b) present through accidental physical contact or dust 
contact; and 3) common in molecular mass spectrometry standards or reagents. A list 
of contaminating proteins can be seen in Appendix C1 (Table 2) or downloaded from 
http://www.thegpm.org/crap/index.html. The resulting database consisted of 20,358 
entries. Importantly, the contaminants database also contains human protein entries 
that already existed in the human SwissProt database. As such, these redundant 
proteins were removed to eliminate potential bias in the database due to duplicate 
protein entries. This non-redundant human-contaminants database now contained 
20,297 protein entries. In this study a target-decoy peptide spectrum match (PSM) 
strategy was employed. The decoy database was produced by creating random 
sequences with the same average amino acid composition as the non-redundant 
human-contaminants database above, the benefits of which have been previously 
discussed (Elias and Gygi 2007). Decoy sequences were produced using Matrix 
Science‘s decoy-perl script (http://www.matrixscience.com/help/decoy_help.html, 
last accessed January 2012) and decoy proteins were labelled with ―###RND###‖ for 
easy identification. These two databases were then combined to create a non-
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redundant human-contaminants decoy database. The complete non-redundant 
human-contaminants-decoy database contained 40,594 protein entries. 
 
5.3.2 SpectraST consensus library 
A custom spectral library was created using the National Institute of Standards 
and Technology (NIST) human ‗QTOF‘ dataset (Stein and Rudnick 2012), the 
Institute for Systems Biology (ISB) human plasma consensus spectral library and 
ISB phosphopeptide spectral library (Desiere et al. 2006; Deutsch et al. 2008). These 
three spectral libraries were combined into an ‗.splib‘ library file and redundant 
peptides removed using the SpectraST library building tools (Lam et al. 2007). 
 
5.3.3 X!Tandem search parameters 
X!Tandem searches were performed against the target-decoy database 
discussed above (section 5.3.1). Precursor ion charge states up to [M+5]
5+
 were 
considered by the X!Tandem algorithm. A carbamidomethylation modification of 
cysteines (+15.949) was the only static modification. Variable modifications 
consisted of oxidized methoinine (+15.999) and a deamidation applied to asparagines 
and glutamines (+0.9840). A positive monoisotopic mass error of 4.0 and a negative 
mass error of 0.5 for precursor masses was used along with a product mass error of 
0.8. Searches were specific for only trypsin, allowing a maximum of one missed 
cleavage site. Only y and b ions were considered for peptide spectrum matching. 
 
5.3.4 OMSSA search parameters  
Due to the scoring algorithm incorporated in OMSSA, MS/MS searches must 
be performed on a decoy database; thus, the target-decoy database outlined above 
was used (section 5.3.1). Again, fixed modification accounting for carbamidomethy-
C along with variable modifications for oxidized methoinine and deamidated 
asparagine and glutamine was incorporated into the search. The product ion tolerance 
was set to 0.8 Da while the precursor tolerance was set to 2.0 Da. Only b and y ions 
were considered with charge states of [M+2]
2+
 and above. This was a tryptic-only 
search, allowing up to one missed cleavage with an e-value cut-off of 1e
6
. 
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5.3.5 SpectraST search parameters 
Spectral library searches were performed against the spectral library created 
above (section 5.3.2) using an adaptive Thomson unit of mass to charge ratio of ± 0.8 
Th. 
 
5.3.6 Trans-Proteomic Pipeline 
Final peptide and protein identifications from each of the three search 
algorithms were statistically validated using the Trans-Proteomic Pipeline (TPP). 
Peptide assignments from each of the search algorithms were validated using 
PeptideProphet‘s Bayesian classification and semi-supervised modelling schema as 
outlined previously (Keller et al. 2002). To take advantage of the high mass accuracy 
of the Hybrid quadrupole (5600 Triple TOF) system, accurate mass binning was 
incorporated into the model building process. PeptideProphet gives the probabilities 
for individual spectr. However, because multiple search algorithms were used, it was 
important to account for all spectra that map to the same sequence (from different 
algorithms) in a statistically sound manner. To do this, the adjusted probabilities 
were estimated using the additional statistical models incorporated within the 
iProphet tool (Shteynberg et al. 2011). These models include: Number Sibling 
Searches (NSS), Number Replicate Spectra (NRS), Number Sibling Experiments 
(NSE), Number Sibling Ions (NSI) and Number Sibling Modifications (NSM). 
Peptide grouping into protein and subsequent protein probabilities was determined 
using ProteinProphet (Nesvizhskii et al. 2003) with a peptide probability cut-off of 
0.05. Each of these validation tools are provided within the TPP schema (Figure 
5.1). 
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Figure 5.1. LC-MS/MS protein analysis schema. GO = Gene Ontology, PSM = peptide spectrum matching. 
The red boxes indicate targeted peptide spectrum matching using spectral library searching. The Trans-
Proteomic Pipeline has the ability to combine multiple algorithms and validate search results. 
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5.3.7 Protein-protein interactions, network visualisation and ontology analyses 
Validated protein identifications for each time-point were used to retrieve 
protein-protein interaction data from the BioGrid, InAct, Bind, DIP, MINT and 
HPRD protein interaction databases. This was facilitated through the BisoGenet 
plug-in (v1.41.01; bio.cigb.edu.cu/bisogenet-cytoscape/) for Cytoscape (v2.8.2; 
www.Cytoscape.org) where identifiers were provided as input and networks created 
by retrieving interaction evidence connecting the input identifiers. Networks were 
visualised in Cytoscape with each node representing an input protein identifier and 
each edge representing protein-protein interaction evidence. Gene ontology analyses 
were performed using the BiNGO plug-in (v2.44; 
www.psb.ugent.be/cbd/papers/BiNGO/Home.html) for Cytoscape to identify 
Cellular Components and Molecular Functions that are over-represented in the 
proteomic data when using the entire gene ontology (GO) annotation as the reference 
set. Analyses were performed using Hypergeometric tests accompanied by 
Benjamini and Hochberg False Discovery Rate (FDR) correction. Ontologies were 
considered significantly over-represented if p ≤ 0.05 following FDR correction. All 
tests were performed using the most current gene ontology annotation acquired from 
the Gene Ontology Project (www.geneontology.org/, last accessed June 2012). 
 
5.3.8 Heatmap visualisation of GO results 
Heatmaps for Molecular Function and Cellular component GO terms were 
generated for ease of interpretation. To make patterns more obvious across each 
timepoints, each of the rows (representing GO terms) were standardised using z-
scores, i.e. , were x is the relative abundance for that GO term at a particular 
timepoint and  is the row mean (average across all timepoints) divided by the row 
standard deviation, s. 
 
5.3.9 Abacus: label-free MS2 quantification 
The TPP results were input into the Abacus framework to estimate 
quantification results (Figure 5.1). The combined file probability threshold was set 
to 0.9. Additionally, only peptides with a probability over 0.5 were considered for 
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quantification. A Normalised Spectral Abundance Factor (NSAF) was calculated 
according to the following equation: 
 
Equation 10 
 
 Thus for protein, k, the total number of MS
2
 spectral counts (SpC) identifying 
protein k is divided by the length (L) of the protein before dividing by the sum of 
SpC/L for all N proteins within the experiment (Zybailov et al. 2006). In addition, 
Abacus performs an adjustment to the NSAF value by using a weighting factor ( p,k) 
that accounts for redundant peptides within the detected proteome. This is done as 
follows: 
 
 
Equation 11 
 
 Where the number of unique spectra, s, that get assigned to each protein k, is 
determined, then for each j=1,...,N proteins with a peptide, p, that is present in > 2 
proteins (i.e. multiple proteins) the contribution to the spectral count of protein k is 
adjusted by p,k. The result is an adjusted NSAF value which from here on will be 
identified as NSAFadj. Refer to Fermin et al. (2011) for a comprehensive discussion 
on Abacus and the NSAFadj calculation (Fermin et al. 2011). 
 
5.3.10 File management 
Raw qTOF-MS/MS ‗.wiff‘ files were converted to mzXML using the Windows 
client of msConvert from the ProteoWizard software suite (version 3.0.3597) 
(Chambers et al. 2012). Conversions were performed on a standard desktop 
computer (32-bit) equipped with an Intel® Core™ i7-2600 CPU consisting of four 
cores and eight threads. The mzXML files were then converted to mascot generic 
files (.mgf) using a continuous wavelet function that chose the top 50 peaks with a 
signal to noise threshold above 1.5. These file conversions were performed in ‗R‘ 
(version 2.15.0, www.r-project.org). Database searches were executed on the 
resulting ‗.mgf‘ files using the aforementioned PSM algorithms and library-searching 
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algorithm on a SGI Altix XE cluster (1316  64 bit Intel Xeon cores, 9376 
Gigabytes shared memory and a SUSE Linux Operating System). 
 
5.4 RESULTS 
Urine samples from six participants, consisting of 48 samples collected across 
the first week of soft tissue damage and recovery, were analysed in duplicate 
resulting in 96 LC-MS/MS runs on a high resolution mass spectrometer. The data 
acquired were searched using SpectraST, OMSSA and X!Tandem and post processed 
(i.e. validated) through the TPP. Search results were combined into timepoints in an 
effort to highlight the dynamic nature of protein presence in the participants‘ urine 
for the seven days following damage. On average, PeptideProphet identified 36,876 
(SD ± 3,682.97) unique peptides across the first seven days which assigned to 
1,9021.9 (SD ± 1,398.83) unique proteins (Table 5.1). Of those proteins identified, 
8,235.13 (SD ± 544.853) were assigned based on a single high-confidence peptide 
identification (Table 5.1). This proportionally large number of single-hit proteins is 
common within MS/MS analyses of this nature (Rohrbough et al. 2006). As such the 
decision on how real a PSM is should be based on intelligent filtering depending on 
the goals of the study and the validation procedures used (Carr et al. 2004; Veenstra 
et al. 2004). To this end, only peptide identities that mapped to a single protein (i.e. 
that were unique) within the database were included in the final list. In addition, the 
TPP and its suite of validation tools was incorporated into the overall analysis 
pipeline, and each peptide needed to pass this series of filters to be classed as a 
positive identification. 
 
There was between 6,895 (D3) and 8,501 (BL) (minimum and maximum 
respectively) protein identities assigned from a single peptide (Table 5.1). These 
single hit PSMs were reported as proteins only if they were non-degenerate 
identifications, i.e. a peptide that was unique to a particular protein and if they passed 
the validation criteria set within the TPP in section 5.3.6 (Table 5.2). Thus using the 
TPP validation tools, the protein sensitivity and error were estimated for each 
timepoint in the dataset (Figure 5.2a and b). Based on these results a minimum 
probability threshold of 0.1 was selected which resulted in maximum sensitivity of 1 
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and produced a false discovery rate (FDR) of 10% or less for each of the data-sets 
(Table 5.2). The number of proteins identified across the first week was between 220 
and 253, where the ‗number of proteins identified‘ is based on a min-probability 
threshold of 0.1 (Table 5.2). 
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Table 5.1 
PeptideProphet Metadata 
Time-point Unique 
Peptides 
Unique 
Stripped 
Peptides 
Unique 
Proteins 
Single Hits Total 
MS
2
 
Spectra 
BL 38,069 35,122 19,584 8,501 111,691 
D1 37,408 34,433 19,317 8,455 111,886 
D2 39,079 35,968 19,821 8,444 116,239 
D3 27,864 24,767 15,586 6,895 99,858 
D4 37,924 34,772 19,488 8,435 117,654 
D5 38,039 34,938 19,387 8,358 121,541 
D6 38,856 35,660 19,654 8,475 121,192 
D7 37,772 34,766 19,338 8,318 112,473 
Mean 36,876 33,803 19,021 8,235 114,067 
SD 3,682 3,685 1,398 544 6,959 
 These results represent the data from six participants. BL= Baseline, D1 = Day 1 after damage, D2 = Day 2 after 
damage, D3 = Day 3 after damage, D4 = Day 4 after damage, D5 = Day 5 after damage, D6 = Day 6 after damage, 
D7 = Day 7 after damage. 
 Unique peptides =  Unique Peptides identified 
 Unique Stripped peptides = Unique peptide identifications stripped of charge and modifications 
 Unique Proteins = non-redundant proteins identified from the database used 
 Single hits = single peptides mapped to a protein within the database used 
 Total MS2 spectra = the number of MS2 peptide assignments made 
 SD = Standard Deviation 
 
Table 5.2 
Protein Identification Results 
Time-
point 
Number of protein 
identifications 
Sensitivity at min-
probability threshold 
Error at min-probability 
threshold (FDR) 
0.00 0.10 0.20 0.00 0.10 0.20 
BL 231mp=0.1 1 1 1 0.280 0.078 0.078 
D1 248 mp=0.1 1 1 1 0.290 0.079 0.079 
D2 244 mp=0.1 1 1 1 0.274 0.080 0.080 
D3 221 mp=0.1 1 1 1 0.294 0.090 0.090 
D4 237 mp=0.1 1 1 1 0.319 0.070 0.070 
D5 253 mp=0.1 1 1 1 0.290 0.094 0.094 
D6 244 mp=0.1 1 1 1 0.320 0.095 0.095 
D7 220 mp=0.1 1 1 1 0.378 0.084 0.084 
 These results represent the data from six participants. BL= Baseline, D1 = Day 1 after damage, D2 = Day 2 after 
damage, D3 = Day 3 after damage, D4 = Day 4 after damage, D5 = Day 5 after damage, D6 = Day 6 after damage, 
D7 = Day 7 after damage. 
 ―mp = 0.1‖ = The number of identified proteins is based on a minimum probability of 0.1 
 FDR = False Discovery Rate 
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Figure 5.2. Sensitivity and false positive error rates across a range of computed minimum probabilities. a) 
The estimated sensitivity, or fraction of all correct results given a specific threshold and; b) estimated error 
(FDR), or the fraction of all results passing a specific filter that are incorrect. The models are calculated for each 
of the combined time-point MS/MS analyses using the TPP tools. A minimum probability of 0.1 was set as the 
threshold for confident identification resulting in maximum sensitivity with under 10% error for each of the 
timpoints (Table 5.2). 
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5.4.1 Muscle-specific GOs are overrepresented in the urine following soft tissue 
damage 
The high-confident protein identifications (after removal of proteins identified 
from the cRAP database (Appendix C1,Table 2) were categorized according to the 
GO annotation terms using the Biological Networks Gene Ontology (BiNGO) plug-
in within the cytoscape analysis framework (Maere et al. 2005). Proteins from each 
time-point were classified into each of two categories, 1) Cellular Component (87 
cellular components identified) and 2) Molecular Function (99 functions identified). 
These results represent only significant GO terms estimated using a significance 
threshold of p ≤ 0.05. If a particular time-point did not show a significance level for a 
particular GO term below that of the cut-off (but surrounding time-points did), it was 
given an abundance value of 0, corresponding to 0% overrepresentation within that 
timepoint.  
 
Analysis of Cellular Component GO-terms 
From both the Cellular Component and Molecular Function data, those time-
points with significant GO-terms that appeared to change over time were investigated 
further. Based on the Cellular Component data, it was clear that there were dynamic 
fluctuations across the seven day recovery period within several key tissues (Figure 
5.3). Of particular interest to this study were the increases in Cellular Components 
relating to muscle specific tissues; these include H zone, myosin complex, I band, 
muscle myosin complex, A band, myosin II complex, sarcomere, contractile fibre, 
myosin filament and contractile fibre part. These data strongly support the 
hypothesis that skeletal muscle tissue constituents are present within the urine 
following eccentric loading of the biceps brachii. A heatmap of all the Cellular 
Component GO terms are listed in Figure 5.3. 
 
Analysis of Molecular Function GO-terms 
The Molecular Function results appear to demonstrate similar trends to the 
Cellular Component data for some of the soft-tissue specific GO terms (Figure 5.4). 
However, a key finding was additional Molecular Functions that were not specific to 
muscle tissue. These included proteins related to Molecular Functions involving 
lipid-protein interactions and ECM-interactions. Some noteworthy functions were 
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titin binding which increased from D2 and remained elevated until D5 (Figure 5.4). 
In addition, thrombospondin activity increased on D2 and D3 before levels were 
reduced to baseline. Furthermore, Fibronectin-binding, alpha actinin binding and 
actin-binding were each more over-represented in D2 and D3 than they were in the 
other time-points. Eukaryotic cell surface binding appeared to peak at D3 before 
decreasing slightly, but was still more prominent at this time-point compared to the 
baseline, D1 and D2 periods. Interestingly, there were also a number of lipid-based 
Molecular Functions which showed increases in prominence from D1 post exercise, 
that were not observed in the baseline samples. These functions include fatty acid 
binding, high-density lipoprotein particle binding, high-density lipoprotein particle 
receptor binding, lipid transporter activity, triglyceride-rich lipoprotein particle, and 
phosphatidylcholine-sterol O-acyltransferase activator activity (Figure 5.4). 
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Figure 5.3. Over represented Cellular Functions in urine following soft tissue damage. A heatmap of 
significantly (p ≤ 0.05) over-represented Cellular Function terms obtained across seven days following soft 
tissue damage. The intensity of each block in the heatmap represents the z-score for that particular GO-term. 
Baseline = before soft tissue damage, Day 1 through Day 7 represent the first week of recovery from soft tissue 
damage. 
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Figure 5.4. Over represented Molecular Functions in urine following soft tissue damage. A heatmap of 
significantly (p ≤ 0.05) over-represented Molecular Function terms obtained across seven days following soft tissue 
damage. The intensity of each block in the heatmap represents the z-score for that particular GO-term. Baseline = 
before soft tissue damage, Day 1 through Day 7 represent the first week of recovery following soft tissue damage. 
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The GO analysis was challenging to interpret due to the ambiguous 
interpretation of multidimensional protein assignments (i.e. the same protein 
assigned to multiple GO-terms). For example phosphatidylcholine-sterol O-
acyltransferase activator activity, high-density lipoprotein particle receptor binding 
and high-density lipoprotein particle binding each have the same proteins assigned to 
them (Apolipoprotein A-I and A-II). The difficulties associated with interpretation of 
these kinds of data have been noted in previous proteomic studies (Nguyen-Khuong 
2011). Thus, it is worth reiterating the authors‘ statements regarding utility of this 
software: “BiNGO assesses the functional themes that are present in a set of genes 
[or proteins]. Even though a P-value gives a good indication about the prominence 
of a certain functional category, it is risky to draw conclusions solely based on P-
value” (Maere et al. 2005).  
 
As such, interpretation needs to be performed carefully and with regard to the 
biological question that is being asked. Within this study, results from GO analysis 
were used to determine some of the important soft tissue specific Molecular 
Functions or Cellular Components that are present within urine. While this analysis 
revealed some potential fluctuations in lipid-based and ECM-based gene ontologies 
(Figure 5.3 and Figure 5.4), these Cellular Components, Molecular Functions, and 
subsequent protein identities are not unique to this cohort. In fact GO terms such as 
Extracellular regions, extra cellular space, extracellular matrix, collagen, basement 
membrane, fibrillar collagen, lipid binding, lipid transporter activity, fatty acid 
binding and phospholipase inhibitor activity are commonly over-represented within 
‗normal‘ human urine which reflects the complex nature of urinary proteins (Adachi 
et al. 2006). In contrast, Adachi et al. (2006) reported no Cellular Component or 
Molecular Function GO terms that related to muscle tissue at all (Adachi et al. 
2006). Taken together, this suggests that detection of muscle-specific GO terms in 
this study may present a novel finding. As such only proteins relating to the muscle 
tissue GO terms in Table 5.3 were extracted and specifically targeted for 
quantification. A list of protein accession assignments to each GO term is provided 
in Appendix C3, Table 4 and Table 5. 
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These proteins specifically targeted for quantification consisted of actin, alpha 
skeletal muscle, filamin-C, myosin-13, myosin light chain 1/3 (skeletal muscle), 
myosin-binding protein C, titin, telethonin and myozenin-1 (Table 5.4). Each of the 
identified proteins had varying sequence coverage. This is a typical trait of 
proteotypic peptides (i.e. commonly reported peptides) because they have a greater 
propensity to be detected by the mass spectrometer (Deutsch et al. 2008) (Table 5.5). 
Of these identified proteins, four proteins were identified with evidence of only a 
single unique peptide. These proteins included myosin-binding protein H (protein 
probability = 0.6461), Myosin-7 (protein probability = 0.3354), myosin light chain 
1/3 skeletal muscle isoform (protein probability = 0.5903) and telethonin (protein 
probability = 0.883) (Table 5.5). The rest were identified with two or more tryptic 
peptides which is reflected in their protein probability scores of 0.999, 1.000, 1.000, 
1.000, 1.000 and 1.000 for actin, alpha skeletal muscle, filamin-C, myosin-13, 
myosin-binding protein C, titin and myozenin, respectively (Table 5.5). 
 
 
Table 5.3 
Molecular functions and Cellular components unique to muscle tissue 
Molecular Function Cellular Component 
 Titin binding 
 Structural constituents of 
muscle  
 Alpha-actinin binding 
 Actinin binding 
 H zone 
 Myosin complex 
 I band 
 Muscle myosin complex 
 A band 
 Myosin II complex 
 Sarcomere 
 Myofibril 
 Contractile fibre part 
 Myosin filament 
 Contractile fibre 
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Table 5.4 
List of protein targets used for quantification by Abacus. The list is based on Molecular Function and Cellular Component GO analysis results 
Entry Entry name Protein names Length (aa) Subcellular location GO group 
P68133 ACTS_HUMAN Actin, alpha skeletal muscle 
 
377 Cytoplasm > cytoskeleton. CC 
Q14315 FLNC_HUMAN Filamin-C (FLN-C) (FLNc) (ABP-280-like protein) (ABP-L) (Actin-binding-like 
protein) (Filamin-2) (Gamma-filamin) 
2725 Cytoplasm. Membrane; Peripheral membrane protein. 
Cytoplasm >cytoskeleton. Cytoplasm >myofibril 
>sarcomere >Z line. 
CC 
Q13203 MYBPH_HUMAN Myosin-binding protein H (MyBP-H) (H-protein) 477  CC 
Q9UKX3 MYH13_HUMAN Myosin-13 (Myosin heavy chain 13) (Myosin heavy chain, skeletal muscle, 
extraocular) (MyHC-eo) 
1938 Cytoplasm >myofibril. CC 
P12883 MYH7_HUMAN Myosin-7 (Myosin heavy chain 7) (Myosin heavy chain slow isoform) (MyHC-
slow) (Myosin heavy chain, cardiac muscle beta isoform) (MyHC-beta) 
1935 Cytoplasm >myofibril. MF & CC 
P05976 MYL1_HUMAN Myosin light chain 1/3, skeletal muscle isoform (MLC1/MLC3) 
(MLC1F/MLC3F) (Myosin light chain alkali 1/2) (Myosin light chain A1/A2) 
194  CC 
Q00872 MYPC1_HUMAN Myosin-binding protein C, slow-type (Slow MyBP-C) (C-protein, skeletal muscle 
slow isoform) 
1141  MF & CC 
O15273 TELT_HUMAN Telethonin (Titin cap protein) 167 Cytoplasm >myofibril >sarcomere. MF & CC 
Q8WZ42 TITIN_HUMAN Titin (EC 2.7.11.1) (Connectin) (Rhabdomyosarcoma antigen MU-RMS-40.14) 34350 Cytoplasm. Nucleus. MF & CC 
Q9NP98 MYOZ1_HUMAN Calsarcin-2, Filamin-, actinin- and telethonin-binding protein 
Protein FATZ 
 Localized to the nucleus and pseudopodia of 
undifferentiated cells and detected throughout the 
myotubes of differentiated cells. Colocalizes with 
ACTN2, FLNC and MYOT at the Z-lines of skeletal 
muscle 
CC 
 CC= Extracted from Cellular Component GO terms 
 MF= Extracted from Molecular Function GO terms 
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Table 5.5 
Muscle-specific proteins identified in urine as a result of eccentric soft tissue loading (biceps brachii) 
Tissue Protein 
Accession 
Entry Name Amino Acid Sequences Identified Peptide Mods 
Present 
Protein 
Probability 
S
k
el
et
al
 m
u
sc
le
 t
ar
g
et
s 
P68133 Actin, alpha skeletal 
muscle 
 SYELPDGQVITIGNER 
 AGFAGDDAPR 
 0.9993 
 
Q14315 Filamin-C  QQEGEASSQDMTAQVTSPSGK 
 TDTYVTDNGDGTYR 
 SLTATGGNHVTAR 
 VGVTEGCDPTR 
 DLAEDAPWK 
 VSGPGVEPHGVLR 
 EVTTEFTVDAR 
 VQYTAYEEGVHLVEVLYDEVAVPK 
 VHVQPAVDTSGVK 
Q[129] 
N[115] 
 
C[160] 
 
 
 
Q[129] 
1.000 
Q13203 Myosin-binding 
protein H 
 VPTAEPPGEVAVSESTR  0.6461 
Q9UKX3 Myosin-13  QREEQAEPDGTEVADK 
 EEQAEPDGTEVADK 
Q[111] & Q[129] 
 
1.000 
P12883 Myosin-7  QREEQAEPDGTEEADK Q[111] 0.3354 
P05976 Myosin light chain 
1/3, skeletal muscle 
isoform 
 ITLSQVGDVLR  0.5903 
Q00872 Myosin-binding 
protein C, slow-type 
 VELECEVSEDDANVK 
 QLEDTTAYCGER 
 LEIPISGEPPPK 
 FTITGLPTDAK 
 YYSQPILVK 
 QQEEEPQVDVWELLK 
C[160] 
Q[111] & C[160] 
 
 
 
Q[111] & Q[129] 
1.000 
O15273 Telethonin  VLPLPIFTPAK  0.8830 
Q8WZ42 Titin  ANVDGLLEGLTYVFR 
 ATNGSGQATSTAELLVK 
 AVPPEEIPPVVAPPIPLLLPTPEEK 
 DGQVISTSTLPGVQISFSDGR 
 DNGSPILGYWLEK 
 FHIENTDDLTTLIIMDVQK 
 GIPPKIEALPSDISIDEGK 
 IEALPSDISIDEGK 
 ISAINDAGVGEPAVIPDVEIVER 
 VLTVACAFTGEPTPEVTWSCGGR 
 SASLAWGKPHYDGGLEITGYVVEHQK 
 VPAPVEIPVTPPTLVSGLK 
 ISWYKEEQLLSTGFK 
 VTGIPTPVVK 
 AETAPPNFVQR 
 ITQFVVPDLQTK 
 LTWFSPEDDGGSPITNYVIEK 
 QDGGLYTLSLGNEFGSDSATVNIHIR 
 TIIVDVLDVPGPVGTPFLAHNLTNESCK 
 ELVSGGSCYITK 
 LTIPAVTK 
 LPGVQISFSDGR 
 VTGIPTPVVK 
 SPTPPSIAAK 
 
Q[129] & N[115] 
 
Q[129] 
N[115] 
N[115] & M[147] 
 
 
N[115] 
C[160] 
 
 
 
 
 
 
 
Q[111] & N[115] 
C[160] & N[115] 
C[160] 
1.000 
 Q9NP98 Myozenin-1  GGAAGTAGVGETGSGDQAGGEGK 
 GGSQAGGSGSAGQYGSDQQHHLGSGS
GAGGTGGPAGQAGR 
Q[129] 
Q[129] 
1.000 
 Shared sequence coverage with other, non-skeletal muscle actins including: ACTH, ACTB, ACTC, ACTA and ACTG 
 Shared sequence coverage with Myosin-1, Myosin-2, Myosin-3, Myosin-4, and Myosin-8 
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Of key interest to this research project was the strong presence of high 
probability titin peptides within the data. Titin is the largest known protein in 
mammalian cells and is far too large to pass into the urine. Furthermore, the day 
following the induction of soft tissue damage, only tryptic fragments from the N- and 
C-terminal ends of titin were present within the urine (Figure 5.5). There is also a 
noticeable increase in the number of tryptic peptides covering a greater portion of the 
titin sequence throughout the recovery phase from D2 to D7. This might suggest that 
additional endogenous degradation pathways are activated during this time (Table 
5.5). Taken in conjunction with the eccentric damage protocol, these data indicate 
that skeletal muscle-specific titin is being degraded from the site of damage (i.e. 
biceps brachii). Furthermore, it suggests that these degradation products are small 
enough that they can pass through the kidney filter system and into the urine.  
 
 
  
Figure 5.5. Endogenous titin fragments after tissue damage. The first day (D1) following muscle damage 
shows only N- and C-most terminal fragments of titin within the urine following eccentric muscle actions 
on the biceps brachii indicating digestion at the Z-disc and M-line regions of the sarcomere. 
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5.4.2 Label-free quantification using Abacus demonstrates perturbations in 
muscle-specific protein constituents as a result of eccentric tissue damage 
Protein accession numbers outlined in Table 5.5 were input into the BisoGenet 
plug-in within Cytoscape and protein-protein interactions were estimated (see Figure 
5.6). In addition to the network diagram, each of these skeletal muscle specific 
proteins was targeted for label-free quantification. To this end, Abacus was employed 
to calculate the NSAFadj values which are an estimate of the relative amount of 
protein that was present within each of the samples (Fermin et al. 2011).  
 
Interestingly, telethonin exhibited a bell-curve abundance profile from D2 to 
D6 which peaked four days after damage. Titin, filamin-C and myozenin-1 were all 
still present at D7 but were completely absent from the baseline samples (Table 5.6 
and Figure 5.6). myosin light chain 1/3 (skeletal muscle isoform), myosin-13, 
myosin-binding protein C slow type and actin, alpha skeletal muscle did not appear 
to follow as clear a temporal pattern as those discussed above, but were 
intermittently present or absent across the seven day recovery period (Table 5.6 and 
Figure 5.6). Importantly, none of them were detectable within the baseline period 
(Table 5.6 and Figure 5.6). Note that myosin-7 and myosin-binding protein H have 
been excluded from the diagram because they did not pass the Abacus filters at either 
the peptide or protein probability-level for estimation of protein abundance. Recall, 
however, that they did satisfy the criteria for a protein FDR < 10%. Each of the 
proteins‘ relative abundance across the seven day recovery period and their 
relationship to each other is summarised in Figure 5.6.  
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Table 5.6 
Abacus quantification results: The mean adjusted Normalised Spectral Abundance Factor (NSAFadj) 
Accession Protein name Pre D1 D2 D3 D4 D5 D6 D7 
Q8WZ42 Titin 0.000 0.095 0.248 0.367 0.405 0.232 0.416 0.499 
Q14315 Filamin-C 0.000 1.110 2.013 5.412 5.354 4.133 3.130 5.605 
P68133 Actin, alpha skeletal muscle  0.000 0.000 2.016 0.000 0.000 0.513 0.000 0.000 
O15273 Telethonin 0.000 0.000 1.517 8.713 13.758 9.297 1.332 0.000 
P05976 Myosin light chain 1/3, skeletal muscle isoform 0.000 0.000 0.000 0.000 3.522 3.004 0.000 0.000 
Q00872 Myosin-binding protein C, slow-type 0.000 0.000 0.000 0.000 0.000 0.000 0.000 6.977 
Q9UKX3 Myosin-13 0.000 0.000 0.000 0.000 0.128 0.000 0.000 0.000 
Q9NP98 Myozenin-1 0.000 0.000 0.847 0.000 3.315 3.237 1.488 1.886 
 Shared sequence coverage with other, non-skeletal muscle actins including: ACTH, ACTB, ACTC, ACTA and ACTG 
 Shared sequence coverage with Myosin-1, Myosin-2, Myosin-3, Myosin-4, and Myosin-8 
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Figure 5.6. Sarcomeric proteins localised at the Z-disk fluctuate after soft tissue damage. Network analysis of muscle specific proteins identified from the ABSCIEX Hybrid Quadrupole 
TripleTOF™ 5600 dataset. The BisoGenet Cytocape plug-in was used to define protein-protein interactions (blue dashed line) based on multiple sources (BioGrid, InAct, Bind, DIP, MINT 
and HPRD protein interaction databases). The bar graph to the right of each protein represents its mean NSAFadj (relative abundance)  which was calculated using Abacus. These data were 
produced from six biological replicates and two technical replicates. 
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5.5 DISCUSSION 
5.5.1 Analytical methodology 
In this study, urinary proteomic data generated by a sensitive mass 
spectrometry platform was combined with an in-depth qualitative protein analysis 
pipeline incorporating search results from three search algorithms, validation through 
the TPP, GO analysis and protein-protein interaction analysis. In addition, an MS
2
 
label-free quantification schema was used to gauge the relative abundance of 
potential markers of skeletal muscle tissue damage or recovery. The goal of this 
study was to identify proteins or fragments of proteins that were associated with 
exercise-induced soft-tissue damage. There were eight proteins identified as being 
potential markers for applications in soft tissue damage and recovery monitoring. 
The study presented in this chapter was a discovery-phase experiment. As such 
additional research is still required to appropriately verify and validate these. 
 
In total 912,534 initial MS
2
 peptide assignments were made to spectra acquired 
during 96 LC-MS/MS runs on the ABSciex hybrid quadrupole tripleTOF® 5600. In 
order to correctly identify genuine tryptic peptides, spectra from this considerable 
amount of data were investigated using three search algorithms (OMSSA, X!Tandem 
and SpectraST) and a target-decoy protein database. This approach took advantage of 
the strengths of each algorithm for correctly identifying peptide sequences. The 
results were then statistically combined to produce validated peptide and protein 
identifications using the tools available through the TPP. Using this approach, 
between 220 and 253 confident protein identifications were made for each timepoint 
(at a minimum probability of 0.1). 
 
A significant effort was made to produce an objective list of protein 
identifications. First by using three search algorithms, one of which relies on a 
database of real experimental data (SpectraST) sourced from two high quality data 
repository (the PeptideAtlas and NIST libraries) to increase confident peptide 
identifications. In addition, only tryptic peptides were targeted and a moderate list of 
PTMs was incorporated into the searches which will improve the quality of 
identifications. Thirdly, by using a non-redundant protein database of real protein 
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sequences in conjunction with a precursor-mass-matched decoy database to eliminate 
the effects of bias that are often present in target-decoy searches (Elias and Gygi 
2007). Using this method, poor peptide assignments were able to be filtered out. 
Finally, the results were statistically validated using the TPP.  
 
Based on the approach described above, a high level of confidence in the 
quality of the data presented in this chapter was achieved. In addition, further gains 
in peptide identifications could be made by extraction of the high quality-unassigned 
spectra and subjecting them to re-analysis using different PTM search parameters 
and/or a semi-tryptic search to increase the number of identified peptides per protein. 
To this end, one additional approach which could be utilised is the Qualscore 
algorithm (Nesvizhskii et al. 2006) which has the capacity to increase peptide 
identifications through alteration of search parameters. As is the case with all 
proteomic studies of this nature, a portion of these protein identities were made with 
evidence of only one peptide. A major difficulty with these high probability peptide 
assignments is to decide if they are real or not. To this end, single peptide protein 
identities were only made if the sequence was; i) unique within the database and, ii) 
above the validation thresholds specified through the TPP at the peptide and protein 
levels. 
 
The onset of soft-tissue damage and subsequent recovery within the first week 
will result in an altered homeostasis at the site of tissue damage that will drive the 
repair response (Schiaffino and Partridge 2008). Initially, tissue catabolism ensues, 
the consequence of which is an increase in protein degradation which is eventually 
followed by tissue regeneration (anabolism) at the site of injury (Kasperek and 
Snider 1985; Chazaud et al. 2009). Within this study, the hypothesis that these 
catabolite products can end up within the urine was initially supported by GO 
analyses. This analysis revealed tissue specific proteins involved in a range of 
metabolic and cellular pathways specific to skeletal muscle which was gauged based 
on their absence from the baseline samples. The Cellular Compartment and 
Molecular Function terms highlighted a reoccurring theme of lipid, muscle and ECM 
related proteins or peptides that appeared to be temporally perturbed. One of the key 
issues was the complex nature of the GO analysis, which demonstrated the 
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multifaceted nature of protein functions that get depleted from the body into the 
urine. Many of the GOs found in this study agree with those published in a number 
of other significant urinary proteomic studies of the ‗normal‘ urinary proteome 
(Adachi et al. 2006; Marimuthu et al. 2011). However, closer examination of the 
literature demonstrated a distinct lack of muscle specific GO terms. By contrast, they 
were significantly over represented within this study. For example, Adachi et al. 
(2006) identified over 1,500 urinary proteins from ‗normal‘ human urine; from their 
cellular component results they did not identify the muscle specific H zone, myosin 
complex, I band, muscle myosin complex, A band, myosin II complex, sarcomere, 
actin cytoskeleton, myosin filament or contractile fibre as being significantly over 
represented (Adachi et al. 2006). Based on the data reported herein, it was clear there 
was a level of tissue damage that could be detected within the urine following 
eccentric muscle actions with a particular emphasis on muscle tissue. As such, 
proteins associated with the muscle specific GO terms were investigated further to 
determine relative quantification and protein-level attenuations. 
 
An MS
2
 label-free quantification approach was adopted due to its success in 
past research studies (Choi et al. 2008; Borg et al. 2011; Nagaraj and Mann 2011). In 
this study Abacus was used to calculate the relative protein abundance between 
timepoints (Fermin et al. 2011). There were several advantages of using this method; 
in general, label-free methods do not require the intensive sample work-up and 
subsequent sample clean-up that other methods such as Isotbaric Tag for Relative 
and Absolute Quantitation (iTRAQ) or Isotope-Coded Affinity Tag (ICAT) demand 
(Wang et al. 2011). In turn, a label-free approach is less prone to sample losses 
because it requires less sample handling which can reduce systematic variability 
(Nguyen-Khuong 2011). The second key advantage of the MS
2
 approach taken in 
this study was that Abacus is completely compatible with the output files produced 
by the TPP, which made subsequent analysis a streamlined process. In addition, MS
2
 
quantification may be less susceptible to errors that come about through fluctuations 
in precursor retention times. This is due to the high likelihood that the MS
2
 spectra 
would still be acquired for a particular precursor if its retention time characteristics 
change slightly from run to run. A key disadvantage with this approach is that 
Abacus does not provide information on biological replicates within its output when 
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analysing the data using the criteria outlined by the authors (Fermin et al. 2011). An 
additional disadvantage of MS
2
 quantification approaches is that the same precursor 
might be present in all samples but at different levels. Consequently, its intensity in 
some samples may be too low to trigger fragmentation (MS
2 
acquisition). As a result 
it may appear to be completely absent from the sample when in fact it is just below 
the detection limits of the instrument under those operating conditions. However, it is 
important to point out that this is more of an issue for spectra acquired under IDA 
conditions over spectra acquired under a directed MS method which targets 
predefined peptides (Schmidt et al. 2009). Nonetheless, use of the MS
2
 method did 
reveal several tissue-specific biological indicators of soft tissue damage that 
appeared to exhibit a temporal change in abundance during the first week of 
recovery, thereby supporting its application within this study. 
 
5.5.2 Summary of protein identifications in the context of soft tissue damage 
and recovery 
Of particular interest to this research program was the identification of skeletal 
muscle-specific proteins in urine samples following eccentric exercise-induced soft-
tissue damage. Actin, filamin-C, myozenin-1, telethonin and titin were all identified 
within the exercise cohort. Interestingly, within this study, three of the four primary 
filamentous structures (titin, nebulin, actin, myosin) in skeletal muscle were 
identified within urine samples following eccentric soft tissue damage.  
 
Actin monomers are one of the most abundant proteins within skeletal muscle 
and have a molecular mass of approximately 43 kDa depending on the particular 
isoform (Kikumoto et al. 2003). In skeletal muscle, actin filaments are comprised of 
globular actin (G-actin) monomers which polymerize to form the filamentous form, 
F-actin. Two α-helical F-actin filaments combine to produce the ubiquitous thin 
actin filaments readily observed in the I-bands of striated muscle. Functionally, actin 
operates as a structural scaffold, providing interaction domains for the myosin 
‗heads‘ during contraction. Within this study actin fragments were detected at their 
greatest level two days after soft tissue damage, and then again at D5, but at a lower 
level. It is unclear if they originated from skeletal muscle or from a different cell type 
as the sequences identified are not unique to skeletal muscle actin. However, it is 
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important to note that these sequences were not observed in the baseline sample of 
the six participants (see Figure 5.6). Interestingly, actin fragments are routinely 
detected within urine, although, it can sometimes be difficult to determine the 
isoform based on the limited sequence coverage from which the protein 
determination was made (Thongboonkerd et al. 2002; Castagna et al. 2005).  
 
As stated above, myosin interacts with actin and is the primary driving force 
behind skeletal muscle contraction. Within each myosin molecule are two heavy 
chains (~ 220 kDa) and four light chains (~ 20 kDa) and the thick filaments within 
striated muscle are formed by multiple myosin molecules. The myosin heavy chain 
contains a ‗head‘ or ‗boot‘ component at the N-terminus, while the C-terminus end 
forms the alpha-helical ‗rod‘ domain (Wick 1999). The conserved head domain has 
the ability to weakly bind F-actin through the catalytic core present on each G-actin 
monomer (Sellers and Goodson 1995). In this study myosin-specific peptide 
fragments were identified from multiple myosin isoforms, along with one myosin 
interacting protein (myosin-binding protein-C, slow type). For this reason, vigilance 
must be exercised when interpreting the quantification results for the myosin 
isoforms, because the tryptic peptides identified are present in multiple isoforms 
within the body (Table 5.5). However, taken in conjunction with the observation of 
other skeletal muscle specific proteins, there is evidence to support its presence 
within urine due to the skeletal muscle damage produced by the eccentric loading. 
 
Interestingly, myosin-binding protein-C has been shown to interact with six 
domains of the C-terminal end of titin in cardiac muscle (Freiburg and Guautel 
1996). Furthermore, myosin-binding protein C was only present within the D7 
sample, which is when titin was most prevalent (Figure 5.6). Both myosin-13 and 
myosin light chain 1/3 appeared at D4 and D5. Note again, that the sequences 
detected for myosin-13 are also shared by other muscle specific myosin isoforms. 
Therefore based on the data it is unclear to which myosin isoform these peptides 
belong. However, none of these myosins/myosin-related proteins were detected in the 
baseline samples of the six participants (Figure 5.6). As is the case with actin, 
various myosin isoforms have been detected within urine previously, but these 
studies have not assessed the physical activity of participants (Pisitkun et al. 2004; 
Gonzales et al. 2009). These results suggest that fragments of proteins related to the 
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actin-myosin cross-linking componentry begin to appear at approximately two to 
three days after soft tissue injury, and disappear within a seven day recovery period 
with the exception of myosin-binding protein C. 
 
One of the more exciting discoveries within this study was the increasing 
presence of titin within urine following soft-tissue damage (Figure 5.6). Titin, is the 
largest protein currently known; it spans from the Z-disc junction of the sarcomere to 
the M-line, where it is fixed. Thus titin is so large that it spans half of the sarcomere 
length and has an approximate molecular weight between 3 and 3.7 MDa (Wang et 
al. 1979; Maruyama 1997). A closer inspection of the sequence coverage revealed 
that, in D1 urine samples, only sequences from the most extreme ends of titin (C and 
N-terminal) (Figure 5.5) were detected. This suggests that there may be an 
enzymatic degradation event occurring at the Z-disc and M-line regions of the 
sarcomere. Interestingly, as recovery progressed, additional titin fragments from 
other regions of the protein begin to appear within the urine, which could indicate 
progressive enzymatic degradation (Table 5.5). The elution abundance profile of titin 
was very similar to filamin-C, which is spatially located adjacent to titin. This 
suggests there may be a similar mechanism under which these two proteins are 
degraded and released from the tissue. Titin is a protein that is readily detected within 
urine samples in PSM-based MS/MS pipelines (Pisitkun et al. 2004; Adachi et al. 
2006; Gonzales et al. 2009; Marimuthu et al. 2011). However, within this study it 
was not detected within the baseline samples at all using a stringent PSM 
identification protocol, but was present in all of the timepoints thereafter. This 
provides compelling evidence for its temporal appearance in urine due to muscle 
damage within this study. 
 
Both telethonin and myozenin-1 also produced temporal patterns associated 
with soft tissue damage. Interestingly, telethonin is the linking protein at the N-
terminal end of titin which tethers it to the Z-disc. It is a relatively small protein (~19 
kDa), and as such would easily pass through the glomerular filtration system of the 
kidney in its complete form, which may provide one explanation as to why it had the 
highest abundance scores (Table 5.6). Alternatively, because the sequence coverage 
was poor (Table 5.5) it is inconclusive as to whether it is getting endogenously 
cleaved, as is suspected with some of the previously mentioned proteins (e.g. titin). 
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Telethonin is a known regulator of sarcomere assembly playing a key role in N-
terminal titin stabilisation at the Z-disc (Faulkner et al. 2001). Based on the MS data, 
telethonin was not detected in the pre sample but was most abundant four days after 
soft tissue damage, which suggests that it does not get released from the damaged 
tissue at the same time as the N-terminal titin fragments. This may be due to an 
uncharacterised secondary mode of protein release, or the detection levels may be a 
reflection of the particular instrument parameters used in this study. Of note 
telethonin has not been reported in some of the major proteomics datasets 
representing ‗normal‘ human urines (Pisitkun et al. 2004; Adachi et al. 2006; 
Gonzales et al. 2009; Li et al. 2010; Marimuthu et al. 2011), thus is likely present in 
urine samples from this cohort due to the muscle damage protocol. 
 
Myozenin-1 is reported to be an important stress sensor within the sarcomere, 
interacting with -actininin-2 and -3 at the Z-disc (Frey et al. 2000). In our cohort it 
was not detected at baseline, but drastically increased at D4 after damage. 
Interestingly, lower levels were detected at D2 but none at D3, which might indicate 
that the precursor peak in the survey scan was below the threshold to switch into 
MS/MS mode. Within ‗normal‘ urine, Myozenin-1 has not been detected in previous 
studies under any of its alternate names, FATZ or Calsarcin (Pisitkun et al. 2004; 
Adachi et al. 2006; Gonzales et al. 2009; Li et al. 2010; Marimuthu et al. 2011). 
However, a single five amino acid peptide of Myozenin-2 consisting of the sequence 
‗VSIPR‘ was detected by others (Marimuthu et al. 2011). The small sequence length 
of Myozenin-2 observed by Marimuthu et al. (2011) and the poor sequence coverage 
within previous urinary proteomic studies indicates the unique nature of its detection 
within this study and thus it is likely present due to the induction of muscle damage. 
 
5.6 CONCLUDING REMARKS 
In this study an in-depth LC-MS/MS analysis was performed which 
incorporated identification, GO analysis and relative quantification. As with previous 
chapters, it was clear that urine is replete with many proteins from unrelated tissues 
that are in a dynamic state of abundance across time. Due to the diversity of proteins 
and constant flux of abundance, only proteins that would otherwise not be present 
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within urine based on previous studies were targeted. Using this criteria, only 
muscle-specific proteins were selected for quantification. 
 
It should be acknowledged that highly abundant proteins in these samples were 
not depleted prior to LC-MS/MS analysis. Such a depletion step would likely 
increase the number of potential identifications of tissue-specific proteins related to 
injury or recovery. This represents an option for future studies. In addition, using the 
Abacus MS
2
 quantification algorithm it was difficult to fully appreciate the biological 
variance of particular proteins. As such the application of MS
1
 label-free methods, 
such as SuperHirn (Mueller et al. 2007) or SpecArray (Li et al. 2005), may 
complement the quantification results presented here, because they are not dependent 
on what the instrument can detect at the MS
2
 level. Alternatively, targeted 
approaches such as antibody-based analysis or supplemental quantitative mass 
spectrometry methods would be appropriate to verify these findings. Additionally, 
while this study presents some intriguing data, caution must be exercised against 
over-interpretation of these potential biomarkers, because urine samples from only 
six participants were analysed in the study. As such, any additional validation 
attempts should involve a larger cohort. 
 
All the same, these data do appear to suggest that even though one of the 
smaller muscle groups were damaged (biceps brachii), the skeletal muscle 
components identified were sufficiently abundant within these urine samples using 
an MS/MS detection strategy. This indicates that even without depletion, these 
proteins are present at a high abundance relative to the rest of the constituent proteins 
within urine. Additionally, they appear to follow an abundance profile that might be 
indicative of functional recovery. The data also suggests that lipid metabolism and 
homeostasis might be an additional avenue for a more targeted approach to 
investigating soft tissue damage. Nonetheless this study does provide compelling 
evidence in support of soft tissue damage markers being present in urine. 
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Chapter 6: High Throughput Targeted 
Analysis of the LG3 Polypeptide 
6.1 INTRODUCTION 
The LG3 polypeptide fragment was recently discovered by our group to be 
elevated in active mining workers compared to a more sedentary control group 
(Parker et al. 2012), additionally we have preliminary evidence that suggests it is 
released following short aerobic bursts of activity such as running and cycling 
(unpublished data). The LG3 polypeptide is the C-terminal bioactive fragment of 
endorepellin which is itself a C-terminal fragment of the so called basement 
membrane specific perlecan. perlecan is a high abundant constituent of all basement 
membranes within the body. Interestingly, Endorepellin and the LG3 polypeptide has 
anti-angiogenic properties (Mongiat et al. 2003) and has been shown to restrict 
neovascularisation of tumours in mice (Chang et al. 2008). Moreover, both 
Endorepellin and especially the LG3 polypeptide have neuroprotective effects during 
oxygen/glucose deprivation in brain endothelial cells (Saini et al. 2011; Saini and 
Bix 2012). Since only recently the LG3 polypeptide has come to be of interest to the 
scientific community there are currently no commercially available kits to quantify 
it.  
There were multiple tryptic peptides from perlecan detected at each time-point 
within the LC-MS/MS work presented in Chapter 5, indicating that perlecan, 
endorepelin or LG3 might be present within these samples. Importantly, a closer look 
at the sequence coverage revealed that the peptides detected were heavily 
concentrated to the LG3 polypeptide sequence (i.e. C-terminal perlecan sequence). It 
is currently unclear why or how the LG3 polypeptide is released following physical 
activity, additionally there is currently no literature that reports on its presence or 
otherwise in urine following soft tissue damage or recovery. Although, based on 
previous work within our group, it is hypothesised that urinary LG3 levels will be 
augmented following eccentric tissue damage. Because it was difficult to distinguish 
levels of the LG3 polypeptide from endorepellin or perlecan using methods in the 
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previous chapter, it was important to develop a novel assay with a high level of 
specificity to distinguish between these proteins. 
 
Many of these studies utilise ELISA or RIA formats to measure an analyte, 
thus require the use of specific antibodies. Unfortunately the availability of 
antibodies appropriate for the vast majority of human proteins (50 - 60%) are 
themselves poorly validated (Stoevesandt and Taussig 2007; Bordeaux et al. 2010; 
Whiteaker et al. 2011). In additionally, such assays require purified controls that can 
be difficult to get, and for many proteins can be just as difficult to solubilise in an 
appropriate buffer for antibody detection (Bordeaux et al. 2010). There are currently 
no commercially available monoclonal antibodies designed to target perlecan-
liberated LG3 polypeptide making it difficult to specifically quantify using an ELISA 
assay. In addition, novel ELISA assays are expensive to develop, an expense that is 
expected to inflate dramatically when additional targets gained from supplementary 
studies are added for multiplex assays. As such, in this study a Selected Reaction 
Monitoring (SRM) assay was designed and implemented on urine samples of 
participants who have undergone soft-tissue damage of the biceps brachii. 
 
Typical biomarker studies progress from discovery using multiplex ‗omics‘ 
techniques, such as those presented in previous chapters, followed by verification in 
a small number of samples to demonstrate biological variation. Therefore, the aim of 
this study was to design an assay based on the LG3 polypeptide and to assess urinary 
LG3 fluctuations due to the soft tissue damage outline in Chapter 2. The hypothesis 
was that LG3 would change due to eccentric tissue damage. Additionally, the 
development of a novel mass spectrometry-based assay for the quantification of the 
LG3 polypeptide in urine is detailed. Furthermore, this assay can be translated to 
other biological fluids with high specificity for perlecan-liberated LG3 polypeptide.  
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6.2 METHODS  
6.2.1 Materials and reagents 
Pure HPLC grade water, (NH4)HCO3 and a Bradford kit were purchased from 
Sigma Aldrich Pty Ltd (Castle Hill, NSW, Australia). Pure HPLC grade ACN was 
used throughout this study (Merck; Darmstadt, Germany). DTT was purchased from 
Roche (Mannhein, Germany). Formic acid (FA) and TFE came from Fluka (Buchs, 
St Gallen, Switzerland). IAA was purchased from GE Life Sciences (Little Chalfont, 
Buckinghamshire, UK). Sequence grade Trypsin was purchased from Promega 
(Madison, WI, USA), while 3K-NMWL Amicon
®
 Ultra-4 centrifugal filter device 
were purchased from Millipore™ (Billerica, MA, USA). 
 
6.2.2 Tissue damage and urine collection 
Urine samples from 11 participants were collected from otherwise healthy 
participants who underwent an eccentric tissue loading protocol (outlined in section 
2.4.2) at the Institute of Health and Biomedical Innovation. Each participant was 
required to provide urine samples across a 60 day damage and recovery period (refer 
to section 2.4.4). Samples were stored at -20°C prior to concentration. 
 
6.2.3 Protein concentration for LC-MS/MS 
Samples were thawed in a 25°C waterbath followed by clarification at 1500--
g for 10 min. Buffer exchange and desalting was achieved according to the method 
outlined in section 5.2.3. 
 
6.2.4 Tryptic digest 
In order to measure the LG3 polypeptide on a mass spectrometer, the full 
sequence needed to be digested into manageable fragments. To do this the protocol 
in section 5.2.4 was followed. The digested peptide was resuspended in 1% FA and 
5% ACN. 
 
 158 Chapter 6: High Throughput Targeted Analysis of the LG3 Polypeptide 
6.2.5 Standard peptide 
The N-terminal tryptic peptide of LG3 (LG3[1-25], see Table 6.1) was purchased 
from Mimotopes Pty Ltd (Clayton, VIC, Australia). Stock solutions were made by 
dissolving 1 mg LG3[1:25] in 2% ACN, 1% FA producing a 1 mg.mL
-1
 suspension 
which was subaliqouted and stored at -80°C. A working solution was prepared by 
taking 1:1000 dilution of the stock solution to make a working concentration of 1 
g.mL
-1
. The calibration standards were prepared at concentrations of 250, 125, 62.5 
and 31.25 ng.mL-1 by sequential serial dilution of the working solution in 2% ACN, 
1% FA. Amount of on-column LG3[1:25] was expressed in mols and calculated based 
on the injection volume. 
Table 6.1 
Mimotopes Pty Ltd standard peptide for SRM analysis 
Naming convention used Peptide standard sequence 
LG3[1:25] DAPGQYGAYFHDDGFLAFPGHVFSR 
 
6.2.6 Sequence analysis 
Prior to assay development the sequence specificity of LG3[1:25] for 
determination of full length LG3 was assessed using Blast-P. The search was 
performed against the non-redundant protein sequences database containing 
18581586 sequences. For this reason, organism was set to human (taxid:9606) and 
the protein-protein BLAST algorithm (BLASTP 2.2.26+) was selected for sequence 
alignments. 
 
6.2.7 LC-QqTOF/MS Fragmentation and characterisation of LG3[1:25] 
The dominant precursor ions were determined by injecting 5 µL of 1 µg.mL
-1
 
LG3[1:25] standard onto a C18 reverse phase column (150  0.3 mm, 5 µm 30 Å; 
Grace; Deerfield, IL, USA) attached to an ultra-high performance liquid 
chromatography (uHPLC) system (Shimadzu, Rydalmere, NSW, Australia) 
containing 1% FA (v/v; buffer A) and 1% FA in ACN (v/v; buffer B). The LG3[1:25] 
peptide was resolved over 24 min at a flow rate of  3 µL.min
-1
, starting with 1% B 
from 0 min to 3.5 min before applying a linear gradient from 1% B to 80% B from 
3.5 min to 12 min, followed by washing at 80% B for an additional 3 min before re-
equilibrating the column with 1% B for 10 min. For IDA MS/MS the uHPLC system 
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was directly coupled to a nanospray ion-source on a QSTAR-Elite Qq-TOF MS/MS 
system (ABSCIEX, Framingham, MA, USA). The instrument was run in positive-ion 
mode where the top two ions from the precursor scan were targeted for fragmentation 
and MS/MS analysis. A Dynamic exclusion was set to exclude ions for 10 s 
following MS/MS analysis. 
 
6.2.8 Chromatography optimisation 
In order to gain optimal elution characteristics of LG3[1:25], three different 
elution gradients were assessed. LG3[1:25] or NC samples were applied to the 
resolving column (C18; 150 mm  2.10 mm 2.6 µm 100 Å, Phenomenex; Torrance, 
CA, USA) in 5% or 23% buffer B (1% FA, 90% ACN, v/v) for 2.2 min or 3.5 min to 
remove non-specific analytes and reduce ion suppression from the sample. Three 
linear gradients were assessed to optimise the LG3[1:25] elution profile; these 
included: 5% to 90% B, 23% to 90% B and 23% to 40% B applied over a 5 min 
period. The column was then washed at 90% B for 2 min before re-equilibrating at 
either 5% or 23% B, respectively, for an additional 2 min in preparation for the next 
sample in the queue. 
 
LC-QqQ development of the SRM assay 
To target and quantify LG3[1:25] a SRM assay was developed by resolving 
peptides through a C18 reverse phase column (150 x 2.10 mm 2.6 µm 100 Ǻ, 
Phenomenex; Torrance, CA, USA) using the gradients discussed previously (section 
6.2.8). The uHPLC system (Shimadzu, Rydalmere, NSW, Australia) was directly 
coupled to a TurboV source on a 4000 QTRAP MS/MS system (ABSCIEX, 
Framingham, MA, USA). The instrument was controlled using Analyst software 
(version 1.5.2, Applied Biosystems) in positive-ion mode. The ion-spray voltage was 
set to 5300V with a source temperature set at 500°C, UHP nitrogen (99.99%) was 
used for the curtain, nebulizer and turbo gasses which were set to a value of 20, 35 
and 35 respectively. 
 
Acquisition of analyte was performed in SRM mode without scheduling. The 
dominant LG3[1:25] peptide of [M+3H]
3+
 (Q1) was selected for collision-induced 
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dissociation (CID) and the transitions, as per Table 6.2, were monitored. The m/z 
924.99 → 799.90 transition was quantified by integration using Skyline (version 
1.2.0.3510) (MacLean et al. 2010). 
 
 In addition to running the instrument in SRM mode, some experiments 
required that the instrument be setup to acquire Enhanced Product Ion (EPI) scans. 
Briefly, the top two ions exceeding 1000 cps were included for EPI detection with a 
linear ion trap (LIT) fill time of 50 msec. Fragmentation of precursor ions were 
calculated on the fly using a rolling collision energy. The EPI scans were extracted 
into ‗.dta‘ file format before submission for spectral library searching using the 
GPMs X!Hunter algorithm (X!Hunter version 2009.08.01.3). The resulting ensemble 
accession numbers were then mapped to the UniProtKB database. 
 
Table 6.2 
 LG3 precursor (Q1) and product ion transitions (Q3) 
SRM Transition  Ion Q1  Q3  
LG3[1:25]
3+
 y7
+
 924.99 799.90 
LG3[1:25]
3+
 y20
2+
 924.99 1152.76 
LG3[1:25]
3+
 y9
+
 924.99 1018.16 
LG3[1:25]
3+
 b3
+
 924.99 283.30 
  
Collision energy (CE), Dwell time (DT), Deculstering potential (DP) and gas 
temperatures were optimised to increase the sensitivity of the assay. The effects of 
each parameter on the signal of LG3[1:25] were assessed using the integrated peak 
area. The area under the curve (AUC) for LG3[1:25] at each of the optimisation steps 
was tested using a one-way ANOVA. If a global difference was observed (p ≤ 0.05), 
Tukey‘s post-hoc tests were employed to determine which signal intensities differed. 
All figures and calculations were performed in the open source „R‟ statistical 
computing and graphics program, version 2.15.0 (www.r-project.org). 
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6.3 RESULTS 
6.3.1 The LG3[1:25] peptide is highly specific for the full length LG3 polypeptide 
Due to a lack of monoclonal antibody availability for the full length LG3 
polypeptide, the aim of this study was to develop a sensitive and specific assay for 
LG3 that would be applicable to human serum or urine samples, all the while 
avoiding confounding or cross reactivity with endorepellin or perlecan. The goal was 
to develop an assay with the capacity to distinguish between a non-specific 
fragmentation product of endorepellin or a fragment which might be indicative of a 
specific biological response (e.g. enzyme cleavage of perlecan to liberate LG3). The 
full-length endorepellin sequence is provided in Figure 6.1a. This sequence contains 
the LG3 fragment (blue) which is known to be proteolytically liberated from 
perlecan or endorepellin by cathepsin-B/L, and tolloid like metalloprotease 
(Gonzalez et al. 2005; Saini and Bix 2012). The underlined regions of sequence in 
Figure 6.1a illustrate the C- and N-terminus tryptic peptides after endogenous 
cleavage between the asparagine (N) and aspartic acid (D) residues (red-blue 
interface) (Figure 6.1a). Importantly, both of these underlined regions are specific 
for endogenous LG3 liberation and as such, both may be useful to target the 
enzymatic activity of cathepsin-B or tolloid like metalloprotease. However, our 
research group is primarily interested in the LG3 polypeptide, thus the N-Terminal 
tryptic peptide (underlined blue) is of interest here. Either way, both are specific for 
LG3 peptide liberation from endorepellin or perlecan. Another positive characteristic 
of this peptide is that while it is considerably large (25 aa long) it contains two 
histidines and a C-terminal arginine which under acidic conditions will retain a 
positive side chain, which will theoretically bring the m/z of the molecule down to an 
optimal range for LC-ESI/MS detection. Furthermore, there are two readily ionisable 
prolines in the sequence which will increase the capacity for this analyte to be 
detected in the MS/MS phase of analysis. 
 
 The top Blast-P protein identities for LG3[1:25] are all derivatives of 
perlecan. Table 6.3 shows the top four identifications based on the N-Terminal LG3 
polypeptide sequence. The top hit for this sequence aligns with full length LG3 
polypeptide itself with an expect-value (E-Value) of 2e
-21
. Thus the number of hits on 
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this sequence that can be expected to be observed by chance (using this database) is 
extremely small (2e
-21
). This indicates that this sequence containing 25 amino acids, 
while not the full length LG3 polypeptide, is highly specific for the LG3 polypeptide. 
 
 
Table 6.3. 
Blast-p results for LG3[1:25] 
Protein Accession Query Coverage E-Value 
-Chain A, Laminin G Like Domain 3 From 
Human Perlecan 
3SH4_A 100% 2e-21 
-Basement membrane-specific heparan sulfate 
proteoglycan core protein precursor variant 
BAD93088.1 100% 3e-21 
-heparan sulfate proteoglycan 2 (perlecan), 
isoform CRA_a 
EAW94994.1 100% 3e-21 
-heparan sulfate proteoglycan 2 (perlecan), 
isoform CRA_b 
EAW94995.1 100% 3e-21 
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                      ......EIKI TFRPDSADGM LLYNGQKRVP GSPTNLANRQ  
PDFISFGLVG GRPEFRFDAG SGMATIRHPT PLALGHFHTV TLLRSLTQGS LIVGDLAPVN  
GTSQGKFQGL DLNEELYLGG YPDYGAIPKA GLSSGFIGCV RELRIQGEEI VFHDLNLTAH  
GISHCPTCRD RPCQNGGQCH DSESSSYVCV CPAGFTGSRC EHSQALHCHP EACGPDATCV  
NRPDGRGYTC RCHLGRSGLR CEEGVTVTTP SLSGAGSYLA LPALTNTHHE LRLDVEFKPL  
APDGVLLFSG GKSGPVEDFV SLAMVGGHLE FRYELGSGLA VLRSAEPLAL GRWHRVSAER  
LNKDGSLRVN GGRPVLRSSP GKSQGLNLHT LLYLGGVEPS VPLSPATNMS AHFRGCVGEV  
SVNGKRLDLT YSFLGSQGIG QCYDSSPCER QPCQHGATCM PAGEYEFQCL CRDGFKGDLC  
EHEENPCQLR EPCLHGGTCQ GTRCLCLPGF SGPRCQQGSG HGIAESDWHL EGSGGNDAPG  
QYGAYFHDDG FLAFPGHVFS RSLPEVPETI ELEVRTSTAS GLLLWQGVEV GEAGQGKDFI  
SLGLQDGHLV FRYQLGSGEA RLVSEDPIND GEWHRVTALR EGRRGSIQVD GEELVSGRSP  
GPNVAVNAKG SVYIGGAPDV ATLTGGRFSS GITGCVKNLV LHSARPGAPP PQPLDLQHRA  
QAGANTRPCP S  
 
 
 
 
 
CQQGSGHGIAESDWHLEGSGGN DAPGQYGAYFHDDGFLAFPGHVFSR 
 
 
 
 
 
 
 
 
CQQGSGHGIAESDWHLEGSGGN  
DAPGQYGAYFHDDGFLAFPGHVFSR 
 
 
 
 
 
 
 
Figure 6.1. LG3[1:25] as a surrogate for the full length LG3 polypeptide. Homo sapiens, 
P98160[3687:4391], full length endorepellin sequence. Blue text represents the LG3 polypeptide sequence, 
blue-underlined text is the N-terminal tryptic peptide of LG3. Red underlined is the C-terminal tryptic 
peptide of endorepellin after cleavage. 
  
C-Terminal tryptic sequenc of 
Endorepellin after LG3 liberation. 
Specific for LG3 liberation from PGBM 
or Endorepellin 
N-Terminal tryptic sequence of LG3. 
Specific for LG3 presence/absence. 
Tryptic sequence covering the Cathepsin-B/L and Metalloprotease cleavage site. Specific for 
the Presence of Endorepellin and Perlecan. 
Endogenous cleavage site. 
a) 
b) 
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6.3.2 The most prominent precursor ion of LG3[1:25] was [M+3]
3+
 
The goal of LC-MS/MS analysis of the LG3[1:25] was to determine the 
dominant precursor charge state in an LC-ESI instrument. To do this, purified 
LG3[1:25] was analysed on a QSTAR-Elite (QqTOF/MS) system. LC-MS/MS analysis 
of LG3[1:25] revealed two primary precursor m/z states arising from the 2771.98 Da 
N-terminal peptide. These were m/z 925 and 694 (average m/z), corresponding to 
[M+3]
3+
 and [M+4]
4+
 precursor charge states, respectively (Figure 6.2a). The 
Extracted Ion Chromatogram (XIC) for both parent ion m/z states demonstrates that 
the [M+3]
3+
 state (z3) has an increased signal that is consistent across the elution of 
LG3[1:25] (Figure 6.2b). The isotopic distribution for both precursor m/z states shows 
the isotopic envelope (Figure 6.2c and d). Importantly, the theoretical m/z of 924.99 
and 693.99 correspond to the measured average m/z of 925 and 694 for z3 and z4 
respectively (Figure 6.2c and d). Based on these results, further development of the 
assay utilised the precursor m/z of 924.99, which corresponds to the dominant 
[M+3]
3+ 
m/z state. 
 
6.3.3 The LG3[1:25] y7
+
 Q3 product ion was optimal for SRM quantification of 
the LG3 polypeptide 
The subsequent fragmentation spectra of m/z 925 (Figure 6.3a) revealed four 
particular transitions corresponding to Q3 ions of m/z 799.9 (y7
+
), 283.3 (b3
+
), 
1018.2 (y9
+
) and 1152.8 (y20
2+
). The b3
+
 and y7
+
 ions were specifically targeted as 
they are the ions containing terminal-end proline amino acids after fragmentation. 
Theseare often targeted at the MS
2
 level due to their intense signal compared to other 
amino acids. In addition, the b3
+
 ion was used to validate the presence of the aspartic 
acid and thus the endogenous enzyme cleavage site of the LG3 polypeptide. As can 
be seen in Figure 6.3b these are the two most intense ions. The other two y-ions, y9
+
 
and y20
2+
 were chosen based on their sequence coverage. As is the case with most y-
ions, these two transitions will provide clean signal as they are not measured from a 
region of the spectra containing a lot of noise (i.e. typically the lower m/z region) and 
therefore will not be as susceptible to erroneous signal from neighbouring ions. Due 
to the high intensity of y7
+
, the transition 925 → 799 was chosen to quantify the 
analyte. 
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Figure 6.2. LG3[1:25] precursor ion selection. a) The survey scan of LG3[1:25] shows the dominant precursor m/z 
state of this peptide was [M+3]3+ (z3) and [M+4]4+ (z4). b) The Extracted Ion Chromatogram (XIC) for z3 and 
z4 showing that the signal from the z3 charge state would provide gains in sensitive over the z4 state across the 
LC gradient for LG3[1:25]. c and d) The isotopic distributions for z4 and z3, respectively. 
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Figure 6.3. LG3[1:25] target ions for SRM analysis. a) Fragmentation spectra for precursor m/z 924.99. b) The 
ions chosen for SRM analysis are indicated in red. 
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6.3.4 Optimised chromatography increased the analyte sensitivity 
After selecting the transitions for the assay, the next step was to optimise the 
liquid chromatography conditions. The initial optimisation involved validation of 
these transitions using an LG3[1:25] standard peptide and a set of NC urinary protein 
samples. This served to establish if the selected transitions would be appropriate for 
application on the QqQ system, and to identify any non specific signals coming from 
real samples. 
 
The initial chromatographic gradient was set from 5% B to 90% B over a 
period of 5 min. For both the standard sample (Figure 6.4a) and the NC (real) 
sample (Figure 6.4b) the quantitative transition (925 → 799) appeared sharp with a 
full width at half maximum (FWHM) of 0.03 min (1.8 sec) and a base-peak width of 
~6 seconds (Figure 6.4). The system was set up to dwell on only four transitions for 
250 msec which resulted in a cycle time of 1.02 s, as a consequence there were only 
~6 data points being collected for each of the four transitions during the experiment. 
Based on these data it was clear that this chromatographic gradient was too steep for 
these MS conditions, thus there were not enough data points under the elution profile 
of LG3[1:25] being collected to accurately quantify it (Figure 6.4). In addition, when 
acquiring these data in NC samples there appeared to be another analyte that shared 
each of the transitions used for the LG3[1:25] analysis (Figure 6.3a and Figure 6.4c). 
Furthermore, this was consistently present across a range of NC samples (data not 
shown). The unknown peak eluted at 4.51 min compared to the standard LG3[1:25] 
which eluted at 4.69 min (Figure 6.4c). Due to the shared transitions, the altered 
retention time and the fact that the native LG3 polypeptide is a fragment of a protein 
with a propensity for glycosylated PTMs, the sequence of this analyte was 
determined to establish if it was a modified isoform of LG3. 
 
To address these two problems the chromatography was adjusted to first 
increase the number of data points collected across the elution profile of LG3[1:25], 
and, secondly, to ensure the instrument had enough time to acquire EPI spectra for 
the unknown peptide.  
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Figure 6.4. LG3[1:25] SRM analysis of a standard and non-critical urine sample. a) The quantitative transition 
(925 → 799) of the LG3[1:25] (standard). b) The 925 → 799 transition of LG3[1:25] in a non-critical sample. c) 
Further analysis revealed that an unknown peak shares several transitions with the LG3[1:25]. 
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The unknown peak sharing the same transitions as LG3[1:25] was not an 
isoform of LG3[1:25] 
Accounting for dead volume, it was estimated that the unknown peak eluted at 
~23% B so the column was equilibrated to 23% B before injection of 5 L of 0.2 
g.mL
-1
 of NC samples. The slope of the elution gradient was adjusted from 5% to 
90% B (Figure 6.4c) to 23% to 90% B (Figure 6.5a) from 2.2 min to 7.2 min; this 
resulted in a shallower slope of 13.4% B.min
-1
 (from 17% B.min
-1
). This allowed the 
instrument enough time to acquire qualitative EPI spectra while also acquiring 
quantitative SRM data. 
 
Using a different NC sample, the dominant unknown peak with the new 
chromatography conditions was clear compared to the LG3[1:25] peak (Figure 6.5a). 
The instrument acquired three EPI scans across the unknown peak (Figure 6.5b 
through d). All three spectra mapped to a peptide identified as secreted pancreatic 
ribonuclease-1 (sp|P07998| RNAS1_HUMAN). Which is a 17.644 kDa RNASE that 
is a high abundance core protein within the urinary proteome (Nagaraj and Mann 
2011) (Figure 6.6). The peptide itself (P07998[68:90]) is a tryptic peptide with two 
end-terminal tryptic sites (Figure 6.6, bold underlined). This particular peptide has a 
calculated average [M+H]
3+
 mass of 924.70 and an observed mass of 924.43. In 
addition, it contains two carbamidomethyated cysteine residues (+57) and an N-
terminal ammonia loss (-17). More importantly, this peptide shares several 
transitions with LG3[1:25] (Figure 6.4c) which is what prompted its characterisation.  
 
Finally, the chromatography was adjusted from 23% to 90% B to 23% to 40% 
B between 2.2 min to 7.2 min to increase the base-peak width and thus the number of 
sampling points across the LG3[1:25] peak. The resulting elution time was 4.6 min and 
the base peak width was ~14 s which equates to ~13.73 sampling points for each 
transition during the LC run. This is an acceptable number of points for accurate 
calculation of peak area.  
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Figure 6.5. EPI scans of the unknown peptide. a) The XICs from an SRM-EPI experiment for each of the 
transitions in a NC urine sample with altered LC conditions. b through d) The fragmentation spectra (EPI scams) 
of the unknown peak in panel a. The unknown peak belongs to RNASE1 (Human). 
 Chapter 6: High Throughput Targeted Analysis of the LG3 Polypeptide 171 
 
 
 
 
 
 
 
 
 
 
 
>sp|P07998|RNAS1_HUMAN Ribonuclease pancreatic OS=Homo sapiens 
GN=RNASE1 PE=1 SV=4 
MALEKSLVRL LLLVLILLVL GWVQPSLGKE SRAKKFQRQH MDSDSSPSSS STYCNQMMRR 
RNMTQGRCKP VNTFVHEPLV DVQNVCFQEK VTCKNGQGNC YKSNSSMHIT DCRLTNGSRY 
PNCAYRTSPK ERHIIVACEG SPYVPVHFDA SVEDST 
 
C
[-17][+57]
KPVNTFVHEPLVDVQNVC
[+57]
FQEK 
 
Calculated mass [M+H]
3+
: mono = 924.11089, ave = 924.70285 
Observed mass [M+H]
3+
 = 924.43 
Mass accuracy of [M+H]
 3+
 = 0.03% 
 
 
 
Figure 6.6. The unknown peak belongs to RNASE1 (Human). Three MS/MS scans from the 
unknown peak were identified as belonging to a tryptic peptide of P07998[68:90] via spectral library 
search of real data. 
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6.3.5 The optimal Collision Energy for 925 → 799 was 50 eV 
Additional sensitivity for the analyte can be gained by altering the amount of 
energy used to fragment the peptide. The product ion spectra in Figure 6.3 a) and b) 
was produced on the Qq-TOF which uses a rolling collision energy estimator based 
on the following relationship: 
 
 
Equation 12 
 
where the absolute CE is calculated from the internal calibration slope and the 
intercept which is hardcoded into the software (see Appendix C2, Table 3 for 
details). In this case the spectra (Figure 6.3a) was produced with a CE of: 
 
 
Equation 13 
 
With this as a starting point, a range of CEs around this value were tested on 
the QqQ for each transition to determine which CE provides the best analyte signal. 
A volume of 5 μL of 0.5 μg.mL-1 LG3[1:25] was injected for LC-MS analysis, which 
was set up to assess each CE in triplicate for each transition. The results as 
determined by AUC for each transition indicated that a collision energy of 50 eV is 
optimal for the 925 → 799 transition (Figure 6.7). This was followed by 925 → 283, 
which required an optimal CE of 55 eV, then 925 → 1152 and 925 → 1018, both 
with optimal CEs at 45 eV. This signal sensitivity was also observed in the replicate 
peak height data for each transition (dashed lines, Figure 6.7). 
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Figure 6.7. Collision Energy (CE) optimisation of LG3[1:25]. The solid lines (—) represent the integrated AUC 
while the dashed lines (---) represent the peak heights for each transition. Error bars represent ± 1SD. The 
optimal CE for transitions 925 → 799, 925 → 283, 925 → 1152 and 925 → 1018 was 50 eV, 55eV, 45 eV and 
45 eV, respectively. 
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6.3.6 The optimal Declustering Potential for LG3[1:25] was 80 
After signal gains through CE optimisation were made, the next instrument 
parameter to adjust was the DP. The MS must ideally measure single ions, this 
makes the ionisation process an important step. To assist with the desolvation and 
disassociation of molecular clusters at the ion-source, a voltage potential can be 
applied. The success of the DP can be measured through signal gains, and is an 
optimisation at the peptide level and not at the Q3 level.  
 
To the column, 37 μL of 0.5μg.mL-1 LG3[1:25] was injected for subsequent LC-
MS analysis. Each DP was tested in triplicate and the result was expressed as the 
total AUC. The AUC across the range of DPs tested differed significantly (F= 108.6, 
DF = 4, p ≤ 0.001). A Tukey‘s post hoc test confirmed that a DP of 60, 70, 80 or 90 
were all significantly higher than a DP of 50 (p ≤ 0.001). While 80 and 90 were also 
significantly increased from both 60 and 70 (p ≤ 0.001), there was no difference 
observed between 80 and 90 Figure 6.8. Therefore based on these data, a DP of 80 
was selected as optimal for this peptide. 
Figure 6.8. Declustering potential (DP) optimisation for LG3[1:25]. The *** indicates a significant cutoff of p 
≤ 0.001, the red bar indicates the optimal parameter that was used for further assays (DP = 80). 
 Chapter 6: High Throughput Targeted Analysis of the LG3 Polypeptide 175 
6.3.7 The optimal Dwell time was 250 msec 
Using the optimised settings previously discussed, the next instrument 
parameter to optimise was the dwell time (DT). The DT is the amount of time the 
instrument will dwell on a particular Q1 → Q3 transition before cycling to the next. 
The longer this period of time, the more ions are accumulated by the detector, 
resulting in greater analyte sensitivity. To optimise this parameter, 5 μL of 0.5 
μg.mL-1 LG3[1:25] was injected into the LC-MS. Each DT was tested in triplicate and 
the result was expressed as total AUC. The AUC across the range of DTs tested 
differed significantly (F= 10.64, DF = 5, p-value < 0.01). A Tukey‘s post hoc test 
confirmed that 250, 300, 350 and 400 msec DTs were significantly greater than 150 
msec (p ≤ 0.01). There was no significant difference between 150 and 200 msec (p = 
0.109) or 200 and 250 (p = 0.115). Moreover no signal gains were observed for DTs 
over 250 msec Figure 6.9. As such, a DT of 250 msec was optimal as it provided 
comparable sensitivity to DTs of 300, 350 and 400 while also requiring less time to 
acquire ions thus resulting in smaller cycle times. 
Figure 6.9. Dwell time (DT) optimsation. The ** indicates a significant cutoff of p ≤ 0.01, the red bar indicates 
the optimal parameter that was used for further assay development. The optimal DT for LG3[1:25] is 250 
ms. 
 176 Chapter 6: High Throughput Targeted Analysis of the LG3 Polypeptide 
6.3.8 The linear range for LG3[1:25] was from 45 pmol to 59 nmol 
To determine the linear range of the assay a calibration curve was generated 
from 56.37 pmol to 1.17 nmol of purified LG3[1:25] standard. The quantitative 
transition (924 → 799) was integrated and plotted against the amount of LG3[1:25] 
loaded onto the column. Across the standard range 56.37 pmol to 1.17 nmol, 
LG3[1:25] produced an exponentially increasing signal (Figure 6.10a). The calibration 
curve was linear across a full order of magnitude from 56 pmol to 59 nmol (R
2 
= 
0.98) with all of the standards exhibiting a CV of < 11% (Figure 6.10b). 
 
The limit of detection (LOD) was estimated from 12 blank samples according 
to Equation 14 and Equation 15 below. 
 
 
Equation 14 
 
 
Equation 15 
 
where LODauc represents the limit of detection based on the signal produced by 
the instrument and LODmols represents number of mols of analyte and is the true 
LOD for this assay. It is calculated based on the linear range of this particular assay 
using the intercept (b) and the slope (m) (see the calibration parameters in Figure 
6.10b). In this case the LOD was 45 pmol and the limit of quantitation (LOQ) was 48 
pmol, which equates to 124 ng and 133 ng of LG3[1:25]. 
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Figure 6.10. Calibration curves for LG3[1:25]. The dynamic range of LG3[1:25] across six different dilutions 
containing 1% FA, 5% ACN. a) The blue regression fit represents the linear range of the assay. b) The linear 
range of LG3[1:25] is between 0 and 59 nmol with a linear fit of R
2 = 0.98. The dotted lines represent the 95% 
confidence intervals across the linear range. 
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6.3.9 Urinary LG3 polypeptide levels did not significantly increase or decrease 
due to eccentric soft tissue damage and recovery at the timepoints 
measured 
The optimised SRM assay was utilised to test for temporal attenuations in 
urinary LG3 polypeptide following soft-tissue damage of the biceps brachii. Due to 
the narrow linear range that the assay works within (see 6.3.8) and the large 
biological range (i.e. dynamic range) that urinary LG3 appears to be present in 
Parker et al. (2012), a relative approach quantification approach was employed 
(Parker et al. 2012). By taking a relative quantification approach the absolute level of 
LG3 within urine is not determined, but the relative levels of LG3 between each 
participant and each timepoint was ascertained. 
 
Our hypothesis that levels of the LG3 polypeptide would increase following 
soft-tissue damage was tested using two approaches. The first involved pooling each 
of the baseline samples for each individual subject and testing it against each time-
point thereafter, and the second involved comparison of the urinary LG3 polypeptide 
levels in each individual baseline against each of the subsequent timepoints. A one-
way ANOVA was used to compare the effect of soft tissue damage on the release of 
LG3 polypeptide into the urine. Based on the ANOVA results, there was no evidence 
to reject the null hypothesis for both the model containing the individual baseline 
samples (F= 1.402, DF = 13, p = 0.159) and the model containing the pooled 
baseline samples (F= 1.507, DF = 11, p = 0.13). Interestingly, there was an 
increasing trend in the post and D1 timepoint which is generally what our research 
team has observe after acute bouts of exercise but it was not significant in this study 
(Figure 6.11a and b). 
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Figure 6.11. Urinary LG3 levels in urine after eccentric tissue loading of the biceps brachii. a) Each of the 
baseline samples were pooled for comparison (white bars). b) The levels of LG3 polypeptide in each of the three 
baseline sampling points (white bars). Error bars represent ± 1SE. 
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6.4 DISCUSSION 
Perturbations in urinary LG3 polypeptide have previously been implicated with 
physical activity in mining workers compared to a more sedentary control group 
(Parker et al. 2012). Due to its recently discovered augmentation following physical 
activity it was targeted for quantification. To this end, a novel SRM assay that is 
highly specific for the LG3 polypeptide was developed to assess whether or not it is 
also involved with actual tissue damage and/or recovery and not just physical activity 
as has been previously shown (Parker et al. 2012). 
 
It is currently unclear if urine also contains the larger endorepellin fragment 
associated with the same cathepsin-B/L or tolloid like metalloprotease cleavage site 
of the LG3 polypeptide (Gonzalez et al. 2005; Saini and Bix 2012). As such it was 
important to design a highly specific assay that would only assess levels of LG3 
polypeptide and not endorepellin. The strategy adopted in this study was to target the 
25 amino acid sequence from the N-terminal LG3 polypeptide which begins with an 
Aspartic acid and ends at the first arginine. Interestingly, this relatively small 25 
amino acid sequence is highly specific for the LG3 polypeptide with a BLAST
®
 
search reporting a 2e
-21
 E-value for laminin G like domain 3 (i.e. LG3) from human 
perlecan with 100% sequence specificity. The following three hits were all for 
HSPG2 or perlecan, each with an E-values of 3e
-21
 and all sharing 100% sequence 
coverage. The E-value gives an indication of the number of hits on this sequence one 
can expect by pure chance when searching a database of a particular size. Taken 
together, the E-value and the high sequence coverage indicate that this sequence is 
extremely specific for the LG3 polypeptide. Furthermore, this approach took 
advantage of the specific N-terminal cleavage site. As a result, a quantification 
strategy which also allows for inferences to be made regarding the biological 
mechanisms leading to its release can be made. Thus, in this study the development, 
validation and utilisation of this 25 aa sequence (LG3[1:25]) in an SRM mass 
spectrometry assay was successfully achieved. The purpose of which, was to 
quantify levels of urinary LG3 polypeptide following the induction of soft tissue 
damage through eccentric exercise. 
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Replicate analyses demonstrated CV values no greater than 11%, and in fact 
most of the CV values were under 5% for replicates indicating that this assay is 
reproducible across a range of molar amounts. A difficulty with this study was to 
accurately quantify the amount of LG3 polypeptide in the sample due to the large 
biological variations in the LG3 polypeptide within urine samples and the limited 
linear range of the assay, thus relative amounts of LG3 were assessed within the 
sample population. In future studies assessment of recovery in conjunction with the 
use of a heavy labelled LG3[1:25] internal standard using the absolute quantification 
(AQUA) method to increase quantification accuracy will be a priority (Gerber et al. 
2003; Kirkpatrick et al. 2005; Gerber et al. 2007). In addition, multiplexing the 
current SRM assay with the additional targets found in previous chapters would be 
beneficial. 
 
Analyte measurements from urinary assays are typically normalised to 
creatinine concentrations under the premise that the glomerular filtration between 
individual subjects is different and this difference is reflected in the amount of 
protein entering the urine from the blood. More importantly, these differences can be 
accounted for by correcting for creatinine. The key assumption here, is that systemic 
creatinine levels remain constant within and between individuals (Boeniger et al. 
1993) and can therefore be used to infer the rate of filtration of the target analyte 
from the blood to the bladder. Within the study reported here it was not deemed 
appropriate to normalise to creatinine level as creatinine is a catabolic biproduct of 
creatine and creatine phosphate which supplies energy to muscle tissue and is thus 
directly related to physical activity. Given the augmented creatinine levels in Chapter 
4 and the exercise procedure used here, levels of creatinine were expected to increase 
following the exercise stimulus (Baxmann et al. 2008). Thus normalising LG3 
polypeptide levels to creatinine would likely confound the results of this study. 
Instead, LG3 was measured from a normalised amount of protein via SRM. This 
approach has demonstrated good applicability in the past for the analysis of LG3 
polypeptide on a different instrument and amongst a different cohort of active 
participants (Parker et al. 2012). 
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Others have previously performed SRM to target LG3 polypeptide from pooled 
in-gel digest samples (Chang et al. 2008). Interestingly, they identified the N-
terminal peptide through ESI-MS/MS analysis and used the less specific LG3[134:151] 
sequence that does not distinguish perlecan, endorepellin or LG3 polypeptide from 
each other. The problem with utilising this approach is that for analysis of clinical 
samples, the selectivity for the LG3 polypeptide (i.e. a tryptic digest of endorepellin 
or perlecan) will be lost. As such their results represent the possible additive effect of 
LG3[134:151] plus endorepellin[644:661] plus perlecan[4330:4347]. Based on this work the 
authors then go on to estimate the concentration range of LG3 polypeptide in 
‗normal‘ blood to be 3.7 pmol.mL-1 (Chang et al. 2008). However, these data may 
have been significantly under estimated due to the large losses of protein that occur 
during gel electrophoresis and in-gel digestion. The approach presented here, which 
uses in-solution digests, while not unaffected, is far less prone to issues around 
sample recovery. Given this information, it is highly likely that the systemic levels of 
LG3 under ‗normal‘ conditions are far greater than the 3.7 pmol.mL-1 reported by 
Chang et al. (2008). Indeed, using relative quantification via western blot analysis 
others have found the amount of LG3 in serum to be as high as 3.5 g.mL
-1
 in 
‗normal‘ samples (Soulez et al. 2012) which equates to 17.03 nmols.mL-1; a full 
order of magnitude greater than the results reported in Chang et al. (2008). 
Importantly, there is currently no published estimate made as to the amount of LG3 
polypeptide in urine and as reported here, this information was unable to be 
interpolated from the calibration curve as the majority of the SRM signal was greater 
than the highest standard within the linear range of this assay. However, there is 
likely a large amount of LG3 polypeptide in urine since the LG3[1:25] SRM signal 
tends to be substantial, even when as little as 1 g of total protein was loaded. This is 
not surprising as there is likely an excretion rate governing the accumulation of the 
LG3 polypeptide into the bladder and thus the urine. Given this possible excretion 
rate it would seem that urine actually provides a reservoir for the collection of LG3 
polypeptide and thus levels might be greater than those observed systemically in the 
blood depending on the time of sample collection. 
 
The preliminary data presented in this study suggests that LG3 polypeptide 
does not appear to be present at greater levels in urine following eccentric tissue 
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loading. However, from Figure 6.11 a) and b) it appears that the first day following 
induction of soft tissue damage (D1) has elevated levels of LG3 polypeptide, albeit 
not at a statistically significant level. In addition, the post sample had, on average, 
greater levels of LG3 polypeptide than the pooled baseline samples, however the 
window of which LG3 is observed may have been missed. Certainly, our research 
group‘s most recent observations were that urinary LG3 polypeptide is augmented 
within 4 to 12 h post exercise (unpublished data). Nevertheless, I was not able to 
control for this time dependency given the participant recruitment was completed 
prior to our understanding of the importance of the sampling window for an 
increased production of LG3 polypeptide. Alternately, these results may be a 
reflection of the general physical activity status of this cohort. It is noteworthy that 
only one participant within this study cohort claimed to be sedentary, the rest were 
either moderately active or vigorously active. Thus fluctuations in the LG3 
polypeptide might be masked due to the baseline samples representing the higher 
individual physical activity status of each participant. Additional participant numbers 
would assist with establishing if this is the case. 
 
It remains unclear why the LG3 polypeptide is elevated in the urine following 
physical activity. However, it could be proposed that due to the ubiquitous 
expression of perlecan throughout the basement membranes of the body, the LG3 
polypeptide might be liberated under the ischemic (oxygen deprived) conditions 
produced during mild aerobic activities such as jogging, swimming, running etc. In 
addition, it appears that the LG3 polypeptide has some anti-proliferative capacity on 
certain endothelial cells and is neuroprotective in nature (Bix 2012; Saini and Bix 
2012), as well as having anti-angiogenic properties (Bix et al. 2004). The result of 
this biological activity during exercise is still yet to be appropriately elucidated. 
 
6.5 CONCLUDING REMARKS 
In summary, this study has produced an analytical method that provides rapid 
and precise quantification of low pmol amounts of LG3 polypeptide within urine 
samples. The assay will also be useful for serum and tissue analysis due to its high 
specificity and analytical sensitivity for the LG3 polypeptide and not perlecan or 
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endorepellin. A key prerequisite of this study was the selective analysis of LG3 
which is liberated from perlecan via endogenous enzymatic cleavage which was 
successfully achieved. As such, this MS method demonstrates its potential 
application in the area of ―degradomics‖ to target other endogenous cleavage 
products within a range of other research areas. Certainly, the degradation products 
discovered in Chapter 5 will be targeted using this method as soon as the terminal 
sequences are elucidated. In addition, applications might also incorporate a terminal-
end peptide enrichment step, such as that proposed by Hoeppe et al. (2011), allowing 
the identification and quantification of entire classes of peptides using C-terminal 
epitope sequences (Hoeppe et al. 2011). 
 
Using such terminal-end analyses, the urinary LG3 polypeptide was not found 
to attenuate or augment to a significant level from baseline levels following eccentric 
soft-tissue loading. However, conduct of studies specifically designed to control for 
the participants general physical activity and the sampling schedule will enable more 
accurate determination of whether or not the LG3 polypeptide is released following 
eccentric muscle damage. Furthermore, by assessing the results from this assay in 
conjunction with the functional recovery data obtained for each participant, a better 
understanding as to why and when LG3 is released can be pursued. 
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Chapter 7: General Discussion 
WR-MSD presents a significant burden on the workplace compensation system 
and on employees, with the cost of workers‘ compensation alone estimated to be 
between 15 and 20 billion dollars according to the Occupational Safety and Health 
Administration in the USA (OSHA 2000). Other reports in the USA have placed the 
indirect cost of WR-MSD in the vicinity of 55 billion dollars annually (NRC 2001). 
Certainly, more recent Australian data tends to agree, with suggestions that the 
overall costs taking into account indirect expenses for medical, legal and retraining 
purposes, as well as loss of productivity and morale, is 57.5 billion dollars (ABS 
2011). A strengthened economy leading to increases in the resources sector within 
Australia, and a lack of skilled workers resulting in an aging workforce, will ensure 
that WR-MSD remains a prominent health burden in the future (Jones et al. 2012; 
Penney et al. 2012). 
  
Typically these kinds of injuries are diagnosed by a qualified physician after 
clinical presentation, by which time the damage has already been done. The effects 
of such injuries impact the employees, resulting in lengthy rehabilitation times which 
occasionally require extended workplace leave. Specific effects on employees are at 
both a mental and physical level, often involving substantial pain, reduced mobility 
and increased psychological morbidity (Mason et al. 2002). Such time off incurs a 
loss of productivity for the employer, as well as excessive medical expenses, and can 
lead to psychosocial problems such as depression (Squires et al. 1996; ABS 2011).  
 
There are many factors involved with the onset and severity of WR-MSD, 
including forceful exertions, high repetitions, prolonged muscle loading, short 
recovery periods, awkward postures, localized mechanical stress and various 
psychosocial factors (Forde et al. 2002; Punnett and Wegman 2004). Irrespective of 
which of these factors are involved, the pathology of severe WR-MSDs are similar, 
involving molecular disruption of ligament, tendon, muscle or bone, which impedes 
normal tissue function and thus day to day living (Buckle and Devereux 2011). 
 186 Chapter 7: General Discussion 
These injuries might present as a mild impediment which may not even be noticed, 
or can present as major structural damage involving tenderness and swelling (Yassi 
1997). In the past, others have investigated the use of biological indicators of soft 
tissue damage within the workforce (Kaergaard et al. 2000; Schell et al. 2008). Such 
technology could theoretically serve as a monitoring tool to diagnose over-use 
disorders within the workplace. However, the primary drawback with these recent 
efforts has been their lack of application using an appropriate sample type. For 
example, these studies utilised serum or plasma which is clearly not a practical bio-
fluid for use in a workplace scenario because blood is invasive to obtain, especially 
for monitoring applications. In addition, they investigate soft-tissue damage using 
biomarkers such as cortisol or LDH. Such markers are often ubiquitously produced 
by various biological systems and are diurnally regulated, and as such, are 
considered to be indirect markers and therefore inherently lack tissue specificity 
(Garde et al. 2007). This highlights the current necessity to develop novel diagnostic 
technologies capable of detecting the onset of damage prior to clinical presentation 
of injury. 
 
The aim of this PhD program was to employ the use of multiple discovery-
phase ‗omics‘ techniques to investigate the presence of tissue specific markers within 
urine. To summarise the hypothesis outlined in 1.13 - urine is a reservoir of soft 
tissue damage products, as such, investigation of its biomolecular components could 
yield novel markers of soft tissue damage or recovery from injury. To test this 
hypothesis, a validated laboratory-controlled soft tissue injury model was used to 
induce tissue damage. Due to the lack of appropriate soft tissue damage targets 
within urine, and the complexity of urine, it was important to use technologies 
capable of measuring multiple analytes in order to economise time and maximise the 
number of potential candidate biomarkers detected. To this end multiple analytical 
platforms were employed throughout this research program to cover a wide range of 
molecules within urine. To summarise: 1) Initially, a subgroup of urinary proteins 
(cationic proteins/polypeptides) ranging from ~2-20 kDa were investigated using 
SELDI-TOF/MS; 2) A metabolomics approach using 
1
H-NMR was utilised to detect 
biomolecules under 3 kDa that the SELDI-TOF/MS was not able to detect. 3) An 
LC-MS/MS approach using the Hybrid quadrupole tripleTOF™ 5600 was utilised to 
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assess urinary protein constituents above 3 kDa; 4) Finally, a targeted quantitative 
LC-MS/MS method using a QqQ was developed to investigate temporal changes in 
the urinary levels of the LG3 polypeptide of Endorepellin across the first week of 
muscle damage/recovery, following up a novel finding from our group‘s previous 
related work (Parker et al. 2012). Through application of these methodological 
approaches, each of these studies advanced current knowledge in their respective 
fields. In addition, aspects of this research program also provided significant novel 
findings in the area of soft tissue damage due to an over exertion injury. 
 
Soft tissue damage was induced through a series of eccentric actions on the 
biceps brachii of 21 volunteers. In this experiment the follow-up measurements of 
functional strength were collected out to 60 days post damage. This represents a key 
approach as it is not uncommon to cease data collection well before this time, even 
when functional recovery may not have returned to basal levels (Jones et al. 1986; 
Chen 2006). Following this type of over-exertion injury, neutrophil lysis of muscle 
cell membranes ensues and the repair process begins by removing cellular debris. 
This occurs via a superoxide dependent mechanism (Tidball 2005) causing a shift to 
a pro-oxidant state as the concentration of reactive oxygen species (ROS) is 
increased. Such an increase in the molar concentrations of ROS results in lipid 
peroxidation, protein modifications and eventually muscle cell lysis (Nguyen and 
Tidball 2003; Niess and Simon 2007). Thus the body needs mechanisms in place to 
shift the oxidative balance towards an antioxidant state. Interestingly, the participants 
in this study exhibited a rapid increase (within 2 h) in two key antioxidants known to 
be present at high levels in skeletal muscle, myo-inositol and taurine (Molitoris et al. 
1980; Huxtable 1992).  
 
Clearly the oxidative balance within skeletal muscle is affected during heavy 
bouts of physical activity. In addition, upon over exertion an immediate mast cell 
response results in an active release of vasodilators, such as histamine, to increase 
capillary permeability thus enabling the localisation of additional phagocytic 
leukocytes to the site of injury (MacIntyre et al. 1995; Smith et al. 2008). Additional 
vasodilators are present upon injury, these include serotonin, bradykinin and nitric 
oxide (MacIntyre et al. 1995; Wang et al. 2005). Importantly, histamine was detected 
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in urine directly after eccentric tissue loading within this PhD project, and perhaps 
may be monitored within a workplace setting to determine if over exertion is 
occuring. Another outcome from the 
1
H-NMR data was the presence of the collagen 
specific 5-hydroxylysine which appeared with myo-inositol and histamine. 
Importantly, ELISA kits have been developed for histamine, serotonin and 
bradykinin, 5-hydroxylysine, along with a variety of enzymes involved in catalyzing 
reactions with myo-inositol. There is also an existing SRM assay for myo-inositol 
trispyrophosphate in horses that could be quickly adapted to human urine samples 
(Wong et al. 2011). The ELISA assays might be adapted into a multiplex system, 
likewise the myo-inositol trispyrophosphate SRM can readily be multiplexed with 
our LG3[1:25] SRM assay, although, careful optimisation of chromatographic 
conditions and sample preparation would be required. Based on the research 
presented in this dissertation, each of these biochemical markers appears to be related 
to acute-phase responses to soft tissue damage, as such, further assessment of their 
temporal abundance across the recovery period using these targeted methods is 
recommended. In addition, such methods would support the high throughput analysis 
of these potential targets in real-world applications. Importantly, others have 
suggested that oxidative stress may play a role in ischemic damage of cardiac and 
skeletal muscle in untrained workers (Mignini et al. 2008). Furthermore, the redox 
state of workers within heavy labour industries has not previously been investigated 
as a monitoring tool for the early diagnosis of soft tissue injuries and may provide a 
novel avenue for future research. 
 
Trauma to the microstructures of skeletal muscle represents another acute-
phase response to over-exertion injuries, particularly within eccentric models 
(Lauritzen et al. 2009). Sarcolemmal ruptures are a particular aberration typically 
observed after over-exertion muscle injuries and are typically defined as a lack of 
continuity and structure between Z-discs of a myofibril. Inherent to this type of gross 
physiological deviation is a compromised sarcoplasmic reticulum. A ruptured 
sarcoplasmic reticulum will result in an influx of Ca
2+
 ions within the damaged 
sarcolemma itself (Brotto and Nosek 1996). Interestingly, others have suggested 
such Z-disk proteins are preferential substrates for the calcium-dependent protease, 
calpain (Friden et al. 1981; Belcastro 1993; Belcastro et al. 1998). Calpains are a 
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family of calcium-dependent cysteine proteases involved in a number of biological 
functions within the body (Goll et al. 2003). What is striking about this insight is that 
Raastad et al. (2010) have demonstrated that such an influx of Ca
2+
 results in 
increased calpain activity following eccentric muscle damage within a quadriceps 
exercise-induced muscle damage model (Raastad et al. 2010). Importantly, calpain is 
a protease that is spatially located very close to a range of filamentous muscle 
proteins at the I and M-bands of the sarcomere (Duguez et al. 2006). Additionally, 
calpain-3 has been implicated with the targeted removal of Z-lines from skeletal 
muscle, which implies it may be involved in myofibrillar protein release during 
muscle damage (Goll et al. 1992; Belcastro et al. 1994).  
 
A study performed by Kramerova et al. (2004) demonstrated calpain-mediated 
cleavage of titin at the carboxyl end (Kramerova et al. 2004). In addition, calpain-3 
has been shown to be anchored to titin at the N2A and M-line regions (i.e. C-terminal 
of titin) (Ono et al. 2004) and has also been localised at the Z-disc region (i.e. N-
terminal of titin) of the sarcolemma (Kinbara et al. 1998; Keira et al. 2003; Ojima et 
al. 2005). Importantly, titin is not the only substrate of calpain-3. Calpain-3 appears 
to degrade other skeletal muscle proteins including F-actin binding protein, myosin, 
nebulin, gelsolin, desmin and troponin-I (Goll et al. 2003). Another mechanism for 
this early-phase degradation of proteins is that it arises from the initial neutrophil 
response (Pizza et al. 2001; Toumi et al. 2006). However, it is now clear there is 
strong evidence to support a skeletal muscle-mediated degradative response to 
exercise-induced muscle damage. In conclusion, it seems plausible that the protein 
fragments that appeared within the work presented in this thesis, at least at D1 (i.e. 
titin and filamin-C), might be due to this initial calpain-mediated degradation. To test 
this hypothesis, future in vitro work might incorporate treatment of damaged muscle 
cells with E64c, a potent calpain inhibitor (Huang et al. 1992). Inclusion of such an 
inhibitor would confirm the digestive effects calpain on these proteins. 
 
Biphasic losses of functional strength have been observed previously after 
eccentric tissue loading exercises in both human and animal models (Faulkner et al. 
1993; MacIntyre et al. 1996). Typically, the largest drop in functional strength is 
observed directly after tissue damage (Nosaka et al. 2005; Lauritzen et al. 2009), an 
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observation supported by the data presented in Chapter 2 of this thesis. In addition, 
there was an attenuation in torque generating capacity that occurred around four days 
following muscle injury. Interestingly, this observation corresponds with a localised 
increase in macrophage levels in eccentric exercise damage models in rodents and 
humans (McCully and Faulkner 1985; Kano et al. 2004; Paulsen et al. 2009). Based 
on the muscle regeneration model proposed by Tidball and Villalta (2010), the 
timing of the secondary loss appears to skip the damaging effect of 
polymorphonuclear neutrophils (PMN) and the aforementioned calpain activity. 
However, it does coincide with an M1/M2 macrophage presence reported by others 
(Figure 7.1a)(Tidball and Villalta 2010), suggesting that the protein degradation 
observed days after injury might be, in part, due to macrophage-related mechanisms. 
A theoretical model based on the data presented throughout this dissertation is 
presented in Figure 7.1b. 
 
Of importance to this body of work, is that the additional functional loss 
observed between three/four days post damage appears to coincide with the increased 
abundance of key muscle-specific proteins within blood (MacIntyre et al. 2001) and 
now, as reported in this project, within urine; in particular, titin, telethonin, filamin-C 
and myozenin-1 (Figure 7.1b). Given the temporal correlation between these protein 
fragments and the observations of macrophage abundance in other eccentric studies it 
is plausible that these proteins are being degraded by macrophage-mediated events. 
Certainly, it is known that macrophages have the capacity to lyse muscle tissue 
(Wehling et al. 2001; Nguyen and Tidball 2003). It has also been suggested that the 
degradation of proteins such as titin is due to macrophages during digestion of 
necrotic myofibres in a rat soleus atrophy model (Goto et al. 2003). Furthermore, the 
realisation that each of these proteins is involved with sarcomere stability supports 
the hypothesis that their subsequent digestion and removal from the myofibre may be 
connected with the additional losses of strength several days post eccentric injury. 
This is due to the myofibre tension produced through sarcomere continuity being 
crucial for correct muscle contraction (Figure 7.1b). This represents a novel finding 
from this research project and provides evidence that Z-disc protein disintegration 
occurs after over-exertion; in particular through eccentric actions, resulting in Z-disc 
protein excretion into the urine.  
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Figure 7.1. Temporal abundance of muscle protein degradation products in urine following eccentric 
tissue loading. a) Adapted from Tidball et al. (2010), the generalized timecourse of leukocyte influx following 
acute muscle damage (Tidball and Villalta 2010). PMN = polymorphonuclear neutrophils, M1 and M2 represent 
pro- and anti-inflammatory macrophage populations during the recovery phase. b) Abundance profiles of 
proteins and metabolites due to over-exertion (i.e. eccentric damaging actions). Note the sarcomeric proteins 
correlate with the M1/M2 phase of recovery which also correlates with secondary reductions in strength. These 
data are based on the semiquantitative results from Chapter 5 up to day 7, thus the dashed lines (---) represent an 
estimate/extrapolation. 
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The literature supports the observation that eccentric muscle actions have a 
propensity to disturb the Z-disk regions of the myofibres (Friden et al. 1981). Such 
Z-disc disruptions appear immediately after injury, but also tend to progressively 
worsen over the following days (Newham 1988). In this dissertation, strong evidence 
in support of the appearance of protein fragments in urine that are otherwise localised 
at the Z-disk region of the myofibre is provided. In particular, titin along with its Z-
disk anchor, telethonin, were identified at each time-point, with the exception of the 
pre-injury baseline samples. Titin connects the Z-disc to the M-line of the sarcomere 
and is thought to act as a molecular spring, as well as being involved with complex 
stress signalling pathways during contraction (Ottenheijm and Granzier 2010). The 
striking feature about this finding is that titin is far too large to pass from the blood 
and into urine via glomerular filtration in the kidneys without prior endogenous 
degradation. This finding indicates titin is being cleaved, most likely at the site of 
injury as discussed above. Filamin-C was also identified as being differentially 
expressed and is characterised as a striated muscle-specific filamin isoform which 
has been shown to bind other Z-disc proteins such as myotilin (van der Ven et al. 
2000). Interestingly, filamin-C is unique among other filamins, due to an insertion in 
the 20
th
 Ig repeat (van der Ven et al. 2000). It has been suggested that filamin-C 
represents a Z-disc targeting motif, hence its localisation within the sarcomere 
(Frank et al. 2006). Similarly, myozenin-1 also colocalizes with myotilin and 
telethonin at the Z-disc region of the sarcomere (Salmikangas et al. 1999). 
Myozenin-1 has also been shown to competitively bind with -actin and filamin-C 
(Takada et al. 2001). The urinary levels of both were found to fluctuate in abundance 
in the study reported herein. Interestingly, the myotilin-1 isoform of myotilin has not 
been reported in previous urinary proteomic studies and thus is an additional novel 
finding (Adachi et al. 2006; Lee et al. 2008; Marimuthu et al. 2011). 
 
It is important to note that these discoveries were made in undepleted urinary 
protein samples, which indicates there is further potential to uncover additional Z-
disc protein constituents by incorporating a depletion strategy into the method. 
Moreover, these data also suggest that there might be merit in targeting other Z-disc 
components in future work and represents a logical progression to build on the 
results presented in this dissertation. The potential in taking such a targeted approach 
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is supported by the identification of other common Z-disc-related proteins within 
urine samples from ‗healthy‘ individuals in previous studies (Table 7.1, tick-marks) 
(Adachi et al. 2006; Lee et al. 2008; Marimuthu et al. 2011). In addition, there are a 
number of well known Z-disc proteins which have not been identified in ‗healthy‘ 
urines, but might provide an additional avenue for discovery of novel markers of 
muscle tissue damage (Table 7.1, crosses). One hypothesis for their presence in these 
studies is that these ‗healthy‘ donors were physically active prior to or during the 
sampling period. 
 
Table 7.1 
List of Z-disc specific proteins and their reported presence in urine 
Protein 
Identified in urine 
previously? 
Molecular Weight 
Nebulin  ~772 kDa 
CapZ  ~31 kDa 
Obscurin  ~420-920 kDa 
Myotilin  ~55 kDa 
Myopalladin  ~145 kDa 
Myozenin  ~32 kDa 
ZASP/Cypher/Oracle  ~77 kDa 
Actinin  ~103 kDa 
Myopodin  ~117 kDa 
Skeletal muscle actin  ~42 kDa 
Skeletal muscle Myosin isoforms  ~223 kDa 
Tropomyosin  ~32 kDa 
Troponin I  ~21 kDa 
Titin  ~3.7 MDa 
Telethonin  ~19 kDa 
Filamin-C  ~291 kDa 
Vinculin  ~124 kDa 
Desmin  ~53 kDa 
Gelsolin  ~86 kDa 
 The observation () or absence () of these proteins in other urinary protein samples was based on data from a 
benchmark urinary proteomic dataset (Marimuthu et al. 2011) which represents a combined non-redundant catalogue 
of high confident urinary proteins from other studies (Adachi et al. 2006; Lee et al. 2008). 
 
In summary, there was a clear peak in abundance for each of the Z-disc 
fragments presented in Chapter 5. Additionally, some tended to follow a temporal 
trend. While the possible causes of such protein cleavage events has been discussed, 
irrespective of the biological reason for their degradation and liberation from the 
sarcomere, it is clear that they can be detected and quantified in urine samples upon 
physical over-exertion. This represents one of the more significant discoveries from 
this body of work as these biochemical markers, along with the other Z-disc proteins 
in Table 7.1, may provide valuable information for monitoring muscle tissue status 
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within heavy labour industries. Some additional key contributions from this body of 
research are: 
 This research was the first to investigate the application of matrix modifiers 
to SPA, combined with SELDI-TOF/MS analysis. By doing this, an increase 
in the S/N ratio at the low m/z region was observed, thus improving peak 
detection while minimising detector saturation. 
 This is the first study to describe and develop a novel SRM assay to 
specifically quantify the liberated C-terminal end of Perlecan, known as 
LG3, which we have previously shown to be increased in urine following 
aerobic-style exercises. Indeed, others have already approached our group 
regarding the application of this method to the monitoring of ischemic events 
within brain tissue (personal communication from Assoc. Prof. Greg Bix, 
University of Kentucky, USA) highlighting the potential impact in this field. 
 The data reported herein clearly demonstrate temporal change in muscle 
specific protein fragments within urine as a result of eccentric tissue damage. 
 At the time of applying the samples on the Hybrid quadrupole tripleTOF™ 
5600, it was not possible to analyse the data without vendor-specific software 
due to the modified file structure compared to previous ABSciex MS 
platforms. As such, a completely open-source analysis pipeline using a range 
of current state of the art computational tools was established to handle the 
updated Hybrid quadrupole tripleTOF™ 5600 files without the necessity to 
purchase software. This analysis pipeline will be useful to other researchers 
working with the next generation of ABSciex instruments that do not have 
ready access to the vendor software (i.e. users who send their samples to an 
MS facility but still want to assess the data for themselves). 
 The data generated through this project demonstrated that even when a small 
muscle group is damaged (relative to body mass), in this case the biceps 
brachii, there was clear evidence that protein fragments could be observed in 
urine without any depletion strategy being required. Based on this 
observation, it can be inferred that these candidate biomarkers are present in 
high enough abundance within the urinary proteome to be detected by MS. 
Thus in a real world sample, such biomarkers will be the result of over-
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exertion from multiple muscle groups (presumably) therefore detection 
should not be an issue. 
 
7.1 FUTURE WORK 
Because efforts were made to discover novel biochemical indicators of soft 
tissue damage, each of the methods used was chosen for its capacity to assess 
multiple biological analytes. As such, further validation efforts are required which 
will include both experimental validation using targeted approaches and biological 
validation using larger cohorts (i.e. increased sample size). The 
1
H-NMR study 
resulted in preliminary identification of a series of putative metabolites released 
following soft tissue damage; these now require validation using 2D-NMR to gain 
confident identities and to remove potential false positives. Furthermore, a targeted 
assay could be established, most likely an SRM assay for laboratory-based research 
purposes. This would be appropriate since this methodology is particularly straight 
forward for metabolite analysis and is simple to multiplex as additional targets of soft 
tissue damage/recovery are discovered. 
 
The Hybrid quadrupole tripleTOF™ 5600 proteomic analysis of the soft tissue 
damage/recovery yielded the most biologically significant results with the 
identification of a range of skeletal muscle specific proteins. However, due to the use 
of tryptic peptides instead of the native protein or polypeptide, it is important to 
further verify these candidate markers using antibody-based methods. Future work 
will include immunoprecipitation (antibody pull-downs) provided the antibody is 
available. This will be followed by mass spectrometry with a particular focus on N- 
and C-terminal characterisation, where applicable (e.g. titin), to determine the 
location of the endogenous cleavage site/s. To this end a terminal amine isotope 
labelling of substrates (TAILS) approach might hold promise to purify and quantify 
N-terminal peptides (Kleifeld et al. 2011). Additionally, these terminal-end peptides 
could be added to the SRM assay described in the LG3 polypeptide study to begin 
multiplexing of subsequent analyses. This will result in significant improvements to 
research productivity in other experiments of tissue repair or degradation in injury 
models. However, such analysis will clearly depend on the individual terminal 
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peptide characteristics. Furthermore, the potential biomarkers discovered here are 
from an eccentric exercise-induced tissue damage model, as such, an additional 
understanding of their levels for other contraction types and different muscle groups 
is of key importance. It is expected that the marker profile will be different to a lower 
limb eccentric model due to the ‗trained‘ nature of the primary leg muscles compared 
to arm muscles. This propensity for an increased severity of damage in the arms 
compared to the legs has been described previously (Jamurtas et al. 2005; Paschalis 
et al. 2010). The capacity to measure levels of different biochemical markers from 
different tissues, or due to different contraction types, will provide greater sensitivity 
for the prognosis of musculoskeletal injuries within the workforce. 
 
Additionally, future work will incorporate a stable isotope-labelled variant of 
LG3[1:25] into the SRM assay, and any other SRM that is developed from this work, 
for AQUA analysis (Gerber et al. 2003; Kirkpatrick et al. 2005; Gerber et al. 2007). 
Further advances to the assay would include additional fractionation to avoid false 
positive peaks and to limit sample matrix effects. While, it is important to formally 
test the benefits of such a depletion strategy, it needs to be kept in mind that 
introduction of redundant sample handling steps can have detrimental effects on the 
final assay by increasing the variability introduced into the method itself. Given the 
proteomic aspect of this research problem is one of a ―degradomics‖ nature, targeting 
the terminal peptide/s may be an effective way to quantify the biological effect (i.e. 
an enzyme cleavage event) provided peptide sequences are specific/unique to the 
target proteins. Of course this will need to be assessed on a peptide-by-peptide basis, 
and clearly non-unique peptides may not be sufficient for such an analysis. Such an 
approach will increase biological specificity for the accurate diagnosis of potential 
over exertion injuries/WR-MSDs. 
 
7.2 ADDITIONAL POTENTIAL APPLICATIONS OF THIS BIOMARKER 
TECHNOLOGY 
This research lays down the basis for future work investigating the accurate 
prediction of work-related MSDs. However, there are also other avenues of research 
that might benefit from such technology. Indeed, the future development of assays to 
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measure these protein fragments may have important clinical applications for the 
monitoring of a variety of inflammatory myopathies such as polymyositis, 
dermatomyositis (Bohan and Peter 1975; Bohan and Peter 1975) or inclusion body 
myositis (Griggs et al. 1995; Griggs 2006; Rose and Griggs 2007). In addition, there 
may be further applications for monitoring MSDs that arise in professional athletes, 
military personal, or for monitoring of exposure to physically demanding tasks in 
other populations. The true potential for such technology lies with assessing levels of 
soft tissue damage early to prevent serious injury via accumulated soft tissue 
microtrauma. In addition, the capacity to accurately determine which tissue types are 
being damaged, and where in the injury cycle (damage or recovery) a person might 
be, would be a significant advantage for implementation of injury prevention 
strategies. Of crucial importance to the real world application of such technology is 
that these indicators of progressive injury, damage or recovery, can be assessed in a 
non-invasive fashion through the utilisation of urine as the diagnostic medium. 
 
7.3 CONCLUDING REMARKS 
Each of the potential contributions of this research to the scientific community 
has been outlined throughout this chapter. However, the single most profound item 
of knowledge to be taken from this dissertation is this: Tissue-specific biomolecules 
resulting from soft tissue damage through over-exertion can be detected within urine. 
This notion alone has potential to open up novel applications in the monitoring of a 
variety of myopathies, workplace monitoring, screening of professional athletes and 
monitoring of military personal to reduce the onset of injury in these professions, and 
as such the exorbitant economic burdern associated with such injuries. 
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Appendix A1 
Initial ‘Cluster Buster’ optimisation 
Standard SPA preparation recommended by Bio-Rad 
SPA (50%) was prepared by adding 100 µl of HPLC grade Acetronitrile 
(ACN) and 100-µl of 1.0% TFA to a tube containing 5 mg SPA and vortexed for 5 
min. Undissolved SPA was pelleted by centrifugation at 10 000 x g for 10 min. The 
supernatant was collected and added to an equal volume of 50% ACN:0.5% TFA. 
CHCA (50% ACN:0.25% TFA) was prepared according to Bio-Rad‘s instructions. 
 
Synthetic peptide standard 
A 14 amino-acid long cyclic peptide was kindly donated by the Harris group to 
serve as an optimisation standard for optimisation of the SELDI-TOF/MS matrix. 
This peptide consisted of Arg-Val-Cys-Trp-Gly-Asn-Pro-Gln-Cys-Ile-Pro-Pro-Glu-
Ser in a cyclic ring, and contained one disulphide bond between the two cysteine 
residues. It had a theoretical m/z of [M+1H]
+ 
=1567.72. 
 
Comparison of Ammonium citrate or ammonium phosphate spiked into SPA  
Ammonium citrate and Ammonium phosphate were assessed for their ability to 
suppress noise and increase analyte signal. A stock solution consisting of 20 mmol 
ammonium salt, 1% TFA in 400 uL ddH2O was made up for both ammonium 
phosphate and ammonium citrate. The matrix consisted of 5 ug SPA dissolved in 210 
uL of 62.5% ACN, 0.625% TFA via vortexing for 5 min. The solution was then 
clarified via centrifugation at 14,000 rpm for 5 min to pellet any undissolved 
material. To two eppendorf tubes 10 mmol of ammonium buffer (phosphate and 
citrate) was made up to a volume of 10 uL before adding 40 ul of 100 % SPA to 
make a final concentration of 80% SPA, 50% ACN, 0.5% TFA and 10 mM Am 
Cit/phosphate. To each spot on a CM10 array 1uL of synthetic peptide standard (400 
mM) of size 1568 Da (section 0 above) was applied to the ProteinChip surface 
followed by the application of two  1 L aliqoutes of ammonium phosphate or 
citrate containing matrix. 
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Each of the spots were analysed with a warming shot of 1200 nj, a data shot of 
1100 and a partition index of 2 of 10 with 252 spectra taken per spot. Following 
SELDI-TOF/MS analysis the spots were analysed under scanning electron 
microscopy. 
 
Here 10 mM of ammonium citrate and 10 mM of ammonium phosphate were 
spiked into the SPA preparation before applying it to the SELDI chip surface. Based 
on this initial optimisation with eqimolar amounts of purified peptide standard 
(section 0) applied to the surface using the two ‗cluster busters‘, the ammonium 
phosphate produced better signal characteristics with a signal to noise ratio of 314.03 
(see Appendix Figure 1a) compared to 227.99 in the ammonium citrate spiked 
samples (see Appendix Figure 1b). A noticeable trait of this protocol was that after 
application of the matrix, each spot took a longer period of time to dry down than 
usual. This observation is possibly due to the hygroscopic nature of the ammonium 
phosphate or citrate on the chip surface. 
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Figure 1. Ammonium phosphate produces superior signal characteristics than ammonium citrate. 
Signal to noise ratio from two ―cluster busters‖ applied to a purified peptide standard during the spotting 
of the analyte matrix. The ―cluster busters‖ used were a) 10 mM Ammonium phosphate spiked into the 
SPA and b) 10 mM Ammonium citrate spiked into the SPA. 
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SELDI–TOF/MS processing 
Figure 2. Proportion of SELDI-TOF/MS data removed due to large normalization factors (Nf). A 
distributions of Nf for all samples in the high energy dataset (figure a, acquired with a laser energy of 5000 nJ) 
and the low energy dataset (figure b, acquired with a laser energy of 2500 nJ). The red hashed line (----) 
indicates the threshold (2  SD) afterwhich the spectra are excluded from further analysis. 
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Figure 3. Batch analysis of SELDI-TOF/MS data. Quality control samples demonstrating good 
homogeneity across batches for the high energy (5000 nJ) and low energy (2500 nJ) datasets. Blocks of 
colours on the left correspond to the day of analysis (detailed on the right). 
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Figure 4. Skewed distributions of SELDI-TOF.MS peaks. Distributions of significant peaks from low energy 
(2500 nj) acquisition protocol demonstrate the skew in the variables detected by SELDI-TOF/MS. Labels a) 
through e) correspond with m/z 15833, 13109, 15582, 3032, and 16253 respectively. 
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Appendix B1  
PLS-LDA extracted NMR resonances 
Table 1 
List of the top 50 variables influences the classification of Pre vs Post samples based on PLS 
modelling 
1.1375 2.3075 2.6725 3.0575 7.1925 
1.1425 2.3475 2.6775 3.1125 7.1975 
1.1475 2.5275 2.6825 3.1175 7.2675 
1.1525 2.5325 2.7025 3.2325 7.3625 
1.1575 2.5525 2.7075 3.2775 7.3675 
1.2275 2.5575 2.7225 3.2825 7.4275 
1.6675 2.5625 3.0375 3.3025 7.5575 
2.2675 2.5675 3.0425 3.3075 7.8325 
2.2725 2.6625 3.0475 3.7975 7.8475 
2.3025 2.6675 3.0525 7.1875 7.9225 
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Figure 5. 1H-NMR peaks of interest due to soft tissue damage.The normalised spectra highlighting the spectral regions of interest based on the PLS-LDA models comparing baseline 3 
(Pre, —) to the first samples after extercise (Post, —) using the Pareto-scaled data. The regions of interest found through PLS modelling are highlighted by the black square (■). 
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List of cRAP proteins to exclude from MS/MS results 
Table 2.  
Common Repository of Adventitious Proteins (version 2012.01.01). This is a list of contaminating 
proteins to exclude from MS/MS ID-based experiments, the most current version can be downloaded 
from ftp://ftp.thegpm.org/fasta/cRAP. 
 
1. Laboratory proteins: 
 Id Description Reason Reason 
1 ALBU_BOVIN (P02769) Serum albumin precursor (Allergen Bos d 6) (BSA) Reagent and lab contaminant 
2 CTRA_BOVIN (P00766) Chymotrypsinogen A (EC 3.4.21.1) [Contains: Chymotrypsin A chain A; 
Chymotrypsin A chain B; Chymotrypsin A chain C] 
Reagent 
3 CTRB_BOVIN (P00767) Chymotrypsinogen B (EC 3.4.21.1) [Contains: Chymotrypsin B chain A; 
Chymotrypsin B chain B; Chymotrypsin B chain C] 
Reagent 
4 LALBA_BOVIN (P00711) Alpha-lactalbumin precursor (Lactose synthase B protein) (Allergen Bos d 4) Reagent and lab contaminant 
5 LYSC_LYSEN (Q7M135) Lysyl endopeptidase (EC 3.4.21.50) (Lys-C) Reagent 
6 PEPA_BOVIN (P00792) Pepsin A precursor (EC 3.4.23.1) Reagent 
7 PEPA_PIG (P00791) Pepsin A precursor (EC 3.4.23.1) Reagent 
8 PEPB_PIG (Q10735) Pepsin B precursor (EC 3.4.23.2) (Parapepsin I) (Fragment) Reagent 
9 PEPC_PIG (P30879) Gastricsin precursor (EC 3.4.23.3) (Pepsinogen C) (Fragment) Reagent 
10 SSPA_STAAU (P04188) Glutamyl endopeptidase precursor (EC 3.4.21.19) (Staphylococcal serine 
proteinase) (V8 protease) (V8 proteinase) (Endoproteinase Glu-C) 
Reagent 
11 TRY1_BOVIN (P00760) Cationic trypsin precursor (EC 3.4.21.4) (Beta-trypsin) [Contains: Alpha-trypsin 
chain 1; Alpha-trypsin chain 2] (Fragment) 
Reagent 
12 TRY2_BOVIN (Q29463) Anionic trypsin precursor (EC 3.4.21.4) Reagent 
13 TRYP_PIG (P00761) Trypsin precursor (EC 3.4.21.4) Reagent 
14 CAS1_BOVIN (P02662) Alpha-S1-casein precursor Reagent and lab contaminant 
15 CAS2_BOVIN (P02663) Alpha-S2-casein precursor [Contains: Casocidin-1 (Casocidin-I)] Reagent and lab contaminant 
16 CASB_BOVIN (P02666) Beta-casein precursor Reagent and lab contaminant 
17 CASK_BOVIN (P02668) Kappa-casein precursor [Contains: Casoxin C; Casoxin 6; Casoxin A; Casoxin B; 
Casoplatelin] 
Reagent and lab contaminant 
18 GFP_AEQVI (P42212) Aequorea victoria Green fluorescent protein Reagent 
19 PLMP_GRIFR (P81054) Peptidyl-Lys metalloendopeptidase precursor - Grifola frondosa (LysN) Reagent 
    2. Dust/contact proteins: 
   Id Description Reason 
1 AMYS_HUMAN (P04745) Salivary alpha-amylase precursor (EC 3.2.1.1) (1,4-alpha-D-glucan 
glucanohydrolase) 
Human saliva 
2 K1C10_HUMAN (P13645) Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) (Keratin-10) (K10) Human skin 
3 K1C9_HUMAN (P35527) Keratin, type I cytoskeletal 9 (Cytokeratin-9) (CK-9) (Keratin-9) (K9) Human skin 
4 K2C1_HUMAN (P04264) Keratin, type II cytoskeletal 1 (Cytokeratin-1) (CK-1) (Keratin-1) (K1) (67 kDa 
cytokeratin) (Hair alpha protein) 
Human skin 
5 K22E_HUMAN (P35908) Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e) (K2e) (CK 2e) Human skin 
6 K1H1_HUMAN (Q15323) Keratin, type I cuticular Ha1 (Hair keratin, type I Ha1) Human hair 
7 K1H2_HUMAN (Q14532) Keratin, type I cuticular Ha2 (Hair keratin, type I Ha2) Human hair 
8 K1H4_HUMAN (O76011) Keratin, type I cuticular Ha4 (Hair keratin, type I Ha4) Human hair 
9 K1H5_HUMAN (Q92764) Keratin, type I cuticular Ha5 (Hair keratin, type I Ha5) Human hair 
10 K1H6_HUMAN (O76013) Keratin, type I cuticular Ha6 (Hair keratin, type I Ha6) Human hair 
11 K1H7_HUMAN (O76014) Keratin, type I cuticular Ha7 (Hair keratin, type I Ha7) Human hair 
12 K1H8_HUMAN (O76015) Keratin, type I cuticular Ha8 (Hair keratin, type I Ha8) Human hair 
13 K1HA_HUMAN (O76009) Keratin, type I cuticular Ha3-I (Hair keratin, type I Ha3-I) Human hair 
14 K1HB_HUMAN (Q14525) Keratin, type I cuticular Ha3-II (Hair keratin, type I Ha3-II) Human hair 
15 KRHB1_HUMAN (Q14533) Keratin, type II cuticular Hb1 (Hair keratin, type II Hb1) (ghHKb1) (ghHb1) 
(MLN 137) 
Human hair 
16 KRHB2_HUMAN (Q9NSB4) Keratin, type II cuticular Hb2 (Hair keratin, type II Hb2) Human hair 
17 KRHB3_HUMAN (P78385) Keratin, type II cuticular Hb3 (Hair keratin, type II Hb3) Human hair 
18 KRHB4_HUMAN (Q9NSB2) Keratin, type II cuticular Hb4 (Hair keratin, type II Hb4) Human hair 
19 KRHB5_HUMAN (P78386) Keratin, type II cuticular Hb5 (Hair keratin, type II Hb5) Human hair 
20 KRHB6_HUMAN (O43790) Keratin, type II cuticular Hb6 (Hair keratin, type II Hb6) (ghHb6) Human hair 
21 K1C15_SHEEP (O77727) Keratin, type I cytoskeletal 15 (Cytokeratin-15) (CK-15) (Keratin-15) (K15) Sheep wool 
22 K1M1_SHEEP (P02534) Keratin, type I microfibrillar 48 kDa, component 8C-1 (Low-sulfur keratin) Sheep wool 
23 K1M2_SHEEP (P25690) Keratin, type I microfibrillar, 47.6 kDa (Low-sulfur keratin) Sheep wool 
24 K2M1_SHEEP (P02539) Keratin, type II microfibrillar (Low-sulfur keratin) (Fragment) Sheep wool 
25 K2M2_SHEEP (P15241) Keratin, type II microfibrillar, component 7C Sheep wool 
26 K2M3_SHEEP (P25691) Keratin, type II microfibrillar, component 5 Sheep wool 
27 KRA33_SHEEP (P02444) Keratin, high sulfur matrix protein, IIIB3 Sheep wool 
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28 KRA34_SHEEP (P02445) Keratin, high sulfur matrix protein, IIIB4 Sheep wool 
29 KRA3A_SHEEP (P02443) Keratin, high-sulfur matrix protein, IIIA3A Sheep wool 
30 KRA3_SHEEP (P02441) Keratin, high-sulfur matrix protein, IIIA3 Sheep wool 
31 KRA61_SHEEP (Q02958) Keratin, glycine/tyrosine-rich of hair Sheep wool 
32 KRB2A_SHEEP (P02438) Keratin, high-sulfur matrix protein, B2A Sheep wool 
33 KRB2B_SHEEP (P02439) Keratin, high-sulfur matrix protein, B2B Sheep wool 
34 KRB2C_SHEEP (P02440) Keratin, high-sulfur matrix protein, B2C Sheep wool 
35 KRB2D_SHEEP (P08131) Keratin, high-sulfur matrix protein, B2D Sheep wool 
36 KRUC_SHEEP (P26372) Keratin, ultra high-sulfur matrix protein (UHS keratin) Sheep wool 
37 SRPP_HEVBR (O82803) Small rubber particle protein - Hevea brasiliensis Latex gloves 
38 REF_HEVBR (P15252) Rubber elongation factor protein - Hevea brasiliensis Latex gloves 
    3. Molecular weight markers/Standard proteins: 
   Id Description Reason 
1 CYC_HORSE (P00004) Horse heart cytochrome C Molecular weight 
marker/mass spec. standard 
2 CAH2_BOVIN (P00921) Bovine carbonic anhydrase 2 (EC 4.2.1.1) Molecular weight marker 
3 ADH1_YEAST (P00330) Yeast alcohol dehydrogenase 1 Molecular weight marker 
4 ALDOA_RABIT (P00883) Rabbit fructose-bisphosphate aldolase A Molecular weight marker 
5 LYSC_CHICK (P00698) Hen egg lysozyme C precursor Molecular weight 
marker/mass spec. standard 
6 MYG_HORSE (P68082) Horse heart myoglobin Molecular weight 
marker/mass spec. standard 
7 OVAL_CHICK (P01012) Hen egg ovalbumin Molecular weight marker 
8 BGAL_ECOLI (P00722) E. coli beta-galactosidase (E.C. 3.2.1.23) Molecular weight marker 
9 DHE3_BOVIN (P00366) Bovine glutamate dehydrogenase 1, mitochondrial precursor (E.C. 1.4.1.3) Molecular weight marker 
    4. Sigma-Aldrich Universal Protein Standard: 
   Id Description Reason 
1 ALBU_HUMAN (P02768) Serum albumin 66,393 Recombinant Pichia pastoris UPS 
2 ANT3_HUMAN (P01008) Antithrombin-III 49,033 Plasma Glycosylation UPS 
3 ANXA5_HUMAN (P08758) Annexin A5 35,782 Placenta Acetylation UPS 
4 B2MG_HUMAN (P61769) Beta-2-microglobulin 11,729 Urine UPS 
5 BID_HUMAN (P55957) BH3 interacting domain death agonist [BID] 21,978 Recombinant E. coli UPS 
6 CAH1_HUMAN (P00915) Carbonic anhydrase 1 28,738 Erythrocytes Acetylation UPS 
7 CAH2_HUMAN (P00918) Carbonic anhydrase 2 29,095 Erythrocytes Acetylation UPS 
8 CATA_HUMAN (P04040) Catalase 59,583 Erythrocytes UPS 
9 CATD_HUMAN (P07339) Cathepsin D 26,624 Liver Glycosylation UPS 
10 CATG_HUMAN (P08311) Cathepsin G 26,751 Sputum Glycosylation UPS 
11 CO5_HUMAN (P01031) Complement C5 [Complement C5a] 8,266 Recombinant E. coli UPS 
12 CRP_HUMAN (P02741) C-reactive protein 23,030 Plasma UPS 
13 CYB5_HUMAN (P00167) Cytochrome b5 16,021 Recombinant E. coli 6-His UPS 
14 CYC_HUMAN (P99999) Cytochrome c [Apocytochrome c] 11,608 Recombinant E. coli UPS 
15 EGF_HUMAN (P01133) Epidermal growth factor 6,211 Recombinant E. coli UPS 
16 FABPH_HUMAN (P05413) Fatty acid-binding protein 14,716 Plasma Acetylation,Phosphorylation UPS 
17 GELS_HUMAN (P06396) Gelsolin 82,954 Plasma Phosphorylation UPS 
18 GSTA1_HUMAN (P08263) Glutathione S-transferase A1 [GST A1-1] 25,482 Recombinant E. coli UPS 
19 GSTP1_HUMAN (P09211) Glutathione S-transferase P [GST] 23,220 Placenta UPS 
20 HBA_HUMAN (P69905) Hemoglobin alpha chain 15,127 Erythrocytes UPS 
21 HBB_HUMAN (P68871) Hemoglobin beta chain 15,867 
Erythrocytes,Acetylation,Nitrosylation,Glycosylation 
UPS 
22 IGF2_HUMAN (P01344) Insulin-like growth factor II 7,464 Recombinant E. coli UPS 
23 IL8_HUMAN (P10145) Interleukin-8 8,381 Recombinant E. coli UPS 
24 KCRM_HUMAN (P06732) Creatine kinase M-type [CK-MM] 43,070 Heart UPS 
25 LALBA_HUMAN (P00709) Alpha-lactalbumin 14,070 Milk Glycosylation UPS 
26 LEP_HUMAN (P41159) Leptin 16,024 Recombinant E. coli UPS 
27 LYSC_HUMAN (P61626) Lysozyme C 14,692 Milk UPS 
28 MYG_HUMAN (P02144) Myoglobin 17,051 Heart UPS 
29 NEDD8_HUMAN (Q15843) Neddylin [Nedd8] 9,071 Recombinant E. coli UPS 
30 NQO1_HUMAN (P15559) NAD(P)H dehydrogenase [quinone] 1[DT Diaphorase] 30,984 Recombinant E. 
coli 
UPS 
31 NQO2_HUMAN (P16083) Ribosyldihydronicotinamide dehydrogenase(quinone) [Quinone 
oxidoreductase 2 or NQO2] 25,817 Recombinant E. coli 
UPS 
32 PDGFB_HUMAN (P01127) Platelet-derived growth factor B chain 12,286 Recombinant E. coli UPS 
33 PPIA_HUMAN (P62937) Peptidyl-prolyl cis-trans isomerase A [Cyclophilin A] 17,947 Recombinant E. coli UPS 
34 PRDX1_HUMAN (Q06830) Peroxiredoxin 1 22,106 Recombinant E. coli UPS 
35 RASH_HUMAN (P01112) GTPase HRas [Ras protein] 21,292 Recombinant E. coli UPS 
36 RETBP_HUMAN (P02753) Retinol-binding protein 21,065 Urine UPS 
37 SODC_HUMAN (P00441) Superoxide dismutase [Cu-Zn] 15,800 Erythrocytes Acetylation UPS 
38 SUMO1_HUMAN (P63165) Small ubiquitin-related modifier 1 [SUMO-1] 37,420 Recombinant E. coli GST UPS 
39 SYH_HUMAN (P12081) Histidyl-tRNA synthetase [Jo-1] 58,223 Recombinant E. coli UPS 
40 TAU_HUMAN (P10636) Microtubule-associated protein tau [Tau protein] 46,810 Recombinant E. coli 
6-His 
UPS 
41 THIO_HUMAN (P10599) Thioredoxin 12,424 Recombinant E. coli 6-His UPS 
42 TNFA_HUMAN (P01375) Tumor necrosis factor [TNF-alpha] 17,350 Recombinant E. coli UPS 
43 TRFE_HUMAN (P02787) Serotransferrin [Apotransferrin] 75,143 Plasma Glycosylation UPS 
44 TRFL_HUMAN (P02788) Lactotransferrin 78,289 Milk Glycosylation UPS 
45 UB2E1_HUMAN (P51965) Ubiquitin-conjugating enzyme E2 E1 [UbcH6] UPS 
46 UBE2C_HUMAN (O00762) Ubiquitin-conjugating enzyme E2 C [UbcH10] 20,473 Recombinant E. coli 6-His UPS 
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47 UBE2I_HUMAN (P63279) Ubiquitin-conjugating enzyme E2 I [UbcH9] 22,907 Recombinant E. coli UPS 
48 RS27A_HUMAN (P62979) Ubiquitin-40S ribosomal protein S27a 9,387 Recombinant E. coli 6-His UPS 
    5. Common viral contaminants: 
    Id Description Reason 
1 GAG_SCVLA (P32503) Major coat protein, Saccharomyces cerevisiae virus L-A (ScV-L-A) (ScVL1) virus infects yeast cultures 
 
 
Appendix C2 
ABSciex QSTAR Elite: Rolling collision energy parameters for IDA 
experiments 
Table 3 
Rolling collision energy parameters for the QSTAR Elite 
Charge Slope Intercept 
Unknown 0.05 6 
1 0.045 5 
2 0.041 4 
3 0.048 3 
4 0.04 2 
5 0.03 2 
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Gene ontotology results 
Table 4 
Significant (p ≤ 0.05) Gene Ontology (GO) terms associated with temporally changing “Molecular 
Functions” 
Index Molecular Function Protein Accession Number 
1 collagen binding P02751 P51884 P16070 P07996 
2 alpha-glucosidase activity O43451 P10253 
3 LIM domain binding Q9Y490 Q9HBW0 
4 receptor regulator activity O95998 O00468 P01133 
5 peptidase activity, acting on L-amino acid 
peptides 
O00187 P02788 P83110 Q9NZP8 P07858 Q16651 P42785 
Q92820 P00740 P07288 P00739 P06870 P07339 Q9UHL4 
P14384 P15144 P00734 P00747 
6 peptidase activity O00187 P02788 P83110 Q9NZP8 P07858 Q16769 Q16651 
Q92820 P42785 P00740 P07288 P00739 P06870 P07339 
Q9UHL4 P14384 P15144 P00734 P00747 
7 exopeptidase activity Q9UHL4 P14384 P15144 Q92820 P42785 
8 endopeptidase activity O00187 P02788 P83110 Q9NZP8 P07858 Q16651 P00740 
P07288 P00739 P07339 P06870 P00734 P00747 
9 ribonuclease activity P07998 P25311 Q9BYK8 P10153 
10 ferric iron binding 
 
D3= P02787 P02788 
D5 = P02787 P02788 P02792 
D7 = P02787 P02788 P02792 
11 ferric iron binding D3 = Q9NP98 P18827 Q8WZ42 P02774 P24855 Q00872 
P12883 Q14315 Q9UKX3 P06396 P12273 P31431 O15273 
12 cell adhesion molecule binding P19320 P12830 P55290 
13 calcium-dependent protein binding D3 = O00187 Q9UGM3 P31949 
D 5 =O00187 Q9UGM3 P31949 
14 arylsulfatase activity Q8IWU5 P15289 
15 vitamin transporter activity D2 = P02753 P02774 
D3 = P02753 P02774 
16 titin binding D1-D5 = Q00872 O15273 
17 thrombospondin receptor activity D2 & D3 = P31431 P00734 
18 sulfuric ester hydrolase activity D2 & D3 = Q8IWU5 P15586 P15289 
19 structural molecule activity 
 
D2 = P02751 Q8N1N4 Q8WZ42 P02452 Q00872 Q99715 
P35555 P02461 P08123 P02545 Q9UKX2 Q16625 Q9UL51 
O15273 P07996 Q13203 
D4 = P02751 P04279 Q8WZ42 Q00872 Q96A32 P23142 
Q99715 P35555 P02461 P05976 P08123 P39059 P02545 
Q9UKX2 Q16625 Q02383 P35908 O15273 P04264 P07996 
D5 = P02751 Q8WZ42 Q00872 P02452 P35527 O00468 
P23142 P35555 P02461 P05976 P08123 P39059 P02545 
Q9UKX2 Q16625 P35908 O15273 P04264 P07996 
D6 = P02751 P04279 Q9Y490 Q8WZ42 Q00872 P23142 
Q99715 P35555 P02461 P08123 P39059 P02545 Q9UKX2 
Q16625 P51884 Q02383 Q9UL51 P04264 P07996 
D7 = P02751 P04279 Q8WZ42 Q00872 P35555 P02461 
P08123 P39059 P02545 Q9UKX2 Q16625 P13645 Q02383 
P35908 Q13885 P04264 P07996 
20 structural constituent of muscle D2 = Q9UKX2 Q8WZ42 Q00872 O15273  
Q13203 
D3 = Q8WZ42 Q00872 O15273 P12883 
D4 = Q9UKX2 Q8WZ42 Q00872 Q96A32 O15273 P05976 
D5 = Q9UKX2 Q8WZ42 Q00872 O15273 P05976 
21 sterol transporter activity D2 = P11597 P02647 
22 sterol binding D2 = P61916 P11597 P02652 P02647 
D3 = P61916 P11597 P02652 
D4 = P61916 P11597 P02652 P02647 
D6 = P61916 P11597 P02652 P02647 
23 steroid binding D2 = P02774 P61916 P11597 P02652 P02647 
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D3 = P02774 P61916 P11597 P02652 
D4 = P02774 P61916 P11597 P02652 P02647 
D6 = P02774 P61916 P11597 P02652 P02647 
24 quaternary ammonium group binding D2 – D4 & D6 = P11597 P02652 
25 phosphatidylcholine binding D2 – D4 & D6 = P11597 P02652 
26 hemoglobin binding D2, D5 & D6 = P00738 P68871 
27 gamma-catenin binding D2 & D3 = P12830 P19022 
28 fibronectin binding D2 & D3 = P31431 P07996 
29 cholesterol transporter activity D2, D4 & D6 = P11597 P02647 
30 cholesterol binding D2 = P61916 P11597 P02652 P02647 
D3 = P61916 P11597 P02652 
D4 = P61916 P11597 P02652 P02647 
D6 = P61916 P11597 P02652 P02647 
31 alpha-actinin binding 
 
D2 & D3 = Q8WZ42 P31431 
 
32 actinin binding 
 
D2 & D3 = Q8WZ42 P31431 
 
34 phosphatidylcholine-sterol O-acyltransferase 
activator activity 
D1 = P02652 P02647 
D2 = P11597 P02652 
D4 = P11597 P02652 
D5 = P02652 P02647 
D6 = P11597 P02652 
35 lipid transporter activity 
 
D1 = P17900 P05413 P02652 P02647 P05090 
D2 = P17900 P05413 P11597 P02652 P02647 P05090 
D3 = P17900 P11597 P02652 P05090 
D4 = P17900 P11597 P02652 P02647 P05090 
D6 = P17900 P11597 P02652 P02647 P05090 
 
36 hydrolase activity, acting on glycosyl bonds 
 
D1 = P17900 P54802 P10253 P19961 P04746 P04745 
 
D2 = O00187 P22891 P07288 Q9NZP8 P06870 P00738 
P00747 P00734 
 
D3 = O00187 P02788 P83110 P07288 Q9NZP8 P06870 
P00747 P00734 P42785 
 
D4 = O00187 P00740 P07288 Q9NZP8 P06870 P00738 
P00747 P00734 
 
D5 = O00187 P02788 P83110 Q9NZP8 Q16651 P42785 
P00740 P07288 P00739 P06870 Q9UHL4 P00734 P00747 
 
D6 = O00187 P02788 P83110 P07288 Q9NZP8 P06870 
Q16651 P00738 P00747 P00734 P42785 
 
37 high-density lipoprotein particle binding D1,D2 & D4 – D6 = P02652 P02647 
38 high-density lipoprotein particle binding D1,D2 & D4 – D6 = P02652 P02647 
39 fatty acid binding D1 & D2 = P05413 P02768 P25311 
40 apolipoprotein receptor binding D1 & D2 = P02652 P02647 
41 serine hydrolase activity D3 = O00187 P02788 P83110 P07288 Q9NZP8 P06870 
P00747 P00734 P42785 
 
D5 = O00187 P02788 P83110 Q9NZP8 Q16651 P42785 
P00740 P07288 P00739 P06870 Q9UHL4 P00734 P00747 
 
D6 = O00187 P02788 P83110 P07288 Q9NZP8 P06870 
Q16651 P00738 P00747 P00734 P42785 
42 chaperone binding 
 
D1 = P02768 P00441 P00450 P36957 
D2 = P02768 P00441 P00450 P36957 
D3 = P02768 P02675 P00441 P00450 P36957 
D4= P02768 P02675 P00450 P36957 
D5 = P02768 P02675 P00450 P36957 
D6 = P02768 P02675 P00450 
D7 = P02768 P02675 P00450 P36957 
43 insulin-like growth factor binding 
 
Baseline = Q16270 O76076 P48745 
D1 = Q16270 O76076 P48745 P17936 
D2 = Q16270 O76076 P48745 
D3 = Q16270 O76076 P83110 P48745 P17936 
D4 = Q16270 O76076 P48745 P17936 
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D5 = Q16270 O76076 P83110 P48745 P17936 
D6 = Q16270 O76076 P83110 P48745 P17936 
D7 =Q16270 O76076 P17936 
44 nuclease activity Baseline = P07998 Q14191 P25311 O94919 Q9BYK8 P24855 
P10153 
45 eukaryotic cell surface binding 
 
Baseline =P02671 P02749 P07996 
D1 = P02671 P02749 P07996 
D2 = P02671 P02749 P07996 
D3 = P02671 P02749 P02675 P25705 P07996 
D4 = P02671 P02749 P02675 P07996 
D5 = P02671 P02749 P02675 P07996 
D6 = P02671 P02749 P02675 P07996 
D7 = P02671 P02749 P02675 P07996 
46 enzyme regulator activity 
 
Baseline =Q6UXB8 Q14508 Q9UHG2 P01042 P00995 P02749 
P02765 P05067 P04216 P19823 P01011 P08519 Q15828 
P17900 Q02747 P05155 P01009 P01133 P02652 P0C0L4 
P01036 P02760 P07602 P01034 
 
D1 = Q6UXB8 Q14508 P00995 Q8WZ42 P04216 P19823 
P17936 P01011 P17900 Q02747 P01009 P11684 P02652 
P02760 A5PKW4 Q9UHG2 P01042 P02749 P02765 P05067 
Q15828 P05155 P01133 P0C0L4 P02647 P07602 P01034 
 
D2 = Q6UXB8 Q14508 P00995 Q8WZ42 P04216 P19823 
P01011 P17900 Q02747 P01009 P11684 P02652 P02760 
Q9UHG2 P01042 P02749 P02765 P05067 Q15828 P05155 
P01133 P0C0L4 P02647 P07602 P01034 
 
D3 = Q6UXB8 Q14508 P00995 Q8WZ42 P17936 P01011 
P17900 Q02747 P01009 P11684 P01024 P02652 P02760 
Q9UHG2 P01042 P05543 P02749 P02765 P05067 Q15828 
P05155 P01133 P01036 P0C0L4 P07602 
D4 = Q6UXB8 Q14508 P00995 Q8WZ42 P04216 P19823 
P17936 P01011 P17900 Q02747 P01009 P11684 P02652 
P02760 Q9UHG2 P01042 P05543 P02749 P02765 P05067 
Q15828 P05155 P01133 P0C0L4 P02647 P07602 P01034 
 
D5 = Q6UXB8 Q14508 P00995 Q8WZ42 P04216 P19823 
P17936 P01011 P17900 Q02747 P01009 P11684 P02652 
P02760 Q9UHG2 P01042 P05543 P02749 P02765 P05067 
Q15828 P05155 P01133 P0C0L4 P02647 P07602 P01034 
 
D6 = Q6UXB8 Q14508 P00995 Q8WZ42 P19823 P17936 
P01011 P17900 Q02747 P01009 P11684 P02652 P02760 
Q9UHG2 P01042 P02749 P02765 P05067 Q15828 P05155 
P03973 P01133 P01036 P0C0L4 P02647 P07602 P01034 
 
D7 = Q6UXB8 Q14508 P00995 Q8WZ42 P04216 P19823 
P17936 P01011 P17900 Q02747 P01009 P01024 P02760 
Q9UHG2 P01042 P12111 P02749 P02765 P05067 Q15828 
P02649 P05155 P01133 P0C0L4 P07602 P01034 
 
Table 5 
Significant (p ≤ 0.05) GO terms assocated with temporally attenuating “Cellular Components” 
Index Cellular Component Protein Accession Number 
1 collagen type VI D7 = P12111 P12109 
2 H zone D4 = O14983 
3 myosin complex D4 = Q9UKX2 Q00872 Q96A32 P05976 
4 I band D4 = Q14315 Q8WZ42 O14983 O15273 
5 muscle myosin complex D4 = Q9UKX2 Q96A32 P05976 
6 A band D4 = Q9UKX2 Q8WZ42 O14983 
D7 = Q9UKX2 Q8WZ42 P12882 
7 myosin II complex D4 = Q9UKX2 Q96A32 P05976 
8 sarcomere D4 = Q14315 Q9UKX2 Q8WZ42 O14983 O15273 P05976 
D5 = Q14315 Q9UKX2 Q8WZ42 O15273 P05976 
9 collagen type XV D3 – D5 & D7 = P39059 
10 zymogen granule D3 – D5 = Q9UGM3 P19835 
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11 collagen type XII D2 – D4 = 99715 
12 collagen typ III D2, D4, D5 & D7 = P02461 
13 hyaline layer D2 – D5 & D7 = Q07654 
14 smooth muscle contractile fiber D2 & D5 = P62736 
15 apical lamina of hyaline layer D2 – D5 & D7 = Q07654 
16 actin cytoskeleton D2 = P62736 Q9NP98 P12830 Q9UKX2 P06396 Q8WZ42 
Q00872 O00499 Q13203 
D4 = Q9NP98 P12830 Q9UKX2 P06396 Q8WZ42 Q00872 
Q96A32 O00499 P05976 
D5 = P62736 Q9NP98 P12830 Q9UKX2 P06396 Q8WZ42 
Q00872 O00499 P05976 
17 myofibril D2 =  
Q14315 Q9UKX2 Q8WZ42 Q00872 P31431 O15273 
D3 =  
Q14315 Q9UKX3 Q8WZ42 Q00872 P31431 O15273 P12883 
D4  
Q14315 Q9UKX2 Q8WZ42 O14983 Q00872 O15273 P05976 
D5 =  
Q14315 Q9UKX2 Q8WZ42 Q00872 O15273 P05976 
D7 = Q14315 Q9UKX2 Q8WZ42 Q00872 P12882 
18 contractile fiber part D2  = Q14315 P62736 Q9UKX2 Q8WZ42 P31431 O15273 
D3 = Q14315 Q9UKX3 Q8WZ42 P31431 O15273 P12883 
D4 = Q14315 Q9UKX2 Q8WZ42 O14983 Q96A32 O15273 
P05976 
D5 =Q14315 P62736 Q9UKX2 Q8WZ42 O15273 P05976 
19 myosin filament D2 = Q9UKX2 Q00872 Q13203 
D3 = Q9UKX3 Q00872 P12883 
D7 = Q9UKX2 Q00872 P12882 
20 contractile fiber D2 = Q14315 P62736 Q9UKX2 Q8WZ42 Q00872 P31431 
O15273 
D3= Q14315 Q9UKX3 Q8WZ42 Q00872 P31431 O15273 
P12883 
D4 = Q14315 Q9UKX2 Q8WZ42 O14983 Q00872 Q96A32 
O15273 P05976 
D5 = Q14315 P62736 Q9UKX2 Q8WZ42 Q00872 O15273 
P05976 
21 protein-lipid complex D2 = P02749 P11597 P02652 P02647 P04180 
D3 = P02749 P11597 P02652 P04180 
D4= P02749 P11597 P02652 P02647 
D5 = P02749 P27169 P00739 P02652 P02647 
D6 = P02749 P27169 P11597 P02652 P02647 
22 anchoring collagen D2 – D4 & D6 = P12109 Q99715 
D7 = P12111 P12109 
23 spherical high-density lipoprotein particle D1, D2 & D4 = P02652 P02647 
D5 = P27169 P00739 P02652 P02647 
D6 = P27169 P02652 P02647 
24 high-density lipoprotein particle D2 = P02749 P11597 P02652 P02647 P04180 
D3 = P02749 P11597 P02652 P04180 
D4 = P02749 P11597 P02652 P02647 
D5 = P02749 P27169 P00739 P02652 P02647 
D6 = P02749 P27169 P11597 P02652 P02647 
25 anchoring junction D1 = P12830 P18827 Q9UKX2 Q02487 P19022 P31151 
Q96AP7 
D2 = P12830 P18827 Q9UKX2 Q02487 P19022 P31431 
Q96AP7 
D3 = P12830 P18827 P19022 P31431 P12883 Q96AP7 
D4 = P12830 P18827 Q9UKX2 Q02487 P19022 Q96AP7 
D5 = P12830 P18827 Q9UKX2 Q9Y490 Q02487 P19022 
Q96AP7 
D6 = P12830 P18827 Q9UKX2 Q9Y490 Q02487 P19022 
Q96AP7 
D7 = P12111 P12109 
26 very-low-density lipoprotein particle D1, D2 & D4-D6  = P02749 P02652 P02647 
27 triglyceride-rich lipoprotein particle D1, D2 & D4-D6  = P02749 P02652 P02647 
28 fibrinogen complex Baseline = P02751 P02671 P07996 
D1 = P02751 P02671 P07996 
D2 = P02751 P02671 P07996 
D3 = P02751 P02671 P02675 P07996 
D4 = P02751 P02671 P02675 P07996 
D5 = P02751 P02671 P02675 P07996 
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D6 = P02751 P02671 P02675 P07996 
D7 = P02751 P02671 P02675 P07996 
29 platelet alpha granule Baseline = P02751 P02671 P05155 P02768 P01009 P01133 
P05067 P07996 
D1 = P02751 P02671 P05155 P02768 P01009 P01133 P05067 
P07996 
D2 = P02751 P02671 P05155 P02768 P01009 P01133 P05067 
P07996 
D3 = P02751 P02671 P05155 P02768 P02675 P01009 P01133 
P05067 P07996 
D4 = P02751 P02671 P05155 P02768 P02675 P01009 P01133 
P05067 P07996 
D5 = P02751 P02671 P05155 P02768 P02675 P01009 P01133 
P05067 P07996 
D6 = P02751 P02671 P05155 P02768 P02675 P01009 P01133 
P05067 P07996 
D7 = P02751 P02671 P05155 P02768 P02675 P01009 P01133 
P05067 P07996 
30 extracellular matrix Baseline =  
P02751 Q96RW7 P39060 P02461 Q9H8L6 P22105 P01009 
Q9HCU0 P07996 P98160 Q14118 Q07654 P14543 Q8N2S1 
Q9UBX5 P02452 P48745 P35555 P08123 P39059 P12109 
Q12805 P04004 Q08380 Q14767 
D1 = Q07654 P02751 P14543 P00441 Q96RW7 Q8N2S1 
Q9UBX5 P48745 Q99715 P35555 P02461 P08123 Q9H8L6 
P12109 P01009 Q9HCU0 P04004 Q12805 Q08380 P07996 
P98160 Q14767 
D2 = Q07654 P02751 P14543 Q96RW7 Q8N2S1 P02452 
Q9UBX5 Q99715 P35555 P02461 P08123 Q9H8L6 P22105 
P12109 P01009 Q9HCU0 P04004 Q12805 Q08380 P98160 
Q14767 
 
D3 = Q07654 P02751 P14543 Q96RW7 Q8N2S1 Q9UBX5 
P02452 P23142 Q99715 P35555 P08123 P39059 P12109 
P01009 Q9HCU0 P04004 Q12805 Q08380 P98160 Q14767 
D4 = Q07654 P02751 P14543 Q96RW7 Q9UBX5 P23142 
Q99715 P35555 P02461 P08123 P39059 Q9H8L6 P12109 
P01009 Q9HCU0 P04004 Q12805 Q08380 P98160 Q14767 
D5 = Q07654 Q9H8L6 P14543 P12109 Q96RW7 P02452 
O00468 P35555 P02461 P98160 P08123 P39059 
D6 = Q07654 Q9H8L6 P51884 P14543 P12109 Q96RW7 
Q99715 P35555 P02461 P98160 P08123 P39059 
D7 = Q07654 P02751 P14543 P12111 Q96RW7 Q8N2S1 
Q9UBX5 P35555 P02461 P08123 P39059 Q9H8L6 P12109 
P01009 Q9HCU0 P04004 Q12805 Q08380 P07996 P98160 
Q14767 
32 extracellular region part Baseline =  
Q16270 P02774 Q9NZP8 Q99988 P10451 P02461 Q92820 
P61769 Q8IWU5 Q9HCU0 P00734 P98160 Q07654 P28799 
P01042 P14543 P31997 P02749 Q8N2S1 P08571 P19652 
P04746 P01344 P08123 P80370 P55290 P08118 P55000 
P01133 P02790 P00747 P01034 P02751 Q14508 P04279 
P02753 Q9UBD9 Q96RW7 P39060 P05090 Q8WVN6 Q9H8L6 
P22105 Q02383 O95502 P01009 P00450 O75882 P07996 
O15240 Q14118 P02652 P02763 P19320 P02671 Q9UHG2 
P02768 P02765 P07858 Q9UBX5 P02452 P15289 P35555 
P19835 P07204 P39059 P04155 P09603 P06396 P12109 
P04004 Q12805 Q08380 P59665 P0C0L4 Q14767 P07602 
D1 =  
Q16270 P02774 Q9NZP8 Q99715 P10451 P02461 Q92820 
P61769 Q8IWU5 Q9HCU0 P00734 P98160 Q07654 P28799 
P01042 P14543 P31997 P02749 Q8N2S1 P08571 P19652 
P04746 P01344 P08123 P80370 P55290 P55000 P01133 
P02790 P00747 P02647 P01034 P02751 Q14508 P02753 
P00441 Q96RW7 Q16651 P17936 P05090 Q8WVN6 Q9H8L6 
O95502 P01009 P00450 O75882 P07996 O15240 P02652 
P02763 P19320 P02671 Q9UHG2 P02768 P02765 P07858 
Q9UBX5 P15289 P43652 P35555 P07204 P04155 P09603 
P06396 P12109 P04004 Q12805 P59665 Q08380 P0C0L4 
P07602 Q14767 
D2 =  
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Q16270 P02774 Q9NZP8 Q99715 P10451 P02461 Q92820 
Q9GZX9 P61769 Q8IWU5 Q9HCU0 P00734 P98160 Q07654 
P28799 P01042 P14543 P31997 P02749 Q8N2S1 Q15113 
P08571 P19652 P11597 P04746 P01344 P04180 P08123 
P80370 P55290 P08118 P55000 P01133 P02790 P00747 
P02647 P01034 P02751 Q14508 P02753 P00441 Q96RW7 
P05090 Q8WVN6 Q9H8L6 P22105 P01009 P00450 O75882 
P07996 O15240 P02652 P02763 P43251 P19320 P02671 
Q9UHG2 P02768 P02765 P07858 P02452 Q9UBX5 P15289 
P43652 P35555 P19835 P07204 P04155 P09603 P06396 
P12109 P07339 P04004 Q12805 Q08380 P0C0L4 Q14767 
P07602 
D3 =  
Q16270 P02774 Q9NZP8 Q99715 P10451 Q92820 P61769 
Q8IWU5 Q9HCU0 P01024 P00734 P98160 Q07654 P28799 
P01042 P14543 P31997 P02675 P02749 Q8N2S1 P08571 
P19652 P11597 P04746 P04180 P08123 P55290 P55000 
P01133 P02790 P00747 P02751 Q14508 P02753 P00441 
Q96RW7 P13671 P17936 P05090 Q8WVN6 P01009 P00450 
O75882 P07996 O15240 P02652 P02763 P43251 P19320 
P02671 Q9UHG2 P05543 P02768 P02765 P07858 Q9UBX5 
P02452 P23142 P15289 P35555 P19835 P07204 P39059 
P04155 P09603 P06396 P12109 P04004 Q12805 P59665 
Q08380 P0C0L4 Q14767 P07602 
D4 =  
Q16270 P02774 Q9NZP8 Q99715 P10451 P02461 Q92820 
Q9GZX9 P61769 Q8IWU5 Q9HCU0 P00734 P98160 Q07654 
P28799 P01042 P14543 P31997 P02675 P02749 Q15113 
P08571 P19652 P11597 P04746 P08123 P80370 P55290 
P55000 P01133 P02790 P02647 P00747 P01034 P02751 
Q14508 P04279 P02753 Q96RW7 P17936 P05090 Q8WVN6 
Q9H8L6 Q02383 O95502 P01009 P00450 O75882 P07996 
O15240 P02652 P02763 P43251 P02671 P19320 Q9UHG2 
P05543 P02768 P02765 P07858 Q9UBX5 P23142 P15289 
P43652 P35555 P19835 P07204 P39059 P04155 P09603 
P06396 P12109 P04004 Q12805 Q08380 P0C0L4 Q14767 
P07602 Q96IY4 
D5 =  
Q16270 P02774 Q9NZP8 P10451 P02461 Q92820 P61769 
Q8IWU5 P00739 Q9HCU0 P00734 P98160 Q07654 P28799 
P01042 P14543 P31997 P02675 P02749 Q8N2S1 Q15113 
P08571 P19652 P04746 P01344 P08123 P55290 Q07507 
P55000 P01133 P02790 P00747 P02647 P01034 P02751 
Q14508 P02753 Q96RW7 O00468 Q16651 P17936 P05090 
Q8WVN6 Q9H8L6 O95502 P01009 P00450 O75882 P07996 
O15240 P02652 P02763 P02671 P19320 Q9UHG2 P05543 
P02768 P02765 P07858 P02452 Q9UBX5 P23142 P15289 
P35555 P19835 P07204 P39059 P04155 P09603 P06396 
P12109 P27169 P07339 P04004 Q12805 Q08380 P59665 
P0C0L4 Q14767 P07602 
D6 =  
Q16270 P02774 Q9NZP8 Q99988 Q99715 P10451 P02461 
Q92820 P61769 Q8IWU5 Q9HCU0 P00734 P98160 Q07654 
P28799 P01042 P14543 P02675 P02749 Q15113 P08571 
P19652 P11597 P04746 P08123 P55290 Q07507 P08118 
P55000 P01133 P02790 P00747 P02647 P01034 P02751 
Q14508 P04279 P02753 Q96RW7 Q16651 P17936 P05090 
Q8WVN6 Q9H8L6 Q02383 O95502 P01009 P00450 O75882 
P07996 O15240 P02652 P02763 P43251 P02671 P19320 
Q9UHG2 P02768 P02765 Q9UBX5 P23142 P15289 P35555 
P07204 P39059 P04155 P09603 P51884 P06396 P12109 
P27169 P04004 Q12805 P54107 Q08380 P0C0L4 Q14767 
P07602 
D7 =  
Q16270 P02774 Q9NZP8 P10451 P02461 P61769 Q8IWU5 
Q9HCU0 P01024 P00734 P98160 Q07654 P28799 P01042 
P14543 P31997 P12111 P02675 P02749 Q8N2S1 P08571 
P19652 P01344 P08123 P02649 P55290 P08118 P55000 
P01133 P02790 P00747 P01034 P02751 Q14508 P04279 
Q96RW7 P17936 P05090 Q8WVN6 Q9H8L6 Q02383 O95502 
P01009 P00450 O75882 P07996 O15240 P02763 P19320 
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P02671 Q9UHG2 P02768 P02765 P07858 Q9UBX5 P15289 
P35555 P07204 P39059 P04155 P09603 P06396 P12109 
P27169 P04004 Q12805 P59665 Q08380 P0C0L4 P07602 
Q14767 
33 extracellular space Baselin =  
Q16270 P02774 Q9NZP8 Q99988 P10451 P02461 Q92820 
P61769 Q8IWU5 P00734 P98160 P28799 P01042 P31997 
P02749 Q8N2S1 P08571 P19652 P04746 P01344 P08123 
P80370 P55290 P08118 P55000 P01133 P02790 P00747 
P01034 P02751 Q14508 P04279 P02753 Q9UBD9 P39060 
P05090 Q8WVN6 Q9H8L6 P22105 Q02383 O95502 P01009 
P00450 O75882 P07996 O15240 Q14118 P02652 P02763 
P19320 P02671 Q9UHG2 P02768 P02765 P07858 Q9UBX5 
P02452 P15289 P35555 P19835 P07204 P39059 P04155 
P09603 P06396 P04004 Q12805 P59665 Q08380 P0C0L4 
P07602 Q14767 
D1 =  
Q16270 P02774 Q9NZP8 Q99715 P10451 P02461 Q92820 
P61769 Q8IWU5 P00734 P98160 P28799 P01042 P31997 
P02749 Q8N2S1 P08571 P19652 P04746 P01344 P08123 
P80370 P55290 P55000 P01133 P02790 P00747 P02647 
P01034 P02751 Q14508 P02753 P00441 Q16651 P17936 
P05090 Q8WVN6 Q9H8L6 O95502 P01009 P00450 O75882 
P07996 O15240 P02652 P02763 P19320 P02671 Q9UHG2 
P02768 P02765 P07858 Q9UBX5 P15289 P43652 P35555 
P07204 P04155 P09603 P06396 P04004 Q12805 P59665 
Q08380 P0C0L4 P07602 Q14767 
D2 =  
Q16270 P02774 Q9NZP8 Q99715 P10451 P02461 Q92820 
Q9GZX9 P61769 Q8IWU5 P00734 P98160 P28799 P01042 
P31997 P02749 Q8N2S1 Q15113 P08571 P19652 P11597 
P04746 P01344 P04180 P08123 P80370 P55290 P08118 
P55000 P01133 P02790 P00747 P02647 P01034 P02751 
Q14508 P02753 P00441 P05090 Q8WVN6 Q9H8L6 P22105 
P01009 P00450 O75882 P07996 O15240 P02652 P02763 
P43251 P19320 P02671 Q9UHG2 P02768 P02765 P07858 
Q9UBX5 P02452 P15289 P43652 P35555 P19835 P07204 
P04155 P09603 P06396 P07339 P04004 Q12805 Q08380 
P0C0L4 Q14767 P07602 
D3=  
Q16270 P02774 Q9NZP8 Q99715 P10451 Q92820 P61769 
Q8IWU5 P01024 P00734 P98160 P28799 P01042 P31997 
P02675 P02749 Q8N2S1 P08571 P19652 P11597 P04746 
P04180 P08123 P55290 P55000 P01133 P02790 P00747 
P02751 Q14508 P02753 P00441 P13671 P17936 P05090 
Q8WVN6 P01009 P00450 O75882 P07996 O15240 P02652 
P02763 P43251 P19320 P02671 Q9UHG2 P05543 P02768 
P02765 P07858 Q9UBX5 P02452 P23142 P15289 P35555 
P19835 P07204 P39059 P04155 P09603 P06396 P04004 
Q12805 P59665 Q08380 P0C0L4 P07602 Q14767 
D4 =  
Q16270 P02774 Q9NZP8 Q99715 P10451 P02461 Q92820 
Q9GZX9 P61769 Q8IWU5 P00734 P98160 P28799 P01042 
P31997 P02675 P02749 Q15113 P08571 P19652 P11597 
P04746 P08123 P80370 P55290 P55000 P01133 P02790 
P00747 P02647 P01034 P02751 Q14508 P04279 P02753 
P17936 P05090 Q8WVN6 Q9H8L6 Q02383 O95502 P01009 
P00450 O75882 P07996 O15240 P02652 P02763 P43251 
P02671 P19320 Q9UHG2 P05543 P02768 P02765 P07858 
Q9UBX5 P23142 P15289 P43652 P35555 P19835 P07204 
P39059 P04155 P09603 P06396 P04004 Q12805 Q08380 
P0C0L4 Q14767 P07602 Q96IY4 
D5=  
Q16270 P02774 Q9NZP8 P10451 P02461 Q92820 P61769 
Q8IWU5 P00739 P00734 P98160 P28799 P01042 P31997 
P02675 P02749 Q8N2S1 Q15113 P08571 P19652 P04746 
P01344 P08123 P55290 Q07507 P55000 P01133 P02790 
P00747 P02647 P01034 P02751 Q14508 P02753 O00468 
Q16651 P17936 P05090 Q8WVN6 Q9H8L6 O95502 P01009 
P00450 O75882 P07996 O15240 P02652 P02763 P19320 
P02671 Q9UHG2 P05543 P02768 P02765 P07858 Q9UBX5 
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P02452 P23142 P15289 P35555 P19835 P07204 P39059 
P04155 P09603 P06396 P27169 P07339 P04004 Q12805 
Q08380 P59665 P0C0L4 Q14767 P07602 
D6 =  
Q16270 P02774 Q9NZP8 Q99988 Q99715 P10451 P02461 
Q92820 P61769 Q8IWU5 P00734 P98160 P28799 P01042 
P02675 P02749 Q15113 P08571 P19652 P11597 P04746 
P08123 P55290 Q07507 P08118 P55000 P01133 P02790 
P00747 P02647 P01034 P02751 Q14508 P04279 P02753 
Q16651 P17936 P05090 Q8WVN6 Q9H8L6 Q02383 O95502 
P01009 P00450 O75882 P07996 O15240 P02652 P02763 
P43251 P19320 P02671 Q9UHG2 P02768 P02765 Q9UBX5 
P23142 P15289 P35555 P07204 P39059 P04155 P09603 
P51884 P06396 P27169 P04004 Q12805 P54107 Q08380 
P0C0L4 Q14767 P07602 
D7 =  
Q16270 P02774 Q9NZP8 P10451 P02461 P61769 Q8IWU5 
P01024 P00734 P98160 P28799 P01042 P31997 P12111 
P02675 P02749 Q8N2S1 P08571 P19652 P01344 P08123 
P02649 P55290 P08118 P55000 P01133 P02790 P00747 
P01034 P02751 Q14508 P04279 P17936 P05090 Q8WVN6 
Q9H8L6 Q02383 O95502 P01009 P00450 O75882 P07996 
O15240 P02763 P19320 P02671 Q9UHG2 P02768 P02765 
P07858 Q9UBX5 P15289 P35555 P07204 P39059 P04155 
P09603 P06396 P27169 P04004 Q12805 P59665 Q08380 
P0C0L4 P07602 Q14767 
34 extracellular region Baseline =  
Q6UXB8 Q16270 P13987 P24855 Q99988 P13591 P02461 
P61769 P05451 P12273 Q86Y38 P98160 P06702 P01591 
P31997 P02749 P08571 P04746 P04745 P80370 P55290 
P55000 O95460 P01133 Q969E1 P10645 P00995 Q96RW7 
Q9ULI3 P41222 P01011 Q9H8L6 O76076 P22105 Q02747 
P01009 O75882 P02652 P02671 P05060 Q9UBX5 P02452 
P15941 P05067 P09603 P06396 P59665 Q96PD5 Q08380 
P0C0L4 P07602 Q14767 P55259 P60022 O94919 P02774 
Q9NZP8 P10451 Q92820 Q8IWU5 O75594 P07288 P10153 
Q9HCU0 P00734 Q6EMK4 Q07654 P08637 P28799 O00187 
P02787 P01042 P14543 Q8N2S1 P48745 Q03403 P19652 
P05109 P01344 P08123 Q15828 P08118 P17213 Q96DR8 
P02790 P19961 P01036 P00747 P01034 P02751 Q14508 
P04279 P02753 Q9UBD9 P25311 O95998 P39060 P61916 
P15328 P19823 P05090 Q8WVN6 Q02383 O95502 P00450 
P07996 O15240 Q14118 P02760 P01833 P02763 P07998 
P19320 Q9UHG2 P02768 P02765 P02766 P07858 O75015 
P15289 P35555 P19835 P07204 P08519 P39059 P04155 
P07911 P05155 P12109 P04004 Q12805 P81172 
D1 =  
Q6UXB8 Q16270 P13987 P24855 P13591 Q99715 P04217 
P02461 P61769 P05451 P12273 Q86Y38 P98160 P06702 
P31997 P02749 Q8N307 P08571 P04746 P04745 P80370 
P55290 P55000 O95460 P01133 P31151 Q969E1 P02647 
P10645 P00995 Q96RW7 Q9ULI3 P41222 Q16651 P01011 
P10643 Q9H8L6 O76076 Q02747 P01009 O75882 P02652 
P02671 P05060 Q9UBX5 P05067 P09603 P06396 Q96PD5 
P59665 Q08380 P0C0L4 P07602 Q14767 P55259 P60022 
P15309 O94919 P02774 Q9NZP8 P10451 Q92820 Q8IWU5 
O75594 P07288 P10153 Q9HCU0 P11684 P00734 Q6EMK4 
Q07654 P08637 P28799 O00187 P02787 P02788 P01042 
P14543 Q8N2S1 P48745 Q03403 P19652 P05109 P01344 
P08123 Q15828 Q96DR8 P02790 P19961 P00747 P01034 
P02750 P02751 Q14508 P02753 P25311 Q8WZ42 P00441 
O95998 P15328 P17936 P19823 P05090 Q8WVN6 O95502 
P00450 P07996 O15240 P02760 P01833 P02763 P07998 
P19320 Q9UHG2 P02768 P02765 P02766 P07858 O75015 
P15289 P43652 P35555 P07204 P04155 P07911 P05155 
P12109 P04004 Q12805 P81172 
D2 =  
Q6UXB8 Q16270 P13987 P24855 P13591 Q99715 P04217 
P02461 Q9GZX9 P61769 P05451 P12273 P22891 Q86Y38 
P98160 P06702 P31997 P02749 Q15113 P08571 P04746 
P04745 P04180 P80370 P55290 P55000 O95460 P01133 
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Q969E1 P02647 P10645 P00995 Q96RW7 Q9ULI3 P41222 
P01011 Q9H8L6 O76076 P22105 Q02747 P01009 O75882 
P02652 P02671 P05060 Q9UBX5 P02452 Q9UIG4 P05067 
P09603 P06396 Q08380 P0C0L4 P07602 Q14767 P55259 
P60022 O94919 P02774 Q9NZP8 P10451 Q92820 Q8IWU5 
O75594 P07288 P10153 Q9HCU0 P00738 P11684 P00734 
Q6EMK4 Q07654 P08637 P28799 O00187 P02787 P01042 
P14543 Q8N2S1 P48745 Q03403 P19652 P05109 P11597 
P01344 P08123 Q15828 P08118 Q96DR8 P02790 P19961 
P00747 P01034 P02750 P02751 Q14508 P02753 P25311 
P00441 Q8WZ42 O95998 P61916 P19823 P05090 Q8WVN6 
P00450 P07996 O15240 P02760 P01833 P02763 P43251 
P07998 P19320 Q9UHG2 P02768 P02765 P02766 P07858 
O75015 P15289 P43652 P35555 P19835 P07204 P04155 
P07911 P05155 P12109 P07339 P04004 Q12805 P81172 
D3 =  
Q6UXB8 Q16270 P13987 P24855 P13591 Q99715 P04217 
P61769 P05451 P12273 Q86Y38 P98160 P06702 P31997 
P02749 P08571 P04746 P04745 P04180 P55290 P55000 
O95460 P01133 Q969E1 P10645 P00995 Q96RW7 P41222 
P13671 P01011 O76076 Q02747 P01009 O75882 P02652 
P02671 P05060 Q9UBX5 P02452 P05067 P09603 P06396 
P59665 Q08380 P0C0L4 P07602 Q14767 P55259 P60022 
O94919 P02774 Q9NZP8 P10451 Q92820 Q8IWU5 O75594 
P07288 P10153 Q9HCU0 P11684 P01024 P00734 Q6EMK4 
P08637 P28799 O00187 Q07654 P02787 P01042 P02788 
P14543 P83110 P02675 Q8N2S1 P48745 Q03403 P19652 
P05109 P11597 P08123 Q15828 Q96DR8 P02790 P19961 
P01036 P00747 P02750 P02751 Q14508 Q9UGM3 P02753 
P25311 P00441 Q8WZ42 P61916 P17936 P05090 Q8WVN6 
P00450 P13727 P07996 O15240 P02760 P01833 P02763 
P43251 P07998 P19320 Q9UHG2 P05543 P02768 P02765 
P07858 O75015 P23142 P15289 P35555 P19835 P07204 
P39059 P04155 P07911 P05155 P12109 P04004 Q12805 
D4 =  
Q6UXB8 Q16270 P13987 P80188 P24855 P13591 Q99715 
P04217 P02461 Q9GZX9 P61769 P05451 P12273 Q86Y38 
P98160 P06702 P31997 P02749 Q15113 P08571 P04746 
P04745 P80370 P55290 P55000 O95460 P01133 Q969E1 
P02647 P10645 P00995 Q96RW7 Q9ULI3 P41222 P10643 
P01011 Q9H8L6 O76076 Q02747 P01009 O75882 P02652 
Q8NES3 P02671 P05060 Q9UBX5 P05067 P09603 P06396 
Q08380 P0C0L4 Q14767 P07602 P55259 P60022 O94919 
P02774 Q9NZP8 P10451 Q92820 Q8IWU5 O75594 P07288 
P10153 P00738 Q9HCU0 P11684 P00734 Q6EMK4 Q07654 
P08637 P28799 O00187 P02787 P01042 P14543 P02675 
P48745 Q03403 P19652 P05109 P11597 P08123 Q15828 
P00740 Q96DR8 P02790 P19961 P00747 P01034 P02750 
P02751 Q14508 Q9UGM3 P04279 P02753 P25311 Q8WZ42 
O95998 P61916 P17936 P19823 P05090 Q8WVN6 Q02383 
O95502 P00450 P07996 O15240 P02760 P01833 P02763 
P43251 P07998 P19320 Q9UHG2 P05543 P02768 P02765 
P02766 P07858 O75015 P23142 P15289 P43652 P35555 
P19835 P07204 P39059 P04155 P07911 P05155 P12109 
P04004 Q12805 P81172 Q96IY4 
D5 =  
Q6UXB8 Q16270 P13987 P24855 P13591 P04217 P02461 
P61769 P05451 P12273 Q86Y38 Q9UHL4 P98160 P06702 
P31997 P02749 Q8N307 Q15113 P08571 P04746 P04745 
P55290 Q07507 P55000 O95460 P01133 Q969E1 P02647 
P00995 Q96RW7 O00468 P41222 Q16651 P01011 Q9H8L6 
O76076 Q02747 P01009 O75882 P02652 P02671 P05060 
Q9UBX5 P02452 P15941 P05067 P09603 P06396 P27169 
P59665 Q96PD5 Q08380 P0C0L4 Q14767 P07602 P55259 
P60022 O94919 P15309 P02774 Q9NZP8 P10451 Q92820 
Q8IWU5 O75594 P07288 P10153 P00739 Q9HCU0 P11684 
P00734 Q6EMK4 Q07654 P08637 P28799 O00187 P02787 
P02788 P01042 P14543 P83110 P02675 Q8N2S1 P48745 
Q03403 P19652 P01344 P08123 Q15828 P00740 Q96DR8 
P02790 P19961 O14498 P00747 P01034 P02750 P02751 
Q14508 Q9UGM3 P02753 P25311 Q8WZ42 O95998 P17936 
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P19823 P05090 Q8WVN6 O95502 P00450 P07996 O15240 
P02760 P01833 P02763 P07998 P19320 Q9UHG2 P05543 
P02768 P02765 P07858 O75015 P23142 P15289 P35555 
P19835 P07204 P39059 P04155 P07911 P05155 P12109 
P07339 P04004 Q12805 P81172 
D6 =   
Q6UXB8 Q16270 P13987 P24855 Q99988 P13591 Q99715 
P04217 P02461 P61769 P05451 P12273 Q86Y38 P98160 
P06702 Q9Y490 P02749 Q15113 P08571 P04746 P04745 
P55290 Q07507 P55000 O95460 P01133 Q969E1 P02647 
P10645 P00995 Q96RW7 P41222 Q16651 P01011 P10643 
Q9H8L6 O76076 Q02747 P01009 O75882 P02652 P02671 
P05060 Q9UBX5 Q9UIG4 P05067 P09603 P06396 P27169 
Q08380 P0C0L4 Q14767 P07602 P55259 P60022 P09466 
O94919 P15309 P02774 Q9NZP8 P10451 Q92820 Q8IWU5 
O75594 P07288 P10153 Q9HCU0 P00738 P11684 P00734 
Q6EMK4 Q07654 P08637 P28799 O00187 P02787 P02788 
P01042 P14543 P83110 P02675 P48745 Q03403 P19652 
P11597 P08123 Q15828 P08118 P17213 P03973 Q96DR8 
P02790 P19961 P01036 P00747 P01034 P02750 P02751 
Q14508 Q9UGM3 P04279 P02753 P25311 Q8WZ42 O95998 
P61916 P17936 P19823 P05090 Q8WVN6 Q02383 O95502 
P00450 P07996 O15240 P02760 P01833 P02763 P43251 
P07998 P19320 Q9UHG2 P02768 P02765 P02766 O75015 
P23142 P15289 P35555 P07204 P39059 P04155 P07911 
P51884 P05155 P12109 P04004 Q12805 P54107 P81172 
D7 = Q6UXB8 Q16270 P13987 P24855 P13591 P04217 
P02461 P61769 P05451 P12273 Q86Y38 P98160 P06702 
P31997 P12111 P02749 Q8N307 P08571 P04745 P02649 
P55290 P55000 O95460 P01133 Q969E1 P00995 Q96RW7 
P41222 P01011 Q9H8L6 O76076 Q02747 P01009 O75882 
P02671 P05060 Q9UBX5 P05067 P15941 P09603 P06396 
P27169 P59665 Q08380 P0C0L4 P07602 Q14767 P55259 
P60022 O94919 P02774 Q9NZP8 P10451 Q8IWU5 O75594 
P07288 P10153 Q9HCU0 P01024 P00734 Q6EMK4 P08637 
P28799 O00187 Q07654 P02787 P01042 P02788 P14543 
P02675 Q8N2S1 P19652 Q03403 P01344 P08123 Q15828 
P08118 Q96DR8 P02790 P19961 P00747 P01034 P02750 
P02751 Q14508 Q9UGM3 P04279 P25311 Q8WZ42 P61916 
P17936 P19823 P05090 Q8WVN6 Q02383 O95502 P00450 
P07996 O15240 P02760 P01833 P02763 P07998 P19320 
Q9UHG2 P02768 P02765 P07858 O75015 P15289 P35555 
P07204 P39059 P04155 P07911 P05155 P12109 P04004 
Q12805 
 
